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Prostate and breast cancer are the leading causes of cancer-related death in men 
and women, respectively, and metastasis is the primary factor underlying the high 
mortality rates.1  Snail transcription factor is an important molecule that drives prostate 
and breast cancer metastasis through the process of epithelial mesenchymal transition 
(EMT).  Proteolytic enzymes that promote invasion and metastasis such as the lysosomal 
cysteine protease cathepsin L (Cat L) have been shown to degrade E-cadherin, promoting 
the epithelial mesenchymal transition (EMT).2  It has also been shown that silencing Cat 
L can inhibit transforming growth factor-beta (TGF-β)-mediated EMT by suppressing 
Snail transcription factor.3  Several recent studies have highlighted an additional 
unexpected localization and site of action for Cat L within the nucleus in breast, colon 
and prostate cancer.4  Natural products have been shown to be efficacious in prevention 
and possible treatment of cancer.5  Specifically, we have been studying Muscadine Grape 
Skin Extract (MSKE) as a possible candidate to inhibit Snail signaling. MSKE has 
ii 
 
previously been shown to promote prostate cancer apoptosis.6  We hypothesized that 
Snail promotes nuclear localization of Cat L, which promotes EMT associated with 
increased migration and invasion, and that antagonizing Snail-Cat L signaling would lead 
to mesenchymal epithelial transition (MET).  We showed for the first time that MSKE 
promotes apoptosis through induction of endoplasmic reticulum stress response and 
autophagy.  Additionally, MSKE could inhibit Snail-mediated EMT via scavenging 
reactive oxygen species. Moreover, Snail could promote nuclear localization of Cat L, 
which then promoted cleavage of CDP/Cux, increased Snail transcription and decreased 
E-cadherin transcription by direct promoter binding of cleaved CDP/Cux, leading to 
EMT associated with increased migration and invasion. Interestingly, Z-FY-CHO, a 
small molecule specific inhibitor of Cat L, as well as MSKE could antagonize this 
signaling by promoting nuclear to cytoplasmic re-localization of Cat L. Therefore, we 
have dissected novel mechanisms of action of Snail and how it can be antagonized by 
MSKE natural product.  
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 Prostate cancer (PCa) is the most frequently diagnosed cancer in men, the second 
leading cause of male cancer deaths in the U.S, and also presents the greatest racial 
disparity of any cancer in the U.S.7  The incidence and mortality of  PCa is higher in 
African-American men (AA), compared to other ethnic groups.8  Triple negative breast 
cancer (TNBC) are defined as tumors lacking the expression of estrogen receptor-alpha 
(ER-α), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER-
2), which accounts for approximately 15% of total breast cancer patients, and is more 
prevalent among young African, African-American and Latino women patients.9  The 
mortality due to TNBC is higher in African-American and Latino patients, compared to 
other ethnic groups.10  The primary cause of prostate and breast cancer death is 
metastasis, which is regulated by several factors and signaling pathways such as 
epithelial mesenchymal transition (EMT), a dynamic process that promotes cell motility 
with decreased adhesive ability between cells to their neighbors.  Snail, a zinc-finger 
transcription factor, has been found to regulate EMT in part by increasing extracellular 
matrix (ECM) degradation via up-regulation of matrix metalloproteinases (MMPs).11  
Cathepsins are proteases that play a role in ECM degradation, but no direct link has ever 




that is overexpressed in prostate and breast cancer and involved in the repression of E-
cadherin, a hallmark of epithelial mesenchymal transition (EMT).12  Treatment options 
for metastatic breast and prostate cancer are associated with adverse side effects and a 
risk for tumor recurrence.  Studies have suggested that fruit and vegetables can have 
chemopreventive and therapeutic effects on tumor cells.5  Muscadine grape skin extract 
(MSKE) has shown its ability to inhibit prostate cancer cell growth and promote 
apoptosis in vitro without toxicity to normal prostate epithelial cells.13  The muscadine 
grape possesses one of the highest antioxidant levels among fruits; yet, the effect of this 
fruit on mammalian metabolic systems has not received significant attention.14  
Muscadine grape skin is a source of polyphenols such as ellagic acid, quercetin, and 
anthocyanins that have demonstrated antioxidant and anticancer activity in preclinical 
studies.15  Anthocyanins and anthocyanin-rich extracts from fruits and vegetables have 
exhibited anti-proliferative activity towards multiple cancer cell types in vitro,16 as well 
as inducing apoptosis,17 and preventing angiogenesis.18  Snail has been shown to increase 
expression of a bone marker, receptor activator of nuclear factor kappa B ligand 
(RANKL) which is associated with increased osteoclastogenesis or bone turnover.19   We 
therefore want to investigate whether there could be a link between Snail and Cat L in 
regulation of bone turnover and whether Snail signaling can be antagonized by natural 
products such as MSKE. This dissertation focuses on delineating the role of Snail 
transcription factor in human breast and prostate cancer and whether it promotes tumor 
progression through Cat L-mediated EMT and whether Snail-mediated osteoclastogenesis 




metastatic potential of breast and prostate cancer.  Few biomarkers have been associated 
with the increased risk and aggressiveness of breast and prostate cancer in African 
Americans.  Tumor cells that metastasize to the skeleton adhere to the endosteal surface 
and colonize bone.  The bone microenvironment is composed of osteoblast and 
osteoclasts, and the mineralized bone matrix.  Crosstalk between tumor cells and the bone 
microenvironment promotes a vicious cycle of tumor growth and bone destruction.  
Tumor cells secrete factors which stimulate osteoclast-mediated bone destruction and the 
consequent release of numerous factors immobilized within the bony matrix that act on 
cancer cells, promoting a more aggressive phenotype and potentiating cancer spread and 
bone destruction.  The goal of this report is to show that Cat L is important in breast and 
prostate cancer progression and metastasis and its activation is stimulated by Snail 
transcription factor.  Another novelty would be to show that Snail can promote nuclear 
translocation of Cat L and elucidate the mechanism by which Cat L may shuttle to the 
nucleus. Yet another novelty is that MSKE may regulate EMT and the Snail-Cat L 
signaling.  Therefore the overall hypothesis is that Snail increases Cathepsin L activity 
to promote breast and prostate cancer progression and metastasis and this activity can 
be abrogated by MSKE.  The studies proposed herein will be investigated using the 
following specific aims: 
Aim 1: To determine whether Snail regulates Cat L activity in breast and prostate 
cancer 
Our preliminary data indicates that Snail overexpressing cells express greater Cat L mRNA 




1) Determine the expression of Snail and Cathepsin L in prostate and breast cancer 
patients’ tissues from different races 
2) Determine whether Snail can regulate Cat L activity 
3) Determine if the downregulation of Cathepsin L will lead to MET and decrease 
invasion 
4) Determine if the inhibition of Cathepsin L will lead to decrease in Snail-
mediated Osteoclastogenesis 
Aim 2: To determine if MSKE can antagonize Snail-mediated signaling and decrease 
the activity and expression of Cathepsin L 
 Our preliminary data shows that treatment of prostate cancer cells with MSKE reverts 
EMT. We will address the following: 
1) Determine whether MSKE can antagonize Snail-mediated EMT 
2) Determine whether MSKE can decrease the expression and activity of Snail-
mediated Cathepsin L 
3) Determine the functional effect of MSKE on cell migration and 
osteoclastogenesis 
4) Determine if MSKE mediates its action by affecting the JAK/STAT pathway 
5) To study the proteomic effects of MSKE. 
6) Determine if MSKE disrupts the nuclear localization of Cat L to prevent the 








2.1 Prostate Gland 
The prostate gland surrounds the urethra at the base of the bladder and functions 
by contributing secretory proteins to the seminal fluid.  In adult humans, the prostate is a 
small acorn-shaped tissue, with ductal–acinar histology, that lacks discernible lobular 
organization.20  The contemporary description of the prostatic anatomy is based on the 
classic work by McNeal,21  who proposed the concept of prostatic zones, based on their 
anatomic location and histologic and embryologic features (Figure 1 pg. 101).  The 
seminal vesicles, located posterosuperiorly to the prostate, drain into the mid prostatic 
urethra via the ejaculatory ducts, in the region of the seminal colliculus. The transition 
zone forms two bulges on either side of the urethra that extend superiorly, anteriorly, and 
laterally from the seminal colliculus The central zone surrounds the ejaculatory ducts and 
is located posterior to the transition zone and the urethra proximal to the seminal 
colliculus. The peripheral zone surrounds both the central zone and the distal prostatic 
urethra.  Mature prostatic ducts contain three major cell types, luminal secretory epithelial 
cells, basal epithelial cells, and stromal smooth muscle cells that can be distinguished by 
their patterns of differentiation marker expression (Figure 2 pg. 102).22  Other less 
common cell types include neuroendocrine cells as well as rare basal epithelial cells with 




lumen is lined by tall columnar secretory epithelial cells. These cells have an apical–basal 
polarity and secrete prostatic proteins and fluids from their apical surface into the 
prostatic lumen.22  In humans, basal epithelial cells form a nearly continuous layer 
between the secretory cells and the basement membrane.  Neuroendocrine cells are 
present as rare cells within the epithelial layer of both developing and adult human 
prostate. The stromal layer of the human prostate is largely composed of smooth muscle. 
Although mostly smooth muscle, the stromal layer also contains fibroblastic, neuronal, 
lymphatic, and vascular cell type.22  Several genes and gene families have been suggested 
to play a role in prostatic development. Androgens are involved in every aspect of 
prostate development, growth, and function from early in male embryogenesis to 
prostatic hyperplasia in aging men.23  Likewise, androgen deprivation at any phase of life 
causes a decrease in prostate cell number and DNA content. The process by which the 
circulating androgen testosterone is converted to dihydrotestosterone in the tissue and 
dihydrotestosterone in turn gains access to the nucleus where it regulates gene 
expression, largely via interaction with a receptor protein, is understood, but the 
downstream control mechanisms by which hormonal signals are translated into 
differentiation, growth, and function are being unraveled.23  Androgen receptor (AR) 
signaling specifically targets the mesenchymal prostate compartment.  Androgens are 
continuously important for adult prostate function and homeostasis. In the adult prostate, 
androgens are involved in regulation of inappropriate prostate growth during benign 
prostate hyperplasia and contribute to progression of prostate cancer. Androgens signal 




complex translocates to the nucleus and functions as a positive or negative transcriptional 
regulator for a multitude of cell cycle and differentiation factors.24  Dihydrotestosterone 
has been found bound to the AR in the male urogenital mesenchyme indicating pathway 
activation.25  Some of the same signals that drive prostate gland development are 
involved in prostate cancer. 
2.2 Prostate Cancer  
The development of prostatic tumor in men is generally slow, taking up to 4 to 10 
years to develop a 0.4 inch-size tumor.26  Prostate cancer begins when the semen-
secreting prostate gland cells mutate into tumor cells, proliferating at higher levels. 
Initially, the prostate cells begin to proliferate leading to tumor formation in the 
peripheral zone of the prostate gland. Over time these cancer cells eventually multiply to 
further invade nearby organs, such as the seminal vesicles, rectum, bladder and urethra 
(Figure 3 pg. 103).27   During the initial metastatic stages, malignant cells from the 
primary tumor detach from their original site and migrate through blood and lymphatic 
vessels.27  In the later stages, cancer cells eventually spread to more distal organs, 
including bones, liver, and lung.27  To determine treatment options for prostate cancer, 
clinicians and pathologist have developed a staging system.   In stage I, the cancer is 
found only in the prostate.  Stage II is divided into IIA and IIB; overall the tumor has 
grown inside the prostate, but not extended outside the gland.  In Stage IIA, the cancer is 
confined to one lobe of the prostate while in Stage IIB the cancer is found in both lobes 
of the prostate.  In Stage III, the cancer has spread beyond the gland, mainly to the 




bladder, pelvis, rectum, and even a distant metastasis such as the bone (Figure 4 pg. 104). 
The different stages of prostate cancer are based on the Tumor, Node and Metastasis 
system (TNM) (see Table 1 pg. 101).  Prostate Cancer is also given a Gleason score by 
pathologist, which is based mainly on the histopathology of the tissue (see Tables 2 and 3 
pg 102).  
2.2.1 Signaling Pathways that Promote Prostate Cancer  
Several signaling pathways have been shown to be involved in the development 
of Prostate cancer.  NF-κB target genes have important anti-proliferative and apoptotic 
roles and may contribute to the development, progression, and resistance of certain tumor 
cells;28  PI3K/AKT signaling is related to cell survival and proliferation; Janus 
Kinase/signal transducers and activators of transcription (JAK/STAT) pathway is 
recognized as an important membrane-to-nucleus cascade, which may be activated by a 
wide variety of stimuli such as reactive oxygen species, cytokines, and growth factors.29  
JAK/STAT is one of the main cascades required for normal development and cell 
homeostasis, as well as in the control of cell proliferation, differentiation, cell migration, 
and apoptosis;29 Mitogen activated protein kinases (MAPKs) comprise a family of 
kinases that have a major role in tumor growth and metastasis. MAPK/ERK pathway is 
shown to be activated in PCa, especially in later stages of the disease, and is often 
deregulated with AKT signaling.30   Simultaneous activation of the ERK and AKT 
signaling pathways has been shown to promote PCa and CRPC both in vitro and in vivo, 
while combined inhibition of these pathways blocks cell proliferation and leads to Bcl-2 




is involved in the regulation of many cellular functions including cell growth, adhesion, 
migration, cell differentiation, embryonic development, and apoptosis.32  Accordingly, 
alterations in the TGF-β/SMAD signaling pathway are implicated in many human 
diseases such as cancer, fibrosis, and several hereditary conditions.32   According to the 
TGF-β central dogma, in normal epithelium or early-stage cancer cells, TGF-β acts as a 
tumor suppressor, by inhibiting cell growth, invasiveness, and motility and promoting 
apoptosis.33  In more advanced cancer cells, TGF-β has tumor-promoting functions; it 
promotes proliferation, invasion, and motility of cells and inhibits apoptosis.34  The Wnt 
family is composed of a large set of soluble proteins that play important roles in the 
embryonic developmental processes including cell proliferation, differentiation, and 
epithelial-mesenchymal interactions.35  Noticeably, Wnt ligands are up-regulated in PCa, 
and their expression often correlates with aggressiveness and metastasis.36  Prostate 
tumors have been shown to adapt to the androgen-deprived environment and become 
castrate-resistant, this is in response to androgen-deprivation therapy.37  Several 
molecular mechanisms for the development of castration-resistant prostate cancer, an 
important step in progression of the disease to the bone, have been elucidated to date: for 
example, prostate cancer cells become hypersensitive to androgen stimulation by 
upregulation of AR expression.38  Also, autocrine and paracrine production of androgens 
is upregulated in castrate-resistant prostate cancer.38  The AR may be activated in this 
setting by steroids other than androgens such as estrogens, and ligand-independent 




castrate-resistant prostate cancer, bypass pathways have been identified that contribute to 
AR independent growth of prostate cancer cells, such as interleukin-6 signaling.38   
2.2.2 Health Disparity of Prostate Cancer 
Prostate Cancer is the most frequently diagnosed cancer among men in the United 
States.  It has been observed that there is a clear association between prostate cancer and 
race; those of African descent have been found to have the highest incidence and 
mortality rates.40  The reason for this disparity remains unclear.  It has been shown that 
African American men are more prone to aggressive prostate cancer as compared to 
Caucasians.41  Survival after the onset of prostate cancer is related to the aggressiveness 
of the tumor, the stage at which the tumor is detected, the timing and type of treatment.  
Overall, black males have a poorer survival rate than white males for prostate cancer.42  
Although it has been consistently reported that African-American men have the highest 
rate of prostate cancer in the world, the findings of one study of Jamaicans by Glover et 
al, suggested that Caribbean men may have an even higher incidence of the disease.43 
Few researchers have looked at the experiences and perspectives towards prostate cancer 
of Afro-Caribbean men residing in the United States, additional research is needed to 
provide insight into what is known about prostate cancer and the attitudes of this ethnic 
group towards the disease. The data on the higher incidence of prostate cancer and 
associated mortality among men of African descent seem to point to the need for 
increased awareness and early diagnosis of the disease.  For example, compared to 
Nigerian men, African-American men are >10 times likely to develop prostate cancer and 




Chinegwundoh et al,45 African-Caribbean men had the highest age-specific incidence 
rates compared to European and Asian men. Interestingly, the relative risk for prostate 
cancer for the African-Caribbean men was three times that of European men.  As noted 
by the authors, this risk is more than the risk documented for African American men in 
the US. A reason that has been suggested for the larger relative difference between 
African-Caribbean and European men is a lower prostate cancer rate for White men in the 
UK.   Awareness and the motivation to seek testing and early diagnosis may be 
associated with the beliefs, experiences, and perceptions of ethnic groups such as Afro-
Caribbean men.   
Subsequently, genome-wide association studies (GWAS) of cancer identified 
numerous susceptibility loci for prostate, other cancers that significantly influence cancer 
risk in the general population and are thought to substantially contribute to the global 
cancer burden.46   Several of these studies reported that the identified cancer risk loci may 
affect some population groups differently than others.47  For example, deleterious 8q24 
variants seem to confer a higher risk for prostate cancer in men of African ancestry than 
men of European ancestry,48 as also suggested by admixture mapping.49  These genetic 
variations do not alone cause cancer, but instead may interact with harmful 
environmental exposures and thereby increase both the effects of these exposures and the 
odds of developing cancer. For example, a recent study observed that pesticide exposure 
modifies the association of 8q24 cancer susceptibility variants with prostate cancer.50 
Several additional GWAS-identified prostate cancer susceptibility loci (i.e. 11q13, 




Other genes have been associated with prostate cancer health disparities.   Notably, the 
epidermal growth factor receptor signaling was found to be more commonly expressed in 
tumors from African-American patients when compared with European-American 
patients.52  Wallace et al 53 and Timofeeva et al 54 found consistent gene expression 
differences between the African-American and European American prostate cancer 
patients. Notably, several known metastasis-promoting genes, including AMFR, CXCR4 
and MMP9, were more highly expressed in tumors from African-Americans than 
European-Americans.53-54   In research by Rose et al.,55 their data pointed to significant 
differences in tumor immunobiology and inflammation pathways between African-
American and European-American patients. Moreover, an interferon γ signature was 
found to be prominent in tumors from African-American patients.  Other studies have 
shown the upregulation and activation of bone morphogenetic protein 2 (BMP2) in 
tumors from African American samples;40-41 which provides supporting evidence for the 
notion that tumor epithelial cells or stroma produce the factors that promote metastases 
are higher in African-American samples. On the other side of the spectrum, a recently 
published study that detected Ets-related gene (ERG) protein, where ERG-positive 
prostate tumors were significantly greater in European American compared to African 
American, which includes the TMPSSR-2:ERG fusion gene.56   Given the importance of 
epigenetic DNA alterations in contributing to prostate cancer, the occurrence of DNA 
hypermethylation in tumors from African-American men has been evaluated. In three 
studies, a pattern emerged consistent with increased DNA hypermethylation in African-




men.57   As prostate cancer disproportionately affects African Americans, the discovery 
of true risk alleles and genes could have important implications for early detection of 
prostate cancer in this high-risk population. 
2.2.3 Treatment of Prostate Cancer 
In its initial stages, when confined to the prostatic capsule, prostate carcinoma is 
essentially curable by surgical intervention and/or radiation therapy. In fact, most cases of 
prostate carcinoma are relatively indolent, such that the majority of men diagnosed with 
prostate cancer will instead die of other causes.58  However, if not detected early, or in 
more aggressive forms of the disease, prostate carcinoma can advance to stages 
characterized by local invasion of the seminal vesicles, followed by metastasis primarily 
to the bone, usually resulting in lethality.59  This transition to metastatic disease is 
generally followed by a shift from androgen dependence to androgen independence, 
which is often provoked by androgen-ablation therapy.60   It is well-known that hormone 
ablation treatment of prostate cancer initially causes the cancer to regress. Regression 
often occurs within 12–18 months, although shorter periods of regression are also known 
to occur.37   The progression to metastatic disease is slow and can be monitored by the 
steady increase in Prostate Specific Antigen (PSA) levels. Androgens maintain the ratio 
of cells within the prostate where there is a balance between proliferating cells and the 
cells undergoing death.39  Upon hormone deprivation, the cells undergoing apoptosis 
increase, and the equal ratio of cells is affected, leading to cancer cell death and the 
regression of prostate cancer.37  Docetaxel and cabazitaxel are the only United States 




mCRPC.61  These tubulin-binding taxanes have been proven to decrease PSA levels and 
palliate symptoms, but survival benefits are modest.  PCa patients with disease showing 
evidence of distant metastasis at diagnosis are considered the most advanced, and 
treatment options for this group are limited.61  The standard of care for 
advanced/metastatic PCa cases is long-term primary Androgen deprivation therapy 
(ADT), which includes surgical castration or medical castration with a luteinizing 
hormone releasing hormone (LHRH) agonist or combined androgen blockade (CAB).62  
Treatment options being confined to ADT for metastatic PCa patients is problematic 
because ADT is correlated with significant morbidity and decreased quality of life.63 
2.3 Mammary Gland 
The mammary gland is a complex secretory organ composed of a number of 
different cell types: epithelial cells that grow from the nipple into a fat pad, formed by 
adipocytes and infiltrated by vascular endothelial cells, fibroblasts and immune cells 
(Figure 5 pg. 105).64  During embryogenesis, these changes are directed by signals from 
the mesenchyme, but during puberty and in adulthood, circulating hormones released 
from the pituitary and ovary provide additional instructive input.65  Two main cell types 
comprise the mammary epithelium: basal and luminal. The basal epithelium consists of 
myoepithelial cells, which generate the outer layer of the gland, and a small population of 
stem cells, which supply the different cell types. The luminal epithelium forms ducts and 
secretory alveoli, and contains populations of cells defined by their hormone receptor 
status.66  Together with the myoepithelium, the luminal epithelium generates a bi-layered, 




myoepithelial cells contract to squeeze milk from the inner alveolar luminal cells.66  After 
puberty, the female human breast undergoes variable amounts of terminal end bud 
formation, duct elongation, dichotomous and lateral branching, terminal duct lobular unit 
formation and stromal expansion.67   Mammary branching can be separated into 
embryonic, adolescent and adult phases, each of which is differentially regulated. For 
instance, adolescent branching requires estrogen and estrogen receptor-α (ER-α), adult 
tertiary side-branching requires progesterone and its receptor (PR), and embryonic 
branching is hormone independent, because it occurs in mice lacking ER-α, estrogen 
receptor beta (ER-β), PR or the receptors for growth hormone (GH) and prolactin.65  
Branching is also coordinated by local cross-talk between the developing duct epithelium 
and nearby stromal cells. Notably, mammary ducts are bi-layered tubes composed of 
inner luminal epithelial cells surrounded by myoepithelial cells, which are in turn 
surrounded by an extracellular basement membrane.65  The ovarian hormone, estrogen, is 
a major regulator of mammary development and is responsible for the tremendous surge 
in growth occurring during this period that generates a functional mammary gland. 
2.3.1 Estrogen Receptor 
Estrogen receptors (ERs) belong to the steroid hormone superfamily of nuclear 
receptors (NRs).68   Other types of steroid receptors among the NRs include the estrogen-
related receptors (EER), progesterone receptors (PR), androgen receptors (AR), 
glucocorticoid, and mineral corticoid receptors.68  The biological functions of estrogen 
are mediated by binding to the ERs: ERα and ERβ. ERα and ERβ are encoded by distinct 




chromosome 6 while the ERβ gene is on chromosome 14.69  The full-length human ERα 
protein has 595 amino acids and a molecular size of 66 kDa while the full-length human 
ERβ protein has 530 amino acids and a molecular size of 54 kDa. Similar to other NRs, 
ERs have five domains with distinct functions: The N-terminal of the A/B domains of 
ERs consist of activation function 1 (AF1), which contributes to the transcriptional 
activity of ERs and is an essential domain for interaction with co-regulators.69  AF1 is the 
least conserved region with only 30% identity between ERα and ERβ. Functional studies 
have shown that ERβ has low levels of AF1 activity. The A/B domains also contain 
amino acids that are targets of post-transcriptional modifications including splicing to 
stimulate AF1 activity.69  The C domain encodes a centrally located DNA binding 
domain (DBD) essential for sequence-specific binging of ERs to DNA and regulating the 
expression of target genes.70  The D domain, a hinge region, includes amino acid 
sequences that stimulate nuclear localization signaling and facilitate post-translational 
modification of ERs, resulting in the activation of ER signaling in cells. Finally, the E/F 
domain, located in the C-terminal region, contains a ligand-binding domain (LBD) that 
serves as an interaction site with co-regulators and ligand-dependent activation function 2 
(AF2). AF1 and AF2 control the transcriptional regulatory activity of ERs because 
activation of ERs are stimulated during cellular responses to the environment.71  The E/F 
domains of ERα and ERβ share a 53% sequence identity and affect cellular responses 
through ligand-dependent ER activation.71  The F domain also affects the activity of ERα 
and ERβ. The differences between the F domain of the ERs may contribute to the ability 




highly expressed in the uterus, prostate stroma, ovarian theca cells, Leydig cells in testes, 
epididymis, breast, and liver; ERβ is highly expressed in prostate epithelium, testes, 
ovarian granulosa cells, bone marrow, and brain.72   In the classical model of ER action, 
ligand-activated ER binds specifically to DNA at estrogen-responsive elements (EREs) 
through its DNA binding domain and brings coactivators and corepressors to 
transcription start sites (TSS).72   
2.4 Breast Cancer 
Breast cancer is one of the major causes of cancer-related morbidity and mortality 
among women worldwide. Breast cancers originate from the epithelial cells of the normal 
mammary gland. The ducts are lined with luminal epithelial cells, which give rise to the 
majority of breast cancers (Figure 6 pg. 106).73  As a heterogeneous disease, breast 
cancer encompasses a wide variety of pathological entities and this heterogeneity is 
reflected by the differences in cell type composition and proportions, the differences in 
the proliferation ability between glandular and myoepithelial cells, the proliferation of 
progenitor cells, the therapeutic responses and patient outcomes.74  Breast cancer patients 
with the same clinical diagnostic and prognostic profiles may exhibit markedly different 
clinical overall outcomes and treatment responses , which may be due to the current 
breast cancer taxonomies based on the morphological groups, dividing the disease into 
clinical classes.75  The current molecular classifications of breast cancer molecular 
subtypes are generally based on the gene expression profiles according to i) luminal cell-
related markers, such as cytokeratins (CKs); ii) hormone receptors, such as ER, PR and 




iv) anti-apoptosis markers, such as Bcl-2 and p53; v) cell proliferation indicators, such as 
Ki-67 and survivin; vi) cell invasion-related factors, such as matrix metalloproteinases 
(MMPs) and integrins; vii) signal transduction pathway members, such as the PI3K/AKT 
pathway members phosphatidylinositol-3-kinase (PI3K) and AKT; viii) cell cycle control 
members, such as cyclins and cyclin-dependent kinases (CDKs); ix) epithelial-to-
mesenchymal transition-indicating factors and regulating factors, such as cadherins and 
zinc-finger transcription factors Snail, Slug, Zeb1 and Twist; x) metastatic control 
factors; and xi) blood vessel-forming control factors.75-76   This spectrum also includes 
stem cell markers, tumor cell and microenvironment interacting factors and other small 
regulatory molecules, such as microRNAs or other non-coding RNAs. The currently 
established molecular classification of breast cancers distinguishes breast cancer 
molecular subtypes into five intrinsic subtypes: i) luminal subtype A (ER+ and/or PR+, 
HER2− and CK8/18+); ii) luminal subtype B (ER+ and/or PR+, HER2+ and CK8/18+); iii) 
HER2-enriched subtype (ER− and/or PR− and HER2+); iv)basal-like subtype [ER− and/or 
PR−, HER2−, CK5/6+, CK14+, CK17+ and epithelial growth factor receptor (EGFR)+]; 
and v)  normal breast-like type (ER− and/or PR−, HER2−, CK5/6−, CK14−, CK17−, 
EGFR−).75-76   The last two subtypes are included in the TNBC group.  The luminal type 
of breast cancer tends to be morphologically well differentiated and exhibits a relatively 
good prognosis, whereas the ER− tumors are poorly differentiated and exhibit a poor 
prognosis. The designation of the luminal type of breast cancer was derived from the 
finding that this type of breast cancer exhibits mRNA and protein expression of CKs 




cells, which express CKs 5/6. The luminal type of breast cancer is further subdivided into 
A and B subtypes, with the luminal B subtype exhibiting significant expression 
differences and worse outcomes.75  Thus, the luminal A and B subtypes are collectively 
referred to as the luminal type, which accounts for 65–70% of breast cancers, whereas the 
HER2-enriched subtype accounts for ~10% of breast cancers and the basal-like subtype 
accounts for 10–15%.75   Since luminal subtype A and B breast cancer cells are ER+ 
and/or PR+, patients with these two types of breast cancer are always subjected to 
endocrine therapy with tamoxifen, to inhibit the functions of ER, and aromatase 
inhibitors or inactivators, to block estrogen production or to inactivate ERs, or even to 
inhibit the dimerization and downregulate ERs.78  
2.4.1 Triple Negative Breast Cancer 
Triple-negative breast cancer (TNBC) is a heterogeneous breast cancer group. 
TNBC constitute 10-20% of breast cancers.  TNBC tumors are generally larger in size 
and or higher grade, have lymph node involvement at diagnosis, and are biologically 
more aggressive. TNBC patients have a higher rate of distant recurrence and a poorer 
prognosis than women with other breast cancer subtypes.  TNBC has been categorized 
into six subtypes including 2 basal-like (BL1 and BL2), an immunomodulatory (IM), a 
mesenchymal (M), a mesenchymal stem–like (MSL), and a luminal androgen receptor 
(LAR) subtype.79  Although the terms TNBC and basal-like cancer are often used 
interchangeably, it is important to clarify that not all TNBCs belong to the basal-like 
subtype.  Basal tumors account for 60% to 90% triple negative cases.80  These tumors are 




any form of standard targeted systemic therapy.81  The metastasis pattern also separates 
basal tumors from the other breast cancers, with a tendency towards visceral organs 
(excluding bone) and less likely to involve lymph nodes.82  The size of basal tumors is, in 
general, larger than the other subtypes, with a median size of 2 cm, and this class tend to 
show rapid growth.82  The BL1 subtype are heavily enriched in cell cycle and cell 
division components and pathways, with high Ki-67 mRNA expression which allows this 
subtype to be highly proliferative.79  BL2 subtype displays unique gene ontologies 
involving growth factor signaling (EGF pathway, MET pathway, Wnt/β-catenin, and 
IGF1R pathway) and has features suggestive of basal/myoepithelial origin as 
demonstrated by higher expression levels of TP63 and CD10.83  The IM subtype include 
processes for immune cell signaling processes include immune cell signaling (TH1/TH2 
pathway, NK cell pathway, B cell receptor (BCR) signaling pathway, and T cell receptor 
signaling), cytokine signaling (cytokine pathway, IL-12 pathway, and IL-7 pathway), 
antigen processing and presentation, and signaling through core immune signal 
transduction pathways (NFKB, TNF, and JAK/STAT signaling).84  The M subtype 
displays a variety of unique gene ontologies that are heavily enriched in components and 
pathways involved in cell motility (regulation of actin by Rho), ECM receptor 
interaction, and cell differentiation pathways (Wnt pathway, anaplastic lymphoma kinase 
(ALK) pathway, and TGF-β signaling).79, 84-85  The MSL subtype shares enrichment of 
genes for similar biological processes with the M subtype, including cell motility (Rho 
pathway), cellular differentiation, and growth pathways (ALK pathway, TGF-β signaling 




components and processes linked to growth factor signaling pathways that include 
inositol phosphate metabolism, EGFR, PDGF, calcium signaling, G-protein coupled 
receptor, and ERK1/2 signaling as well as ABC transporter and adipocytokine signaling. 
79, 83, 85-86  Another interesting difference between the M and MSL subtype is that MSL 
subtype expresses low levels of proliferation genes along with a more stromal-epithelial 
interaction between genes.87 The MSL subtype also displays low expression of claudins 
3, 4, and 7, consistent with a recently identified claudin-low subtype of breast cancer.86    
LAR group has hormonally regulated pathways including steroid synthesis, porphyrin 
metabolism, and androgen/estrogen metabolism, with high AR mRNA expression.87  
Tumors within the LAR group also expressed numerous downstream AR targets and 
coactivators (DHCR24, ALCAM, FASN, FKBP5, APOD, PIP, SPDEF, and CLDN8).86-87  
Since TNBC lack the common molecular targets used in targeted therapies, patients are 
usually managed with standard treatments, and chemotherapy is the primary, if not the 
only, choice of systemic therapy. Taxanes, such as paclitaxel, alone or in combination 
with anthracycline reagents and/or alkylation reagents are the first-line chemotherapeutic 
drugs being used for TNBC.83  Although patients generally have a favorable initial 
response to taxane regimens, rapid development of resistance to taxanes is prevalent.83  
Platinum Agents are particularly interesting for management of patients with TNBC, 
partially based on their ability to bind directly to DNA. This causes the DNA to crosslink, 
resulting in double-strand DNA breakage.88   It has been theorized and shown in 
preclinical models, that neoplastic cells harboring BRCA mutations, and thus lacking one 




that induce DNA damage.88   TNBC tumors that lack functional BRCA1 or BRCA2 are 
sensitive to PARP inhibitors in preclinical studies.89  There are new agents, such as 
inhibitors of  tyrosine kinases and mTOR, treating AR positive TNBC with 
antiandrogens, which are currently in different phases of development and will hopefully 
change how patients affected with TNBC will be treated.81   
2.4.2 Health Disparity of Breast Cancer 
African-American and Hispanic/Latina women with breast cancer have poor 
outcome compared with other groups along with higher a higher incidence and mortality 
rate from TNBC.9   Studies have suggested that differences in tumor receptor subtypes 
may potentially play a role in the disparate outcomes from breast cancer observed among 
these ethnic groups.  In a study completed by Ihemelandu et al,90  they found that the 
luminal A subtype was the most prevalent subtype (55.4%) compared with luminal B 
(11.8%), basal cell-like (21.2%), and Her-2/neu (11.6%) subtypes. The molecular 
subtypes did not differ by menopausal status. However, when stratified into age-specific 
groups, the basal cell-like subtype (57.1%) was the most prevalent in the age group <35 y 
compared with luminal A, luminal B, and Her-2/neu subtypes at 25.0%, 14.3%, and 
3.6%, respectively. The basal cell-like subtype also showed an age-specific bimodal 
distribution with a peak in the <35 y and 51 to 65 y age groups. The basal cell-like and 
the Her-2/neu subtypes showed an increased association with clinicopathologic variables 
portending a more aggressive clinical course when compared with luminal A subtype, 
suggesting that the basal subtype is more prevalent in young African-American women.   




and conclusions revealed that The basal-like breast cancer subtype was more prevalent 
among premenopausal African American women (39%) compared with postmenopausal 
African American women (14%) and non-African American women (16%) of any age 
(P<.001), whereas the luminal A subtype was less prevalent (36% vs 59% and 54%, 
respectively). The HER2+/ER- subtype did not vary with race or menopausal status (6%-
9%). Compared with luminal A, basal-like tumors had more TP53 mutations (44% vs 
15%, P<.001), higher mitotic index (odds ratio [OR], 11.0; 95% confidence interval [CI], 
5.6-21.7), more marked nuclear pleomorphism (OR, 9.7; 95% CI, 5.3-18.0), and higher 
combined grade (OR, 8.3; 95% CI, 4.4-15.6). Breast cancer-specific survival differed by 
subtype (P<.001), with shortest survival among HER2+/ER- and basal-like subtypes, 
which indicated that basal-like breast tumors occurred at a higher prevalence among 
premenopausal African American patients compared with postmenopausal African 
American and non-African American patients in this population-based study. This 
showed that a higher prevalence of basal-like breast tumors and a lower prevalence of 
luminal A tumors could contribute to the poor prognosis of young African American 
women with breast cancer.  In a study by Kurian et al, 91 in the state of California, they 
found that the luminal breast cancer subtype predominates across racial/ethnic groups, 
with lifetime risk lowest in Hispanic women (4.60%, 4.41-4.80%) and highest in white 
women (8.10%, 7.94-8.20%). HER2-positive breast cancer varies less by race (1.56-
1.91%). Lifetime risk of triple-negative breast cancer is highest in black women (1.98%, 
1.80-2.17%), compared to 0.77% (0.67-0.88%) for Asians, 1.04% (0.96-1.13%) for 




Georgia also confirmed that there is a high prevalence of TNBC in younger women and 
particularly younger African American women, along with unique protein expression 
patterns and poorer survival, suggests varying gene-environment etiologies with respect 
to age and race/ethnicity and a need for effective therapies.   
2.5 Metastasis 
Metastasis is a multistep process that is referred to as the invasion-metastasis 
cascade, and the first critical step of this process is the invasion of primary cancer cells 
into the surrounding extracellular matrix (ECM) and stromal cell layers.93  These cells 
enter the systemic circulation (intravasate), translocate through the vasculature, and arrest 
in distant capillaries where they extravasate into the surrounding tissue parenchyma, and 
these microscopic growths (micrometastases) proliferate into macroscopic secondary 
tumors.94   Metastasis is the result of several sequential steps and represents a highly 
organized, non-random and organ selective process 95 that involves interactions from a 
variety of proteolytic enzymes, growth factors, and cell-cell and cell-substrate adhesion 
molecules.96  Cancer cells must therefore shed many of their epithelial characteristics, 
detach from epithelial sheets, and undergo a drastic alteration, a process referred to as the 
epithelial-mesenchymal transition (EMT).  After EMT,  cancer cells must go through a 
multistep process to metastasize to bone, which involves dislodgement from a primary 
site, survival in the circulation, binding to the resident cells in bone, and survival and 






2.5.1 Bone Metastasis 
Patients with bone metastasis are at risk of skeletal complications, including 
spinal cord compression, pain, pathological fracture, and hypercalcemia.  Cancer patients 
who develop bone metastases, particularly those with breast and prostate cancer, can 
survive for many years after diagnosis, but will suffer significant morbidity.  Once cancer 
cells intravasate into circulation, they must survive in the circulation, attach to the 
vascular endothelium, and then extravasate into the bone. These later steps in metastasis 
are the most poorly understood, but likely require interaction of tumor cells with other 
cells for metastasis to develop.   The bone microenvironment is composed of osteoblast 
and osteoclasts, and the mineralized bone matrix.  Crosstalk between tumor cells and the 
microenvironment promotes a vicious cycle of tumor growth and bone destruction.  
Tumor cells secrete factors which stimulate osteoclast-mediated bone destruction and the 
consequent release of numerous factors immobilized within the bony matrix that act on 
cancer cells, promoting a more aggressive phenotype and potentiating cancer spread and 
bone destruction.  It has been reported that differentiation of osteoclasts occurs first 
during bone remodeling when PCa cells metastasize to the bone 98 therefore, inhibition of 
osteoclast differentiation is important for interrupting PCa bone metastasis and homing. It 
is well known that RANK/RANKL/OPG signaling is key regulator for osteoclast 
differentiation.98  RANKL is a member of the TNF family and is normally expressed on 
the cell surface of stromal cells and osteoblasts and mediates osteoclast differentiation 
and osteolysis or bone resorption.99  Most prostate cancer bone metastases are either 




integrins αvβ3 and α2β1, which are also expressed in osteoclasts,101 facilitate tumor 
spreading in the bone. Alterations in cadherin-11 may also be responsible, in part, for the 
bone-tropic nature of prostate cancer metastasis. Cadherin-11, also known as osteoblast-
cadherin, is highly expressed in human prostatic bone metastases as well as in prostate 
cancer cell lines derived from bone metastases, but is not detectable in prostate cancer 
metastases to other organs.102  Knockdown of cadherin-11 in metastatic prostate PC3 
cells using an short-hairpin RNA (shRNA) strategy led to reduced incidence of metastasis 
to the bone following their intracardiac injection into immunodeficient mice.102 
Importantly, re-expression of cadherin-11 in C4-2B4 cells, a metastatic bone-tropic 
variant of LNCaP that lacks intrinsic cadherin-11 expression, increases cell migration and 
invasiveness as well as spreading and intercalation into osteoblast layer.103  These results 
suggest that functions of cadherin-11 are bone specific and may facilitate the metastatic 
colonization of prostate cancer cells in the bone.  In prostate cancer, bone metastasis is 
usually osteoblastic with elevated bone formation, resulting in increased bone mineral 
density.104  Osteoblastic metastasis of prostate cancer may be, in part, due to prostate 
cancer cells promoting osteoblast proliferation. The number of osteoblasts adjacent to 
prostate cancer cells is increased in bone metastases, while in osteoclastic tumors an 
increase in osteoclasts is observed.104  Although bone formation is increased in prostate 
cancer bone metastases, the tumor-generated bone is abnormal, lacking typical lamellar 
structure of the normal bone and is thus termed woven bone. This type of bone formation 
easily leads to bone fractures that are frequently seen in prostate cancer patients with 




growth by limiting the space for cancer cells, which delays further progression of prostate 
cancer metastasis.97  On the other hand, breast cancer bone metastasis is mainly 
osteoclastic.  Osteoclasts have a pivotal role in the pathology of the clinically overt 
osseous lesions of breast carcinoma. The clinical appearance of osseous metastases is 
associated with increased proliferation of cancer cells, which succeed to mount a 
supportive microenvironmental reaction. Breast cancer cells induce intense osteoclastic 
response which perpetuates the growth of cancer cells at the involved bone tissues 
through resorption of bone matrix and the release of growth factors stored in that matrix. 
This reaction potentially derives more cancer growth at the metastatic site in what came 
to be known the vicious cycle of bone metastases Interleukin-8 (IL-8) was identified as 
one such molecule produced by bone metastatic sub-clone of breast carcinoma cells 
MDA-MB-231.105  It was shown to directly induce osteoclastogenesis, and its expression 
was found to correlate with bone metastases in vivo.105  Breast cancer cells can also 
secret M-CSF that directly promotes osteoclasts formation 106 and survival.107  In 
addition, breast cancer-derived factors induced unique signaling profile in differentiating 
pre-osteoclasts and mature osteoclasts, which was distinct from normal RANKL-induced 
differentiation and survival signals,108 suggesting the involvement of pathological 
mediators of osteoclastogenesis.  Cancer metastasis in the bone almost invariably leads to 
an imbalance of bone formation and bone resorption, resulting in osteolytic or 
osteoblastic lesions.97  Although the underlying mechanism for the imbalance is still not 
clear, different types of cancer cells have the propensity to secrete more osteoblastic or 




bone resorption is increased as shown by increased serum and urine markers, since both 
involve processes involved in bone turnover.109  Normally, RANKL expressed by the 
osteoblast binds RANK receptor on the osteoclast and this interaction can be blocked by 
osteoprotegrin (OPG), a decoy receptor of RANKL.110  A vicious cycle (Figure 7 pg. 
107) has been postulated, in which increased bone resorption stimulates metastatic 
growth in bone through release of activated growth factors and calcium, which in turn 
causes cancer cells to stimulate RANKL production in other cells in bone.111  
2.6 Epithelial Mesenchymal Transition  
Epithelial Mesenchymal Transition (EMT) is a normal developmental process 
controlled by distinct molecular processes that include the activation of transcription 
factors, expression of specific cell surface proteins, reorganization and expression of 
cytoskeleton proteins, production of ECM-degradation enzymes and changes in the 
expression of specific microRNAs.   EMT is classified into three different subtypes.112  
Type I is involved in the transition of primordial epithelial cells into motile mesenchymal 
cells and is associated with the generation of diverse cell types during embryogenesis.    
Type II is associated with wound healing, tissue regeneration and organ fibrosis.  Type III 
occurs in neoplastic cells that have previously undergone genetic and epigenetic changes, 
specifically in genes that favor clonal outgrowth and the development of localized 
tumors.  Epithelial and mesenchymal cells have been identified on the basis of their 
unique visual appearance and the morphology of the multicellular structures they 
create.113  A typical epithelium is a sheet of cells, often one cell thick, with individual 




and adhesions between neighboring epithelial cells hold them tightly together and inhibit 
the movement of individual cells away from the epithelial monolayer.114   The epithelial 
sheet itself is polarized, meaning that the apical and basal surfaces are likely to be 
visually different, adhere to different substrates, or have different functions.115   
Mesenchymal cells, on the other hand, generally exhibit neither regimented structure nor 
tight intracellular adhesion. Mesenchymal cells form structures that are irregular in shape 
and not uniform in composition or density. Adhesions between mesenchymal cells are 
less strong than in their epithelial counterparts, allowing for increased migratory capacity. 
Mesenchymal cells also have a more extended and elongated shape, relative to epithelial 
cells, and they possess front-to-back leading edge polarity.116  Moreover, mesenchymal 
migration is mechanistically different from epithelial movement. Epithelial cells move as 
a sheet in block, whereas mesenchymal migration is considerably more dynamic by 
leaving a trailing region behind.116 
2.6.1 Role of EMT in Cancer 
The occurrence of EMT during tumor progression allows benign tumor cells to 
acquire the capacity to infiltrate surrounding tissue and to ultimately metastasize to 
distant sites. The most compelling evidence for the involvement of EMT in oncogenesis 
is the ability of multiple EMT regulators to enhance tumor formation and/or 
metastasis.117  EMT is also a key event in the tumor invasion process whereby epithelial 
cell layers lose polarity together with cell-cell contacts and then undergo a dramatic 
remodeling of the cytoskeleton.118  An epithelial cell, which normally interacts with 




enable it to assume a mesenchymal phenotype, which includes enhanced migratory 
capacity, invasiveness, elevated resistance to apoptosis, and greatly increased production 
of extracellular matrix (ECM) component (Figure 8 pg.108).115  The completion of EMT 
is signaled by degradation of underlying basement membrane and the formation of a 
mesenchymal cell that can migrate away from the epithelial layer in which it 
originated.112, 115  One of the key hallmarks of EMT is the loss of E-cadherin, a cell 
adhesion protein that is regulated by multiple transcription factors.119  This is 
accompanied by the acquisition of a mesenchymal genotype that includes the expression 
certain markers such as vimentin and N-cadherin, and the increased production of ECM-
degrading enzymes.120  For example, the epithelial-like cell line ARCaP-E, which is 
derived from parental androgen-refractory ARCaP prostate cancer cells, was used for 
successive intracardiac inoculations into nude mice.121  After only one inoculation, the 
ARCaP-E cells from the resulting tumors exhibited EMT-like phenotypic changes. Cells 
from the tumors harboring those changes were then injected intracardiac into a second 
group of mice, and those cells exhibited increased metastasis to several different organs, 
including the bone, demonstrating—at least in this model—a role for EMT in increasing 
metastatic potential.   Activation of EMT program is also facilitated by disruption of cell-
cell adherens junctions and the cell-ECM adhesions mediated by integrins.122  
Pathological EMT in tumor cells results from transcriptional reprogramming of abnormal 
survival signals via receptors such as transforming growth factor-Beta1 receptor (TGF-
β1).123  TGF-β1 is a potent EMT inducer in normal development and organ homeostasis 




induction of transcriptions factors such as Snail, slug, zinc finger E-box binding 
homeombox 1 (ZEB1), and twist. 
2.7 Snail Transcription Factor 
Snail, a zinc finger transcription factor, is a key regulator of EMT and represses 
transcription of the cell adhesion molecule E-cadherin while inducing transcription of 
mesenchymal genes such as vimentin.123  The Snail family of zinc-finger transcription 
factors consist of Snail1 (Snail), Snail2 (Slug) and Snail3 (Smuc), which shares an 
evolutionary conserved role in mesoderm formation in vertebrates.  These molecules are 
composed of a highly conserved carboxy-terminal region containing four to six C2H2-
type zinc fingers, which mediate sequence-specific interactions with DNA promoters 
containing an E-box sequence (CANNTG).124  The amino termini of all vertebrate Snail 
family members contain the evolutionarily conserved SNAG (Snail/Gfi) domain, which 
is essential for transcriptional repression and nuclear localization.124  In the central 
region of Snail, a serine-rich domain (SRD) and a nuclear export sequence (NES) are 
found in the regulation of protein stability and subcellular localization of Snail, 
respectively.   Research has shown that Snail1 can bind to a functional E-box in its own 
promoter region and control its own expression.125  Different signaling pathways have 
been linked with the induction of Snail family members in the EMT.  For example, 
receptor tyrosine kinases (RTKs) signaling, activated by HGF, FGF, or EGF, acts through 
the RAS-MAPK or PI3K-Akt pathway and results in the induction of Snail.126  Signaling 
via MAPK or PI3K has been reported as necessary and sufficient to regulate EMT in 




multifunctional cytokine that regulates cell proliferation, differentiation and apoptosis.126  
It suppresses tumor development at early stages; however, it promotes tumor progression 
when cells become resistant to TGF-β.126  Snail plays an important role in mediating the 
escape from the tumor suppressive effects of TGF-β. It confers resistance to TGF-β-
mediated apoptosis and switches the response to tumor progression.123  In the late stages, 
TGF-β induces EMT by up-regulating Snail via a Smad-dependent manner.95  It has been 
demonstrated that TGF-β, via the Smad pathway, induces expression of high mobility 
group A2 (HMGA2) which regulates expression of many important repressors of E-
cadherin. Smads and HMGA2 cooperatively bind to the Snail promoter and induce Snail 
expression, E-cadherin repression, and the overall EMT phenotype.127  During TGF-β-
induced EMT, it has also been shown that Snail forms a transcriptional repressor complex 
with SMAD3/4.128  This complex targets the adjacent E-boxes and Smad-binding 
elements in genes encoding junction proteins such as E-cadherin and occludin, resulting 
in gene repression.128  In the presence of Wnt signaling, GSK-3β is unable to 
phosphorylate two of its known targets, β-catenin and Snail, and therefore stabilizes these 
two molecules in the nucleus. In human breast cancer cells, canonical Wnt signaling 
activates the EMT by inducing the expression of intracellular protein Axin2 to stabilize 
Snail.129  Therefore, by blocking the activity of GSK-3β, Wnt can stabilize the level of 
Snail and β-catenin to induce EMT and cancer metastasis.  NF-κB pathway regulates 
Snail expression via transcriptional and post-translational mechanisms. NF-κB can also 
bind to the human Snail promoter at the region between −194 and −78 bp to increase the 




phosphorylation of IKKα,130 and this results in the upregulation of Snail. Loss of ERα in 
breast cancer is correlated with poor prognosis, increased recurrence after treatment, and 
an elevated incidence of metastasis. Metastasis-associated protein 3 (MTA3), which is 
directly activated by ERα, is a component of the histone deacetylation Mi-2/NuRD 
complex in breast epithelial cells. This complex is dedicated to gene repression, and one 
direct target is Snail. Therefore, the absence of ERα or of MTA3 results in aberrant 
expression of Snail, and loss of expression of E-cadherin. Activated Snail in turn 
diminishes the ERα activity by transcriptional repression of ERα, thus maintaining the 
cell resistance to tamoxifen.131  ERα also down-regulates Slug transcription by forming a 
co-repressor complex consisting of ligand-activated ERα, HDAC1 and nuclear receptor 
co-repressor (N-CoR) that binds to the estrogen-response elements at the Slug 
promoter.132  This shows that Snail plays a central role in the regulation of EMT (Figure 
9 pg. 109).   
2.7.1 Regulation of Snail Localization and Activity 
Snail activity is mainly regulated through the central part of the protein which 
contains most sites for post-translational modifications: serine phosphorylation sites in 
the SRD, two lysine oxidation sites and the NES for CRM1-dependent nuclear export.133   
Glycogen synthase kinase-3β (GSK-3β) is the major kinase responsible for the 
phosphorylation at the SRD region; 134 thus promoting Snail’s export from the nucleus 
and subsequent degradation by the proteasome in the cytosol.134  GSK-3β negatively 
regulates Snail by phosphorylation of Snail at two consensus motifs resulting in β-TRCP-




degradation.134-135  Phosphorylated Snail interacts with and is degraded by β-Trcp.   
Besides β-TrCP1, FBXL14, an F-box E3 ubiquitin ligase, also interacts with Snail and 
promotes its ubiquitination and proteosomal degradation.136  In addition, lysoyl oxidase-
like 2 (LOXL2) binds to the SNAG domain of Snail and antagonizes the association of 
FBXL14 or β-TrCP1 to Snail, resulting in Snail stabilization.136  The C-terminal zinc 
finger region mediates sequence-specific interactions with DNA. It is also responsible for 
the repressor activity of Snail. PAK1 phosphorylates Snail on Ser 246 to promote Snail’s 
nuclear accumulation and consequently enhances its repressor activity in the nucleus and 
thus its repressor functions.133, 135  Protein kinase D1 (PKD1) phosphorylates Snail on 
Ser11 which leads to its nuclear export via 14-3-3σ binding and thus inhibition of 
EMT.135, 137  Although, it has been reported that the nuclear export of Snail is controlled 
in a phosphorylation-dependent manner, the regulation of its nuclear import is controlled 
by importins. Importin β1 mediates the nuclear import of Snail through direct binding 
with its zinc finger domains.138  More recently, it has been shown that other importin β 
family members, importin-7 and transportin, are also involved in the nuclear transport of 
Snail.139  Another protein involved in the nuclear localization of Snail is LIV-1.  The 
expression of the zinc transporter LIV1, downstream of signal transducer and activator of 
transcription 3 (STAT3), controls the nuclear import of Snail in zebrafish embryos.140 
2.8 Cathepsins 
Cancer invasion requires partial degradation of the extracellular matrix (ECM). 
The ECM is comprised of basement membrane and connective tissue. Partial degradation 




associated with ECM degradation in prostate cancer are MMPs and serine proteinases 
such as urokinase-type plasminogen activator (uPA).  In more recent years, cathepsins 
have been identified as a group of proteins that can breakdown the ECM, among other 
functions. Acidosis of the bone microenvironment results in increased osteoclast 
resorption pit formation with osteoclasts being maximally stimulated at pH levels less 
than 6.9.141  Acidosis alters cellular dynamics at the interface between the tumor and 
normal tissue, promoting apoptosis in adjacent normal cells and facilitating extracellular 
matrix degradation through the release of proteolytic enzymes such as Cathepsin (Cat) B, 
D, and L which degrade the extracellular matrix and facilitate metastasis.141  Cathepsins 
include serine, cysteine, and aspartyl type proteases.   Although MMPs have been 
extensively studied as proteases that degrade the extracellular matrix and contribute to 
tumor invasion, 142 the contribution by cathepsins to prostate cancer progression is not 
well delineated.  Cathepsins are a group of protease enzymes originally discovered in the 
cell lysosome, with several members ubiquitous in the human body.  Cathepsins A, G are 
serine proteases; cathepsins D, E are aspartate proteases; and the remainder are lysosomal 
cysteine proteases, including the human isoforms B, C, F, H, K, L, O, S, V, X and W 143.   
Cathepsins B, F, H and L occur throughout the CNS, while C, S, V and X are expressed 
in specific cell types within the CNS. The pH for optimum cathepsin activity is slightly 
acidic, corresponding to the environment found in the lysosome.  The cysteine cathepsins 
include 11 members (B, C, H, F, K, L, O, S, V, W, and Z).144   Cysteine Cathepsins are 
primarily intracellular proteases that function in terminal protein degradation in 




are primarily intracellular proteases that function in terminal protein degradation in 
lysosomes and protein processing in other intracellular organelles.144  Cysteine cathepsins   
have been shown to have specific roles in bone remodeling and EMT.144  Mature 
osteoclasts secrete proteinases such as Cat K and matrix metalloproteinase (MMP)-9, 
which are needed to degrade the organic matrix of bone in the microenvironment of low 
pH.145  One widely used marker of tumor invasion is the cell adhesion protein E-cadherin, 
which is typically reduced in levels or absent in invasive tumors.146  Gocheva et al have 
identified E-cadherin as a target substrate of Cat B, L, and S, cleaving E-cadherin and 
causing its down regulation.12   Studies have shown that Cat B and L are expressed at 
high levels in tumor tissues compared to normal tissues.147  Cat L is either secreted or 
associated with the plasma membrane  and degrades the extracellular matrix during tumor 
progression.148  Procathepsin L and processed Cat L can degrade laminin and fibronectin 
extracellular matrices,149 while Cat L can also degrade collagen in vitro.150  Cysteine 
Cathepsins have been shown to have specific roles in bone remodeling and EMT.144 
Enhanced levels of secreted cysteine cathepsins can lead to excessive extracellular matrix 
degradation thereby paving the way for cancer cells to escape from the primary tumor 
sites and thus also facilitating extravasation and invasion of distant tissue during 
metastasis. However, several recent studies highlighted an additional unexpected site of 
action for cysteine cathepsins, namely the nucleus. 
2.8.1 Regulation of Cathepsin Activity 
The expression of cysteine proteases are either ubiquitous or tissue and cell 




cathepsins have an acidic pH optimum which allows for full activity within the lysosomal 
compartment.152  Lysosomal cathepsins are synthesized as preproenzymes.  Following 
synthesis, the propeptide is removed during the passage to the endoplasmic reticulum, 
removal of the propeptide can be facilitated either by activation by other proteases such 
as pepsin or cathepsin D, or by autocatalytic activation at acidic pH.143, 152  Procathepsin 
undergoes proteolytic processing to the active, mature enzyme form in the acidic 
environment of late endosomes or lysosomes.153  Limited proteolysis is thus a crucial step 
in controlling the proteolytic activity of lysosomal cysteine proteases and numerous other 
proteases.152  The propeptide, part or all of which is removed during activation, is 
responsible for proper targeting of the enzymes, for the stability and for the proper 
folding of the enzymes, as well as, being able to specifically inhibit the activity of mature 
enzymes.144  Conversion to the mature form occurs intracellularly in lysosomes at pH 
3.0-3.5 by autocatalytic removal of the pro-segment.2  Once activated, lysosomal cysteine 
proteases have enormous disruptive potential, and inappropriate action is controlled by 
their endogenous protein inhibitors, the cystatins.154  On the basis of sequence homology, 
the cystatin superfamily is divided into three subfamilies: stefins, cystatins and 
kininogens.  Stefins are intracellular inhibitors, whereas cystatins and kininogens are 
extracellular inhibitors.155  The cystatin superfamily members bind in a non-substrate-like 
manner, inserting the hairpin loop and the N-terminal trunk region into the protease-
binding cleft.155  Cystatins are reversible, tight‐binding inhibitors against cysteine 
proteases that exert various physiological functions.156 Cystatin family members are 




proteins that are present in most cells (cystatin A and B).157  Type 2 cystatins are secreted 
proteins found in most body fluids (cystatin C, D, E⁄M, F, G, H, S, SA, and SN).157  Type 
3, also referred to as kininogens, are large multifunctional glycoproteins in body fluids 
that work as acute phase proteins.157  Cystatin C, the most abundant type 2 cystatin, 
inhibits cathepsins L and S,  which are involved in antigen processing in antigen‐
presenting cells, resulting in the suppression of MHC class II molecule‐mediated immune 
responses.158   
2.9 Cathepsin L 
The human cathepsin L gene encodes a 333-amino acid cysteine protease that 
contains a 17-amino acid signal peptide, a 96-amino-acid propeptide, and a 220-amino 
acid mature region.154  The 38-kDa procathepsin L is processed to mature, active 
cathepsin L (Cat L), and exists either as a single chain form of 30 kDa or as a two-chain 
form of 25 and 5 kDa.154  Cat L belongs to the cysteine protease class of the papain 
superfamily that is involved in intracellular and extracellular protein degradation 154. The 
intracellular role of Cat L has long been regarded as related exclusively to terminal 
degradation of proteins in the lysosomal compartment given its relatively high abundance 
in lysosomes and its ubiquitous distribution.143  Cat L is synthesized as a preproenzyme 
and targeted to the endoplasmic reticulum for subsequent processing into its active, 
mature enzymatic form in the acidic environment of late endosomes or lysosomes.149 
However, alternative routing has also been reported to account for the specific targeting 
of extracellular procathepsin L.159  A growing amount of evidence supports a direct link 




colorectal cancer.160  It is now well accepted that cysteine proteases such as Cat L 
promote the degradation of basement membranes and extracellular matrix, thereby 
facilitating invasion and metastasis.2  Yang et al, 161 have linked over-expression of Cat L 
to metastasis following ras transformation of NIH/3T3 cells. It has been reported that 
non-metastatic melanoma cells were converted to metastatic cells by over-expression of 
Cat L.161 Elevated expression levels of Cat L have also been reported in kidney and 
testicular tumors, meningiomas, non-small cell carcinomas of the lung and in most 
cancers of the breast, ovary, colon, adrenal, bladder, prostate, and thyroid.159  Gain of Cat 
L activity might be explained on several levels of regulation. First, Cat L mRNA can be 
elevated in tumor cells either by enhanced transcription as observed in ErbB2 positive 
breast cancer 162 or by epigenetic regulation.163  Second, Cat L protein stability and 
activity may be modulated by protein turnover and expression of endogenous cathepsin 
inhibitors.156  Recent evidence has challenged the intracellular lysosome-restricted role of 
this cysteine protease with the demonstration that Cat L may have nuclear functions in 
the regulation of cell cycle progression through its ability to proteolytically process the 
CDP/Cux transcription factor.164  Cat L has also been show to process other nuclear 
proteins such as 53BP1, Histone 1 and 3.  The presence of Cat L in the nuclei of TNBC 
and colon cancer has been associated with poor prognosis.4  These observations suggest 
that nuclear Cat L expression could be an important player in tumor progression. It has 
also been shown that nuclear Cat L activity is responsible for acceleration into the S-
phase of various cancers leading to a poor prognosis.164  A possible group of interaction 




cathepsins such as Cat L from the cytoplasm into the nucleoplasm are the serine 
proteinase inhibitors (serpins).164  These cross-class inhibitors of serine and cysteine 
peptidases are expressed in the cytoplasm, and some serpins can enter the nucleus 
mediated by their nuclear localization sequence (NLS). However, it is unclear as to how 
Cat L is shuttled in and out of the nucleus.   
2.10 CCAAT-Displacement Protein/Cut Homeobox CDP/CUX 
CDP/Cux (CCAAT-displacement protein/Cut homeobox), belongs to a family of 
transcription factors present in all metazoans and is involved in the control of 
proliferation and differentiation.165  CDP/Cux is a complex protein with four 
evolutionarily conserved DNA binding domains, namely, three Cut repeats (CR1, CR2, 
and CR3) and a Cut homeodomain (HD).166  The full-length protein, which we refer to as 
CDP/Cux p200 has been found to act as a tumor suppressor.167  CDP/Cux p200 is subject 
to post translation modifications, such as being proteolytically processed by Cat L 
thereby generating the CDP/Cux p110 isoform that contains three DNA binding domains, 
CR2, CR3, and HD.166  CDP/Cux p110, but not CDP/Cux p200, was capable of 
stimulating expression of Snail by direct binding to the Snail promoter, leading to the 
repression of E cadherin and increased cell migration and invasion.167  Studies have 
confirmed that siRNA-mediated knockdown of CDP/Cux caused a decrease in cell 
migration as measured by video time-lapse microscopy, two-chamber and wound healing 
assays.167  Individual Cut repeats cannot bind to DNA on their own but need to cooperate 
with a second Cut repeat or with the Cut HD.168  Two CDP/Cux DNA binding activities 




domains and carries the CCAAT-displacement activity.168  At the G1-S transition of the 
cell cycle, proteolytic cleavage of p200 by Cathepsin L generates CDP/Cux p110, which 
contains CR2CR3HD and exhibits distinct DNA binding specificity and kinetics.169   In 
particular, p110 is able to make a stable interaction with DNA.  The increase in DNA 
binding involves two regulatory events, a specific proteolytic cleavage and 
dephosphorylation of the Cut homeodomain by the Cdc25A phosphatase, an important 
regulator of the G1/S transition.164, 170  Cdc25A, one of the three members of Cdc25 
homologs in human, is a tyrosine phosphatase and one of its activities is to remove an 
inhibitory phosphate molecule from the G1 cyclin-dependent kinases (CDK).170  Cdc25A 
is also a target of E2F and can cooperate with cyclin E, another target of E2F, to induce S 
phase. As cells progress into S phase, a fraction of CDP/Cux p200 molecules are 
proteolytically processed into an amino-truncated form of 110 kDa, known as CDP/Cux 
p110.170  It is generally assumed that transcriptional activation requires stable DNA 
binding with the promoter. CDP/Cux p200 and CDP/Cux p110 show similar DNA 
binding affinity but very different DNA binding kinetics.164  It is found that CDP/Cux 
p200 only transiently binds to DNA.166, 171  The presence of the N-terminal region in the 
full-length CDP/Cux protein inhibits its DNA binding activity and interferes with its 
transcriptional activation ability. Antibodies recognizing the N-terminal region of 
CDP/Cux p200 can enhance its DNA binding.166  However, p110 has a slow and stable 
interaction with the DNA binding sequence. Importantly CDP/Cux p110, but not 
CDP/Cux p200, is capable of stimulating expression of a reporter containing the 




proteolytic processing of CDP/Cux to generate CDP/Cux p110 is an important 
mechanism for cell cycle regulation.   Apart from CDP/Cux p110, there is another 
isoform, CDP/Cux p75 that is detected in many breast tumor cell lines and breast tumors. 
It was found that its expression was activated in breast tumor cell lines and in primary 
human breast tumors.165  Like CDP/Cux p110, CDP/Cux p75 can localize to the nucleus, 
repress the P21WAF1/CIP1 reporter, and stimulate expression of the DNA polα reporter 
Studies indicated higher expression of p75 in invasive carcinoma is associated with a 
more diffused growth pattern.172  The oncogenic potential of CDP/Cux p75 was further 
studied by Cadieux et al. with p75 transgenic mice. In their experiment, they found that 
transgenic mice overexpressing CDP/Cux p75 developed a myeloproliferative disease-
like myeloid leukemia. Thus, increased p75 expression might play a causative role in the 
neoplastic process.173  Other isoforms of CDP/CUX have been discovered, such as the 
p90, which seems to act cooperatively with the p110 isoform and displays similar DNA-
binding and transcriptional activities.174  The p90 isoform, like p110, was found to be 
generated by proteolytic processing.171, 174-175  The steady-state level of both p90 and 
p110 correlated with the level of cathepsin L activity.174   DNA binding studies using 
recombinant fusion proteins suggested that this CCAAT displacement activity was 
carried out by the combined action of Cut repeats 1 and 2, which exhibit rapid but 
transient binding to DNA sequences containing two half-sites loosely conforming to the 
CGAT or CAAT consensus positioned in either orientation and at various distances from 
each other.168  Apart from this transient DNA binding activity, Cut repeat 3 and the Cut 




the ATCGAT consensus.176  The carboxyl-terminal region of the protein was shown to 
contain two active repression domains that can recruit histone deacetylase activity.176 
Thus, CDP/Cux can repress gene expression by two mechanisms, competition for binding 
site occupancy and active repression.  CDP/Cux was initially identified as a 
transcriptional repressor.177  Overexpression of CDP/Cux revealed that it functions as a 
repressor of these target genes in proliferating precursor cells. In terminally differentiated 
cells, these target genes are induced when CDP/Cux DNA binding activity is down-
regulated.177 The similar effects have been observed in the regulation of the osteocalcin 
gene. Endogenous CDP/Cux complex in osseous cells is proliferation-specific and down-
regulated at the cessation of cell growth.177  It is thus proposed that CDP/Cux functions as 
a transcriptional repressor that inhibits gene expression in terminally differentiated cells. 
The repression of gene expression involves two distinct mechanisms: active repression 
through the recruitment of the histone deacetylase 1; and competition for binding site 
occupancy, probably through its CCAAT displacement activity.178  Targeting this protein 
directly or indirectly maybe important in decreasing tumor progression. 
2.11 Natural Products and Cancer 
Over the years natural products have been shown to have chemopreventive effects 
in various cancers.  Several natural products, such as, grains, nuts, cereals, spices, fruits, 
vegetables, beverages, medicinal plants and herbs and their various phytochemical 
constituents including, phenolics, flavonoids, carotenoids, alkaloids, nitrogen containing 
as well as organosulfur compounds confer protective effects against wide range of 




thousands of years to treat various forms of diseases including cancer. Several studies 
have revealed that natural products exhibit an extensive spectrum of biological activities 
such as, stimulation of the immune system, antibacterial, antiviral, anti-hepatotoxic, anti-
ulcer, anti-inflammatory, antioxidant, anti-mutagenic, and anti-cancer effects.179  A 
variety of grains, cereals, nuts, soy products, olives, beverages such as tea and coffee, and 
spices including turmeric, garlic, ginger, black pepper, cumin and caraway confer a 
protective effect against cancer.180  Several studies have also documented the relationship 
between decreased cancer risk and high consumption of vegetables, including cabbage, 
cauliflower, broccoli, brussels sprout, tomatoes, and fruits such as, apples, grapes, and 
berries.181  In particular, natural products consist of a wide variety of biologically active 
phytochemicals including phenolics, flavonoids, carotenoids, alkaloids and nitrogen 
containing as well as organosulfur compounds, which have been shown to suppress early 
and late stages of carcinogenesis.182   Studies have suggested that the use of a 
combination of natural agents with distinct molecular mechanisms offer an opportunity 
for maximizing chemopreventive effects while minimizing any adverse effects. The soy 
isoflavone, daidzein, has been shown to improve the efficacy of tamoxifen against 
mammary tumors.183 
Phytochemicals are among the most promising chemopreventive and treatment 
options for the management of cancer.184  Studies of grapes and isolated grape 
constituents such as resveratrol, flavonols, catechins, procyanidins, and anthocyanins 
suggest that these natural agents may help to protect against certain cancers, nerve and 




Several in vitro and in vivo studies have demonstrated that grape phytochemicals may be 
involved in a broad spectrum of biological activities related to cancer pathophysiology. 
Most of the grape types contain resveratrol, albeit at varying levels. Although resveratrol 
has been under investigation for several of its beneficial effects for a long time, its cancer 
chemopreventive effects were first shown in 1997 by John Pezzuto's group.185  Quercetin 
(3,3′,4′,5,7-pentahydroxyflavone), is another grape antioxidant that has been extensively 
investigated for its cancer chemopreventive effects.186  Quercetin possesses high free 
radical scavenger ability and has been shown to neutralize highly reactive species such as 
peroxynitrite and the hydroxyl radical.186  Quercetin is a known inhibitor of PI3K, NF-
κB, and several other important targets involved in cell growth and proliferation.186  
Anthocyanins are water-soluble pigments responsible for giving blue, purple, and red 
colors to fruits and vegetables.187  The existence of multiple anthocyanins together in 
dietary sources presents an excellent opportunity for their evaluation as cancer 
chemopreventive or therapeutic agents.18  The most abundant of the naturally occurring 
anthocyanins in grapes are the glycosides of cyanidin, malvidin, and peonidin.187 
Although anthocyanins rich extracts or individual agents have been used in several 
studies, the combination of specific anthocyanins or a combination of specific 
anthocyanin(s) with other grape antioxidants have not been assessed for potential 
chemopreventive effects.18  In a study by Park and colleagues, anthocyanins extracted 
from Korea wild berry Meoru (a wild grape) was found to decrease the expression of 
pGSK3β and β-catenin and increase AMPK activity resulting inhibition of tumorigenic 




cyanidin-3-glucoside has been investigated in combination with trastuzumab (a 
monoclonal antibody that interferes with the human epidermal growth factor receptor 2; 
HER2) in HER2-positive breast cancer cell in vitro (in MDA-MB-453, BT474 and 
HCC1569 cells) and in vivo (in xenograft model), and found to exert synergistic 
antitumor activity.189  These studies and several others where anthocyanins have been 
tested in the form of extract or as bioactive agents suggest that it may be worth assessing 
specific anthocyanin-based combinations in further studies. 
2.11.1 Muscadine Grape Skin Extract  
The muscadine grape possesses one of the highest antioxidant levels among fruits; 
yet, the effect of this fruit on mammalian metabolic systems has not received significant 
attention.14   Muscadine grapes have unique aroma and flavor characteristics. Although a 
few studies reported high polyphenols content of muscadine grapes, little research has 
been conducted to evaluate the phenolic compounds bioactivities in any muscadine 
grape.15  Muscadine Grape Skin Extract (MSKE) derived from the muscadine grape (Vitis 
rotundifolia) differs from the more common red grapes used to produce red wines. Based 
on the skin color muscadine varieties are referred respectively as bronze and purple 
compared to white and red for all other grapes.187  Muscadine grapes are native to 
Southeastern United States and can be found growing wild from Delaware to the Gulf of 
Mexico and westward from Missouri to Texas.13  They come in varieties such as Noble 
(mainly found in Georgia) or Ison (popular in North Carolina); among other types.   In a 
study done by Hudson et al,13 it was determined that the major phytochemical constitute 




phenolic structure of anthocyanins is responsible for their antioxidant activity (ability to 
scavenge ROS).13  Unlike other grape varieties, the phytochemical constituents of 
muscadine grapes have a higher concentration of anthocyanin 3,5-diglucosides, ellagic 
acid, and ellagic acid precursors.190  In the case of purple skinned muscadine grapes, the 
anthocyanins are primarily delphinidin-3,5-diglucoside; cyanidin-3,5-diglucoside; and 
petunidin-3,5-diglucoside.190  Anthocyanin 3,5 diglucosides are known to inhibit invasion 
in human hepatoma cells,17 and induce apoptosis and inhibit invasion in colorectal cancer 
cells.18  MSKE has been shown to decrease tumor incidence, promote growth inhibition 
and stimulate cell death in various human cancer cell lines.6  It can also revert the 
epithelial mesenchymal transition process.191  MSKE has been shown to induce apoptosis 
and reduce cell proliferation in prostate cancer cells but not normal cells, by antagonizing 
ERK and PI3K signaling.13  As of now, muscadine grape skin extract is in Phase II 






MATERIALS AND METHODS 
 
3.1 Cell Culture, Antibodies and Reagents 
The human breast cancer cells lines, MCF-7, MDA-MB-231, MDA-MB-468, 
were obtained from ATCC, Manassas, VA. The prostate cancer cell lines ARCaP-
epithelial (ARCAP E) and ARCaP-mesenchymal (ARCaP M) that represent an EMT 
model and C4-2 cells were a kind gift from Dr. Leland Chung, Cedars-Sinai Medical 
Center, Los Angeles, CA. The MCF-7 and ARCaP E cells stably transfected with empty 
Neo vector (MCF-7 Neo, ARCaP-Neo) and or constitutively active Snail (MCF-7 Snail, 
ARCaP-Snail) used for most of these studies represent an EMT model and were 
generated previously. 134  Cells were grown in RPMI or DMEM medium (VWR Int., 
West Chester, PA) supplemented with 10% fetal bovine serum (FBS, Hyclone, South 
Logan, UT) and 1% penicillin/streptomycin (VWR Int., West Chester, PA), at 37°C with 
5% CO2 in a humidified incubator. Charcoal/dextran treated FBS (DCC-FBS) was from 
Hyclone, South Logan, UT. Anti-mouse α-tubulin antibody was from Sigma–Aldrich, St 
Louis, MO.  Rat monoclonal anti-Snail and horseradish peroxidase (HRP)-conjugated 
goat anti-rat antibodies were from Cell Signaling Technology, Danvers, MA.  Goat 
monoclonal anti-Cat L antibody and Cat L-specific inhibitor (Z-FY-CHO) were 




goat was purchased from Santa Cruz Biotechnology (Santa Cruz, CA).  HRP-conjugated 
sheep anti-mouse and sheep anti-rabbit secondary antibodies were purchased from 
Amersham Biosciences, Buckinghamshire, UK. Luminata Forte HRP chemiluminescence 
detection reagent was purchased from EMD Millipore (Billerica, MA). The protease 
inhibitor cocktail was from Roche Molecular Biochemicals, Indianapolis, IN.  
Dihydroethidium bromide (DHE) and Mitosox staining kit were obtained from 
Invitrogen, Carlsbad, CA. Hydro-Cy3 dye was kindly provided by Dr Niren Murthy, 
Georgia Institute of Technology, Atlanta, GA. 
3.2 Animal Experiments 
This study was carried out in strict accordance with the recommendations in the 
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. 
All of the animal procedures were approved and performed in accordance with 
Morehouse School of Medicine IACUC guidelines. Four-week-old male athymic nu/nu 
mice (National Cancer Institute) were injected subcutaneously with 2 x 106 cells per 
mouse of Neo or Snail-overexpressing LNCaP cells mixed 1:1 volume with matrigel (BD 
Biosciences). There were 6 mice in each group. The mice were sacrificed after 5 weeks 
by carbon dioxide overdose followed by cervical dislocation, the tumors excised and 
tumor volume measured with a caliper (tumor volume was calculated as 3.14 / 6 x largest 
diameter x smallest diameter squared). The tumors were used for immunofluorescence.  
3.3 short Interfering RNA Transfection  
Transient transfections were performed with 50 nM of non-silencing ON-




005841-00); ON-TARGET plus importin-B1; ON-TARGET CUX1 siRNA Thermo 
Scientific - Dharmacon, Lafayette, CO) as per the manufacturer's instructions. Briefly, 
cells were seeded overnight in 6-well dishes then incubated with either non-silencing 
control or siRNA (50 nM) in phenol-free RPMI without FBS or antibiotics for 5 h; 
subsequently the media were replaced with 5% DCC phenol-free RPMI for an additional 
72 h. Lysates from whole cell, nuclear and cytoplasmic extracts were harvested and 
quantitated for respective experiments. 
3.4 Western Blot Analysis 
Cells were lysed in a modified RIPA buffer.193  Supernatants were collected and 
quantified using a micro BCA assay (Promega, Madison, WI). 30-40 µg of cell lysate 
was resolved using 10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis, 
followed by trans-blotting onto nitrocellulose membrane (Bio-Rad Laboratories, 
Hercules, CA). Membranes were incubated with appropriate primary and secondary 
antibody, followed by visualization using Luminata Forte ECL reagent. The membranes 
were stripped using Restore western blot stripping buffer (Pierce Biotechnology, 
Rockford, IL) prior to reprobing with a different antibody.  
3.5 Immunohistochemistry  
Prostate and breast tumors with  matched normal tissues were obtained from the 
following sources- a) Protein biotechnologies, Ramona, CA; b) US Biomax, Inc. 
(PR956a, Rockville, MD). Protein Biotechnologies Inc. provides pharmaceutical, 
biotechnology, government, and academic institutions with human clinical specimen 




centers that employ IRB approved protocols and strict ethical guidelines to ensure patient 
confidentiality and safety. Identical procedures are used to prepare all patient samples. 
Specimens are flash frozen to -120 °C within 5 min of removal to minimize autolysis, 
oxidation, and protein degradation. Tissue specimens are homogenized in modified RIPA 
buffer (PBS, pH 7.4, 1 mM EDTA, and protease inhibitors) to obtain the soluble proteins, 
and centrifuged to clarify.  Examination of the expression and distribution of Cat L in 
human prostate and breast cancer tissue was performed by immunohistochemistry (IHC) 
using tissue microarray from US biomax.  IHC was performed using the Avidin-biotin 
immunohistochemical method. The microarray was deparaffinised in xylene and 
rehydrated using alcohol. Endogenous peroxidase activity was blocked by 3% hydrogen 
peroxide. After antigen retrieval, sections were incubated with 10% serum to avoid the 
non-specific binding. Sections were incubated with 1:200 primary antibody against Cat L 
or Snail at 4°C overnight followed by biotinylated secondary antibody, and incubation 
with avidin-biotin complex (Vector, Burlingame, CA). Immunoreactivity was visualized 
using diaminobenzidine (Sigma-Aldrich, St. Louis, MO, USA). The slide was 
subsequently counterstained with hematoxylin and mounted with xylene solution.  
Images were acquired using the Axiovision Rel 4.8.   
3.6 Immunocytochemistry  
The tumor xenograft sections were deparaffinized with  xylene, dehydrated with 
alcohol series from 100% ethanol to 50% ethanol, antigens were retrieved at 125°C for 
30 seconds, peroxidases were blocked using 0.03% hydrogen peroxide, and blocked 




Vimentin anti-mouse, and Cat L anti-goat) were added to the slide and incubated 
overnight at 4°C. After washing with 1X Tris Buffered Saline-Tween (TBS-T), 
secondary antibodies anti-rabbit Oregon green 488 (Invitrogen, Carlsbad, CA) and anti-
goat Texas red (Vector Laboratories, Burlingame, CA) were added and incubated for 30 
minutes in darkness. The slide was washed with 1X TBS-T, counterstained with DAPI to 
detect nuclei, washed briefly with double deionized water, and mounted using Fluorogel 
mounting medium (Electron Microscopy Sciences, Hatfield, PA). Fluorescence 
microscopy was performed using Zeiss (Axiovision Rel 4.8) and Apotome software. 
5×103 cells were plated into 16 well chamber slides (Bio-Tek, Nunc, Winooski, VT). For 
treatments, cells were either untreated, treated with 5 or 20 µm Z-FY-CHO or 5 or 
20ug/mL MSKE for 3 days. Fixation was performed with methanol/ethanol 1∶1 volume 
for 5 min, followed by washes with 1× PBS and blocking with protein blocking solution 
without serum (Dako, Camarillo, CA) for 10 min at room temp. Subsequently, slides 
were incubated with primary antibody at 1∶50 or 1∶100 dilutions in Dako antibody diluent 
solution for 1 h at room temp. Slides were washed with 1× TBS-T (Dako, Camarillo, 
CA), then incubated with secondary antibody in the dark for 1 h at room temp. Secondary 
antibodies used were anti-rabbit Oregon green 488, anti-mouse Alexa red 594 
(Invitrogen, Carlsbad, CA) or anti-goat Texas red (Vector Laboratories, Burlingame, 
CA). Slides were washed with 1× TBS-T and double deionized water, prior to 




were mounted using Fluorogel mounting medium (Electron Microscopy Sciences, 
Hatfield, PA). 
3.7 In vitro Cell Migration Assay 
We utilized Costar 24-well plates containing a polycarbonate filter insert with an 
8-μm pore size, to coat with 4.46 μg/μl rat tail collagen I on the outside for 24 h at 4oC.  
5x104 cells were plated in the upper chamber containing RPMI supplemented with 0.1% 
fetal bovine serum (FBS) while the lower chamber contained RPMI supplemented with 
10% FBS.  After 5 h, cells that migrated to the bottom of the insert were fixed, stained 
with 0.05% crystal violet, and counted to obtain the relative cell migration. 
3.8 In vitro Cell Invasion Assay 
The invasive properties of the cell lines were measured using the BD BioCoat 
Matrigel Invasion guidelines.  Briefly, Boyden chamber inserts (Thermo Fisher 
Scientific, Waltham, MA, USA) were coated with 40 μl of 1:4 matrigel and allowed to 
solidify at 37°C for 1 h. 5×104 cells were seeded in triplicate in 0.1% FBS, while the 
lower chamber contained 10% FBS.  Cells were allowed to invade through the porous 
membrane coated with Matrigel at 37°C for 24–72 h.  Inserts were fixed, stained with 
0.05% crystal violet.  Cell counts were performed for the determination of relative cell 
invasion. 
3.9 Subcellular Fractionation 
Subcellular fractionations were performed per the manufacturer's instructions 
(Thermo Scientific, city state). Briefly, cells at 80–90% confluence were lysed in a series 




NER (100 µl). Centrifugation steps were performed to obtain a non-nuclear fraction and 
an intact nuclear pellet, followed by further lysing to isolate the nuclear fraction. 30 µg of 
non-nuclear and nuclear fractions were utilized for Western blot analysis. Mouse anti-
topoisomerase I (Santa Cruz Biotechnology Santa Cruz, CA) and rabbit anti-GAPDH 
antibodies (Cell Signaling Technology, Inc., Danvers, MA) were used to ensure the 
integrity of nuclear and non-nuclear fractions, respectively. 
3.10 In vitro Osteoclastogenesis Assay 
3X103 ARCaP-Neo/ MCF-7 Neo or ARCaP-Snail/ MCF-7 Snail was co-cultured 
with 40X104 spleen macrophages in 48-well plates plus 1 ng/ml M-CSF plus or minus 5 
μg/mL MSKE, 20μg/mL MSKE or 5μM Z-FY-CHO Cat L inhibitor.  The cells were fed 
every three days by replacing half the media with fresh media plus or minus MSKE or Z-
FY-CHO.  Macrophages alone were utilized as a negative control. After 7-14 days the 
cells were fixed with 3% formaldehyde and processed for TRAP staining according to 
manufacturer instructions, to visualize the formation of mature osteoclasts.  
3.11 Real Time (RT)-PCR 
Total RNA was isolated by using an RNeasy Mini Kit (Qiagen, Valencia, CA). 
Gene expression was defined as the threshold cycle number (CT). Mean fold change in 
expression of the target genes were calculated using the comparative CT method (RU; 2
-
ΔCt). All data were normalized to the quantity of RNA input by Glyceraldehyde 3-





3’);Snail(Forward 5’GCACTGGTACTTCTTCTTGACATCT-3’ ; Reverse 5’-
GGCTGCTACAAGGCCAT-3’) 
3.12 Gel-free Isobaric Labeling Tandem Mass Tag Quantitative Proteomic Profiling 
3.12.1 Cell Lysis and Protein Extraction 
Cells were plated on 150 cm2 culture plates at a cell density of 5 × 106 and treated 
the following day with 20 µg/ml MSKE for 72 h. Cells treated with 0.1% ethanol were 
used as controls. Proteins were extracted with RIPA buffer (1.5 M Tris pH 8.8, 1.75 g 
NaCl, 2 mL sodium dodecyl sulfate 10%, 2 mL Triton X-100; all reagents from Thermo 
Fisher Scientific, Waltham, MA). The cells were incubated on ice for 30 min, followed 
by 5 min sonication and centrifugation at 20,000 rpm for 5 min in preparation for protein 
extraction. Protein concentration was calculated on microtiter plates by measuring the 
absorbance at 595 nm of samples containing a commercial protein assay (Bio-Rad 
Laboratories, Hercules, CA) supplemented with 10 µL of phosphatase inhibitor cocktail 
and 10 µL of protease inhibitor cocktail (Roche Molecular Biochemicals, Indianapolis, 
IN). 
3.12.2 Reduction, Alkylation, and Trypsin Digestion 
Aliquots with 100 mg of proteins from each sample were added to 100 ml of 200 
mM triethyl ammonium bicarbonate TEAB (Sigma-Aldrich, St. Louis, MO). Reduction 
was performed by adding 5 ml of 200 mM tris (2-carboxyethyl) phosphine TCEP 
(Sigma-Aldrich, St. Louis, MO) to each replicate and incubating for 1 h at 55°C. 
Alkylation was carried out by adding 5 ml of 375 mM iodoacetamide (Bio-Rad 




temperature. After alkylation, 1 ml of pre-chilled acetone was added and precipitation 
was allowed to proceed for 3 h at 20°C. Acetone-precipitated protein pellets were 
suspended in 100 ml of 200 mM TEAB and digested overnight at 37°C with 2.5 µg of 
sequencing grade modified trypsin (Promega Corp., Madison, WI) as previously 
described.194 
3.12.3 Isobaric Labeling with Tandem Mass Tag 
Tandem mass tag (TMT) with varying molecular weights (126 ~ 131)  (Thermo 
Scientific, Waltham, MA) were applied as isobaric labels for the comparison of 
differential protein expression between C4-2 cells treated with ethanol (0.1%) and C4-2 
treated with 20 µg/ml MSKE. Six digested samples were individually labeled with TMT6 
reagents according to the manufacturer’s protocols. Three control (ethanol-treated) 
samples: TMT-126 (batch 1), TMT-127 (batch 2), and TMT-128 (batch3); and three 
MSKE-treated samples: TMT-129 (batch 1), TMT-130 (batch 2), and TMT-131 (batch3) 
were used in the studies. The labeled peptide mixtures were combined at equal ratios. 
3.12.4 Fractionation of Labeled Peptide Mixture by using a Strong Cation Exchange 
Column 
The TMT-labeled peptide mixture was fractionated with a strong cation exchange 
SCX column (Thermo Fisher Scientific, Waltham, MA) on a Shimadzu 2010 high 
performance liquid chromatography (HPLC) equipped with an ultraviolet detector 
(Shimadzu, Columbia, MD) and a mobile phase consisting of buffer A (5 mM KH2PO4, 
25% acetonitrile, pH 2.8) and buffer B (buffer A plus 350 mM KCl). The column was 




a flow rate of 1.0 ml/min was set as follows: 1) 0 ~ 10 min: 0% buffer B; 2) 10 ~ 40 min: 
0 ~ 25% buffer B; 3) 40 ~ 45 min: 25 ~ 100% buffer B; 4) 45 ~ 50 min: 100% buffer B; 
5) 50 ~ 60 min: 100 ~ 0% buffer B; and 6) 60 ~ 90 min: 0% buffer B. Sixty fractions 
were initially collected, lyophilized, and combined into 14 final fractions based on SCX 
chromatogram peaks. 
3.12.5 Desalination of Fractionated Samples 
A C18 solid phase extraction SPE column (Thermo Fisher Scientific, Waltham, 
MA) was used to desalt all collected fractions as previously described 195. Briefly, the 14 
combined fractions were each adjusted to a final volume of 1 ml in a 0.25% 
trifluoroacetic acid TFA aqueous solution. The C18 SPE column was preconditioned with 
1 ml acetonitrile and eluted in approximately 3 min before it was rinsed with 3 × 1 ml 
0.25% TFA. The fractions were loaded on to the top of the SPE cartridge column slowly, 
and were reloaded once again to decrease lost peptide during column binding. Columns 
were washed with 4 × 1 ml 0.25% TFA aliquots before the peptides were eluted with 3 × 
400 µl 80% acetonitrile/0.1% formic acid (aqueous). The eluted samples were lyophilized 
prior to the liquid chromatography mass spectrometry LC-MS/MS analysis. 
3.12.6 LC-MS/MS Analysis  
Peptides were analyzed on an LTQ-Orbitrap XL (Thermo Fisher Scientific, 
Waltham, MA) instrument interfaced with an Ultimate 3000 Dionex LC system (Dionex, 
Sunnyvale, CA). High mass resolution was utilized for peptide identification and high-
energy collision dissociation (HCD) was used for reporter ion quantification as 




Trap cartridge (0.5 × 2 mm) (Michrom BioResources, Auburn, CA) and a pre-packed 
BioBasic C18 PicoFrit analytical column (75 µm. × 15 cm length, New Objective, 
Woburn, MA) fitted with a FortisTip emitter tip. Samples were loaded onto the trap 
cartridge and washed with mobile phase A (98% H2O, 2% acetonitrile, and 0.1% formic 
acid) for concentration and desalting. Peptides were eluted over 180 min from the 
analytical column via the trap cartridge by using a linear gradient of 6 to 100% mobile 
phase B (20% H2O, 80% acetonitrile, and 0.1% formic acid) at a flow rate of 0.3 µl/min.   
The Orbitrap mass spectrometer was operated in a data-dependent mode in which each 
full MS scan (60,000 resolving power) was followed by six MS/MS scans where the 
three most abundant molecular ions were dynamically selected and fragmented by 
collision-induced dissociation with a normalized collision energy of 35% and 
subsequently scanned by HCD-MS2 with a collision energy of 45% as previously 
described 195. Only the 2+, 3+, and 4+ ions were selected for fragmentation by collision-
induced dissociation and HCD. 
3.12.7 Database Search and TMT Quantification 
The protein search algorithm SEQUEST was used to identify unique protein 
peptides using the Proteome Discoverer data processing software (version 1.2, Thermo 
Fisher Scientific, Waltham, MA). The ratios of TMT reporter ion abundances in MS/MS 
spectra generated by HCD from raw data sets were used For TMT quantification. Fold 






3.13 Analysis of Autophagy 
Acridine Orange (AO) was used to analyze autophagy. Briefly, 5 × 103 cells were 
plated into Nunc 8-well chamber slides (Bio-Tek Instruments, Winooski, VT). Cells were 
serum-starved for 4 h and treated with increasing concentrations (0 µg/mL, 5 µg/mL, 10 
µg/mL or 20 µg/mL) of MSKE for 72 h.  Fixation was performed with methanol/ethanol 
(1 1 volume) for 5 min, followed by washes with 1 × PBS. Cells were exposed to 5 μg/ml 
AO for 15 min at 37°C, washed with 1 × PBS, and counterstained with 1 µg/ml DAPI 
(Santa Cruz Biotechnology, Santa Cruz, CA) before they were fixed with Fluorogel 
mounting medium (Electron Microscopy Sciences, Hatfield, PA). Co-treatments with the 
autophagy inhibitor (20 µM chloroquine) for 72 h was also performed. Fluorescence 
microscopy was performed at 40 × oil magnification on a Zeiss fluorescence microscope 
equipped with the AxioVision (release 4.8) imaging software and the ApoTome.2 optical 
sections system (Carl Zeiss Microscopy GmbH, Jenna, Germany).  
3.14 TUNEL Assay 
The terminal deoxynucleotidyl transferase (TdT) dUTP nick-end labeling 
(TUNEL) assay was used to detect apoptosis.  Briefly, 5 × 103 cells were plated into 16-
well Nunc chamber slides (Bio-Tek, Winooski, VT). Cells were serum starved for 4 h 
and treated with increasing concentrations of MSKE (0 µg/mL, 5 µg/mL, 10 µg/mL or 20 
µg/mL) for 72 h.  The cells were fixed with 4% paraformaldehyde and permeabilized 
with 0.1% sodium citrate and 0.1% Triton X-100. DNA fragmentation was determined by 
TUNEL according to the manufacturer’s instructions (Roche Applied Science, Penzberg, 




Cruz, CA). Slides were mounted with Fluorogel mounting medium (Electron Microscopy 
Sciences, Hatfield, PA) and visualized under 40 × oil magnification on a Zeiss 
fluorescence microscope equipped with the AxioVision (release 4.8) imaging software 
and the ApoTome.2 optical sections system (Carl Zeiss Microscopy GmbH, Jenna, 
Germany). 
3.15 Annexin V/Cell Death Apoptosis Kit 
 
Annexin V was also used to detect apoptosis.  Briefly C4-2 Cells were serum 
starved for 4 h and treated with different concentrations of MSKE (0 µg/mL, 5 µg/mL,) 
for 72 h, with or without 20 µM chloroquine.  Apoptosis was assessed by Alexa Fluor 
488 Annexin V and propidium iodide double staining and flow cytometry was performed 
using AccuriR C6 Flow Cytometer (Accuri Cytometers Inc., Ann Arbor, MI.) according 
to the manufacturer instructions. Cells that stained positive for Annexin V- Alexa Fluor 
488 and negative for PI (Alexa Fluor 488+/PI-) were considered to be undergoing early 
apoptosis; Alexa Fluor 488+/PI+ were considered as late apoptosis; Alexa Fluor 488-/PI- 
considered non-apoptotic (viable). Experiments were performed in triplicate in two 
independent experiments, and a representative result displayed in the form of early/late 
apoptosis graphs.  
3.16 Zymography 
We utilized the cathepsin zymograpy technique as previously described (27).  
Briefly, 1 mL of conditioned media (CM) containing 0.1 mM leupeptin was concentrated 
utilizing vivaspin tube (GE Health Care Piscataway, NJ). The concentrated CM was 




determination of the protein concentration using BCA protein assay kit.  Gelatin (Scholar 
Chemistry, Rochester, NY) (0.2%) was utilized as the zymography substrate and CM was 
electrophoresed followed by incubation in cathepsin renaturing buffer (65 mM Tris 
buffer, pH 7.4 with 20% glycerol), overnight incubation in pH 6 sodium phosphate assay 
buffer (0.1 M sodium phosphate buffer, 1 mM EDTA, 2 mM DTT) at 37°C.  The gel was 
stained with Coomassie blue stain (10% acetic acid, 25% isopropanol, 4.5% Coomassie 
Blue), destained (10% isopropanol and 10% acetic acid) and proteolytic activity 
visualized as cleared bands.  Cathepsin activity was subsequently quantified by 
densitometry using NIH Image J software. 
3.17 Chromatin Immunoprecipitation (ChIP) Assay 
ChIP analysis was performed using the EZ-ChIP kit according to manufacturer’s 
instructions (EMD Millipore). Briefly, 2.5 × 106 cells were cross-linked with 
formaldehyde for 10 min at 37°C, washed in ice cold PBS, unreacted formaldehyde was 
quenched with glycine, then washed with PBS and re-suspended in SDS buffer. Samples 
were sonicated to approximately 600 bps with Sonicator (Misonix Sonicator S-3000), 
diluted in dilution buffer with inhibitors and precleared with agarose G beads. The 
supernatant was used directly in immunoprecipitation with anti-CDP/Cux, goat-IgG (for 
negative control) or RNA polymerase II (for positive control). The immunocomplexes 
were mixed with 120 μl of DNA coated agarose G beads followed by incubation 
overnight. Pellets were washed in a low salt wash buffer (x1), high salt wash buffer (x1), 
LiCl wash buffer (x1) and TE buffer (x2). This was followed by elution of the 




protein was then digested with proteinase K followed by DNA purification with elution 
buffer and.  2 μl of the DNA eluates from the ChIP assay were added into a 96 well 
QPCR plate for each corresponding sample. Subsequently, a master mix was made using 
promoter primers to Snail or E-cadherin that have been previously published as CDP/Cux 
binding regions.196  QRT-PCR was then done using an I-cycler (Bio-Rad) to quantitate 
transcript levels by the SYBR Green method. Cycle threshold differences were then 
determined using an I-cycler (Bio-Rad) relative to input chromatin (chromatin initially 
used for the immunoprecipitation). Fold changes in transcript levels of Snail and E-
Cadherin gene were then calculated in samples immunoprecipitated with either anti-RNA 
polymerase II antibody (positive control), goat IgG (negative control), or CDP/Cux 
antibody. The results were graphed. Samples were also resolved on an agarose gel. As 
another control, PCR was performed with primers for Snail control (region previously 
published where CDP/Cux does not bind to the Snail promoter).   The following specific 
primer pairs specific for each promoter.  Snail Promoter (Forward 5’ 
CAGTTGCCACTTCTTCCCTCG-3’; Reverse 5’CACCCGTTCCTTCCCTTATCC-3’) 
E-cadherin Promoter (Forward 5’-CGAACCCAGTGGAATCAGAA-3’; Reverse 5’-
GCGGGCTGGAGTCTGAACTG-3’) Snail Control (Forward 5’-
CGGCACCAAGTGACTAAACAGAC-3’; Reverse 5’-
AGCCTGGCGGGAGAAAGAAG-3’).  
3.18 In vitro Measurement of Superoxide with Dihydroethidium (DHE) 
For in vitro experiments, 70% confluent cells were washed with PBS followed by 




cells resuspended in 500 L of HANKS with 5 % FBS. 10 M DHE was added to cells, 
followed by incubation for 30 min while gently rocking in the dark. 20,000 cells were 
gated and analyzed by Fluorescence Activated Cell Sorting (FACS). 
3.19 In vitro Measurement of Superoxide with HydroCy3 
20,000 cells were plated in RPMI without antibiotics in a 6-well plate. The cells 
were then placed overnight in 37oC with 5% CO2 in a humidified incubator. The next day 
cells were serum starved in RPMI without L-glutamine and phenol red for three hours 
followed by replacement of media with PBS/HEPES buffer plus 25 M Hydro-Cy3 for 
15 min at 37oC, and subsequent imaging with a fluorescence microscope. To measure 
superoxide in cell lysate, 100 l whole cell lysates prepared from untreated or treated 
cells was mixed with HEPES/PBS buffer and 25 M of HydroCy3 for 1 h followed by 
OD measurement at 530/590 nm. Protein concentration was assayed with BCA reagent in 
whole cell lysates to be used to normalize OD readings. 
3.20 Mitosox Staining 
5,000 cells were plated overnight in RPMI supplemented with 10% fetal bovine 
serum and 1X penicillin-streptomycin in 16-well chamber slides. The MitoSOX staining 
was performed as per manufacturer protocol. Briefly, 1 mL of MitoSOX reagent 
was added to the cells, covered with foil and placed at 37oC with 5% CO2 in a humidified 
incubator for 10 minutes. The cells were then washed three times with warm 
HBS/CA/Mg buffer. Cells were counter-stained with DAPI to view the nucleus and 





3.21 Statistical Analysis 
Data were analyzed by a paired student's t-test or ANOVA using GraphPad Prism 
software. For all experiments * means 0.05 > p value > 0.01, ** means 0.01 > p value > 






4.1 Proteomic Analysis of MSKE in C4-2 Cells 
4.1.1 Proteomic Profiling of C4-2 Cells Treated with MSKE with a Gel-Free 
Isobaric Labeling TMT Quantitative Proteomic Approach 
The differential expression of proteins between untreated (0.1% ethanol) and 
treated (20 µg/ml MSKE) C4-2 cells was determined based on a gel-free isobaric labeling 
TMT quantitative proteomic approach for further validation and identification of novel 
proteins. Over 1,855 proteins were identified from control and treated C4-2 cell lysates. 
Among them, 465 significantly differentially expressed proteins contained TMT signals 
that were used to determine protein expression ratios between treated and control C4-2 
cells. The detailed information including protein ID, gene name, and number of amino 
acids, molecular weight, calculated pI, description, coverage samples, protein expression, 
change folds, and p-values.  Proteins that had a fold change of at least 1.2 and p-values ≤ 
0.05 were closely examined.  MSKE-treated C4-2 cells expressed 254 up-regulated and 
211 down-regulated proteins when compared to C4-2 control cells.   Among the proteins 
that were differentially expressed, ER stress markers, such as 78 kDa glucose-regulated 
protein (GRP78) and protein disulfide isomerase A4 and A6 (PDIA4, PDIA6), as well as 




were up-regulated.  Additional ER stress-related proteins identified among the up-
regulations are eukaryotic translation initiation factor 2B (eIF2B) and eukaryotic 
translation initiation factor 4 binding protein (eIF4EBP1) with a respective significant 
fold change of 1.5 and 1.3 and the protein disulfide isomerase (PDI) A4 and A6 with a 
differential expression of1.21 and 1.26 respectively. Key differentially expressed proteins 
induced by MSKE in C4-2 cells included those associated with apoptosis (e.g., STEAP2, 
PDCD6, MTDH, RAB5B, cytochrome c oxidase), autophagy (e.g., ACIN1, PI4KA, 
PGK2, MTDH), cytoskeleton and protein transport (e.g., cortactin, taxilin, radixin, 
filamin B), among others (Table 4 pg. 159). Furthermore, C4-2 control cells had a higher 
percent of anti-apoptotic proteins compared to the MSKE-treated cells, suggesting that 
MSKE induces an ER stress/autophagy/apoptosis signature (Figure 10 pg. 110). 
4.1.2 MSKE Induces Expression of ER Stress Mediated Pro-apoptotic Response 
Proteins 
Western blot was used to measure the expression of proteins associated with ER 
stress response. Key ER stress response markers IRE-1 alpha and GRP78 (Figure 11 pg. 
111) were up-regulated when compared to control cells. Apoptotic markers PARP, 
caspase-12 and DFF45 (Figure 11 pg. 111) were up-regulated in cells exposed to MSKE. 
These data suggest that MSKE may induce ER stress and UPR-mediated apoptosis 
(Figure 11 pg.111).  
4.1.3 MSKE Treatment Induces Autophagy 
Since MSKE induced expression of ER stress response proteins, we sought to 




or 20 µg/ml MSKE for 72 h and stained with acridine orange. Treatment with higher 
concentrations of MSKE (10 and 20 µg/mL) showed extensive acridine orange leakage 
into the cytosol (orange staining), indicating that MSKE induces autophagy (Figure 12 A 
pg. 112).  Since the 20 µg/mL MSKE treatment showed extensive acridine orange 
staining we decided to see if co-treatment with chloroquine, a known autophagy inhibitor 
would reverse the effects of MSKE on C4-2 cells. Co-treatment with 20 µg/mL MSKE 
and 20 µM chloroquine lead to a decrease in acridine orange staining compared to 20 
µg/mL MSKE alone, indicating that MSKE may promote autophagy (Figure 12 B pg. 
112). To further validate a role for MSKE in autophagy, we also performed 
immunofluorescence and western blot with the autophagic marker, LC3B. There was 
increased punctate staining for LC3B in MSKE plus chloroquine co-treatments, which 
indicates that chloroquine prevents fusion of autophagosomes to lysosomes, and thus 
causes an accumulation of autophagosomes (Figure 12 C pg. 112). Similarly, western 
blot analysis showed increased LC3BII expression in MSKE plus chloroquine treatments 
indicating that chloroquine had inhibited MSKE-mediated autophagy and caused 
accumulation of LC3BII lipidation products (Figure 12 D pg. 112). Of note, we did not 
observe increased LC3BII with MSKE treatment alone (Figure 12 D pg. 112), possibly 
due to high autophagic flux that can sometimes not be detected unless one includes an 
autophagy inhibitor as previously reported.208. 
4.1.4 MSKE Promotes Apoptosis 
To confirm that MSKE causes apoptosis, we treated the C4-2 cells with 5, 10, or 




observed with higher doses of MSKE (Figure 13 A pg. 114).  These findings correlate 
with the Western blot analysis where up-regulation of pro-apoptotic markers PARP and 
caspase-12 was observed (Figure 13 C). These results support the hypothesis that MSKE 
induces apoptosis in C4-2 prostate cancer cells.   To support the findings in the TUNEL 
assay and show that there was a correlation between autophagy and apoptosis, we 
performed quantitative apoptosis assay using flow cytometry via the Alexa Fluor 488 
Annexin V in the presence or absence of chloroquine (autophagy inhibitor). Graphical 
representation of the apoptosis assay showed that treatment with MSKE led to an 
increase of apoptosis which was abrogated by treatment with chloroquine (Figure 13 B 
pg. 114).   Western blot analysis confirmed these findings by showing that MSKE-
mediated increase in pro-apoptotic proteins BAX, cleaved caspase-3 and -7, and decrease 
in anti-apoptotic protein BCL2 was abrogated by co-treatment with chloroquine (Figure 
13 C pg. 114).  Therefore, MSKE-mediated autophagy leads to apoptosis. 
4.2 Muscadine Grape Skin Extract Reverts Snail-Mediated Epithelial Mesenchymal 
Transition via Superoxide Species in Human Prostate Cancer Cells 
 4.2.1 Mitochondria is the Source of Superoxide Species in ARCaP Cells Transfected 
with Snail 
Hydrogen peroxide ROS-Snail signaling has been implicated with breast 
cancer,197 while prostate cancer cells have been shown to spontaneously produce 
hydrogen peroxide.198  We have previously shown that Snail upregulates superoxide 
species in ARCaP cells in vitro and in vivo.199  We sought to confirm this and elucidate 




cells transfected stably with Snail that displayed increased Snail expression as compared 
to Neo control cells (Figure 15 A pg. 117). We treated live ARCaP-Neo and -Snail cells 
with phorbol myristate-12 13-acetate (PMA) to induce superoxide, and stained with 
Hydro-Cy3, a novel hydrocyanine (Hydro-Cy) dye, which can detect superoxide and 
hydroxyl radical and is supposed to be more stable than the DHE stain, and imaged the 
staining (red). We found that PMA induced superoxide, while less staining was observed 
when SOD antagonist was added (Figure 15 B pg. 117). More importantly, it appeared as 
if the ARCaP-Snail cells displayed higher staining for superoxide species as compared to 
ARCaP-Neo (Figure 15 B pg. 117). These results were also confirmed by using 
dihydroethidium (DHE) staining which revealed elevated levels of superoxide in 
ARCaPE cells transfected with Snail (ARCaP-Snail low, −Snail high) in vitro as 
compared to the control (ARCaP-Neo) (Figure 15 C pg. 117). We assayed for the source 
of increased superoxide species in response to Snail transfection by staining with Mitosox 
dye that detects mitochondrial superoxide. As shown in Figure 15D (pg. 117), there was a 
prominent increase in staining in the Snail-transfected ARCaP cells. Therefore, Snail is 
associated with increased levels of mitochondrial superoxide in vitro in ARCaP prostate 
cancer cells. 
4.2.2 Snail Increases Superoxide Levels in LNCaP Cells 
Next we examined whether Snail can increase ROS in an androgen-dependent 
LNCaP prostate cancer cell line in order to compare the results obtained from Snail 
overexpression in androgen-independent ARCaP prostate cancer cells. We utilized 




We verified Snail expression by Western blot analysis in the Snail-transfected cells and 
showed that some clones expressed low (lo), medium (med) and high (hi) Snail 
expression (Figure 16 A (pg. 119)). We found that, in vitro, superoxide levels increased 
significantly in the Snail clones that expressed the most Snail (Figure 16 B, C pg. 119). 
The source of superoxide production in the LNCaP-Snail cells appeared to be 
mitochondrial in origin, as shown by mitosox staining (Figure 16 D pg. 119). Therefore, 
our results suggest that in the LNCaP cells, Snail can increase levels of mitochondrial 
superoxide. 
4.2.3 MSKE and SOD Antioxidants Decrease Superoxide Levels in LNCaP and 
ARCaP Cells Transfected with Snail, and is Associated with Decreased Cell 
Migration 
MSKE, a plant product has recently been shown to promote apoptosis of prostate 
cancer cells, but not normal cells at 20 μg/ml.6  For studies with MSKE, we decided to 
focus on the more aggressive ARCaP cells overexpressing Snail. We tested the effect of 
MSKE on cell viability in ARCaP Snail high cells. As shown in Figure 17A (pg. 121), 5 
μg/ml did not affect cell viability after 3 days, while 20 μg/ml MSKE led to a significant 
decrease in cell viability. We examined the effects of MSKE on superoxide levels in both 
LNCaP- and ARCaP-Snail transfected cells. Interestingly, we found that 5 μg/ml MSKE 
was more effective in decreasing superoxide levels when compared to 20 μg/ml MSKE, 
which was comparable to superoxide dismutase (SOD), a superoxide scavenger (Figure 
17 B pg. 121). We further tested whether the MSKE could also affect cell migration. For 




with MSKE for 3 days followed by cell migration assay on collagen type 1 using boyden 
chambers. As shown in Figure 17C (pg. 121), Snail overexpression resulted in greater 
migratory potential, which could be abrogated by MSKE in ARCaP and LNCaP cells. 
Therefore, we show that MSKE can antagonize superoxide production which is 
biologically associated with decreased cell migration. 
4.2.4 MSKE can Revert EMT 
Since Snail can induce EMT and increase superoxide levels, we examined 
whether there could be a possible link between superoxide species and EMT by using 
MSKE and SOD antioxidant that can inhibit superoxide. ARCaP-Snail med and –Snail 
high cells displayed EMT as shown by increased levels of Snail and vimentin, and 
decreased levels of E-cadherin, as compared to ARCaP-Neo (Figure 18 A, B pg. 123). 
Treatment of ARCaP-Snail med and-Snail high cells with 5 μg/ml MSKE was more 
effective at reverting EMT than 20 μg/ml MSKE, as shown by greater re-expression of E-
cadherin and decrease in vimentin protein in Western blot analyses when compared to 
untreated or control EtOH treated cells (Figure 18 A, B pg. 123). Similarly to treatment 
with 5 μg/ml MSKE, 500 U/ml SOD could also revert EMT (Figure 18 B pg. 123). Both 
MSKE and SOD could inhibit Snail expression in both ARCaP-Snail clones. These 




ARCaP prostate cancer cells likely by suppressing Snail-mediated increase in ROS 
concentration 
4.2.5 MSKE Inhibits STAT-3 Activity 
Since reactive oxygen species have been shown to activate the JAK/STAT 
pathway 201 and we have shown that MSKE can inhibit the expression of Snail-mediated 
superoxide, we wanted to examine the involvement of the JAK/STAT pathway.  ARCaP-
Snail med and ARCaP Snail high cells were treated with 5 μg/ml MSKE and 20 μg/ml 
for 3 days followed by analysis of STAT-3 levels and activity by western blot analysis. 
Interestingly, STAT-3 activity (p-STAT-3) was inhibited by 5 μg/ml MSKE while 20 
μg/ml inhibited both STAT-3 levels and p-STAT-3 (Figure 19 pg. 124). Taken together, 
our data indicates that MSKE may exert its inhibitory effect in part by antagonizing the 
JAK/STAT pathway in prostate cancer cells. 
4.3 MSKE Extract can Antagonize Snail-Cathepsin L-Mediated Invasion, Migration 
and Osteoclastogenesis in Prostate and Breast Cancer Cells  
4.3.1 Cat L is Increased in Patient Prostate and Breast Tumor Tissue 
To confirm previous findings that Cat L is increased in patient prostate and breast 
tissue,4b, 159 we stained for Cat L by IHC using prostate tumor tissue microarray and 
analyzed Cat L expression by western blot using patient breast tissue. Normal prostate 
epithelial tissue expressed low levels of Cat L in the cytoplasm, while higher levels were 
detected within prostate adenocarcinoma which increased with tumor grade (Figure 21 A 
pg. 126). Moreover, Cat L expression was predominantly cytoplasmic in stages II and III 




metastatic tissue (Figure 21 A pg. 126). However, Cat L staining was low in cancer cells 
that metastasized to the abdominal wall (Figure 21 A pg. 126).  Using normal/tumor-
matched breast cancer lysates (see  Figure 21 C pg. 126), we observed that tumor lysate 
expressed higher levels of mature Cat L as compared to normal tissue (Figure 21 B pg. 
126). This shows that Cat L expression increases with tumor progression in prostate and 
breast cancer. 
4.3.2 Snail is Correlated with Increased Cat L and Cat S Activity in Prostate and 
Breast Cancer Cell Lines 
Since Snail and Cat L are both involved in bone turnover, 19, 135, 202 we speculated 
that Snail may regulate Cat L expression/activity. We therefore examined the expression 
and activity of Cat L by western blot analysis and zymography, respectively. Western 
blot analysis showed that immature (pre-pro and pro) as well as mature Cat L expression 
were higher in ARCaP (prostate), LNCaP (prostate) and MCF-7 (breast) Snail-
overexpressing cells compared to the Neo controls but not significantly altered in C4-2 
non-silencing control (C4-2 NS) versus C4-2 Snail shRNA with stable Snail knockdown 
(Figure 22 A pg. 128). However, C4-2 Snail shRNA cells with Snail knockdown 
displayed decreased Cat L and Cat S activity compared to C4-2 NS as shown by 
zymography, while MCF-7, LNCaP and ARCaP cells overexpressing Snail displayed 
increased amounts of active Cat L and Cat S (Figure 22 B pg. 128). To determine the 
effects of Snail overexpression in vivo, we injected LNCaP-Neo and LNCaP-Snail 
subcutaneously into male athymic nu/nu mice. Significantly larger tumor volumes were 




(Figure 22 C pg. 128), while LNCaP-Snail tumor xenograft immunofluorescent staining 
demonstrated higher expression of Snail and Cat L as compared to LNCaP-Neo xenograft 
tissue (Figure 22 D pg. 128). Therefore, Snail is positively correlated with Cat L 
expression and activity. 
4.3.3 STAT-3 Regulates Cat L Activity in Prostate Cancer Cells 
Next, we wanted to examine the signaling pathway by which Snail may regulate 
Cat L activity. Since STAT-3 signaling pathway has been shown to regulate Snail via 
Liv-1 203  and also regulate Cat L activity,204  we tested the hypothesis that the STAT-3 
pathway was involved. STAT-3 knockdown with siRNA in C4-2 and ARCaP-Snail cells 
decreased Snail and mature Cat L expression (Figure 23 A pg. 130) and amounts of 
active Cat L (Figure 23 B and C pg. 130). This shows that JAK/STAT pathway may be 
involved in Snail activation of Cat L. 
4.3.4 MSKE Antagonizes Snail Signaling  
Next, we examined whether Snail/Cat L signaling could be antagonized by natural 
products. MSKE, a plant product has recently been shown to promote apoptosis of 
prostate cancer cells, but not normal cells,6 and revert epithelial mesenchymal 
transition.205  We also utilized Z-FY-CHO, a potent and reversible selective inhibitor of 
Cat L, which has been shown to inhibit bone resorption in rat bone cells by inhibiting 
collagen degradation.206  C4-2, ARCaP-Snail and MCF-7 Snail cells treated with 5 or 20 
µg/ml MSKE, or 5 µM Z-FY-CHO for 72 h led to decreased Snail, mature Cat L and 
pSTAT-3 expression as shown by western blot analysis, as well as decreased Cat L 




antagonized Snail-mediated Cat S. Therefore, Snail activation of Cat L can be 
antagonized by MSKE as effectively as Z-FY-CHO. 
4.3.5 MSKE and Z-FY-CHO can Antagonize Cell Migration and Invasion 
Next, we examined if MSKE and/or Z-FY-CHO can inhibit Snail mediated cell 
migration and invasion. ARCaP-Snail and MCF-7 Snail showed increased migration and 
invasion, as compared to empty vector Neo controls, which could be abrogated upon 
treatment with MSKE or Z-FY-CHO (Figure 25 A-D pg.134). Similarly, cell migration in 
C4-2 cells decreased upon treatment with Z-FYCHO or MSKE. Therefore, MSKE and Z-
FY-CHO can antagonize cell migration and invasion. 
4.3.6 MSKE Antagonizes Snail-Mediated Osteoclastogenesis 
Since we have previously shown that Snail can increase osteoclastogenesis by 
increasing the expression of RANKL,19 and Cat L has been shown to be involved in bone 
resorption,202 we investigated whether, Cat L similarly to RANKL may be involved in 
Snail-mediated osteoclastogenesis, and whether this biological function can be 
antagonized by MSKE. ARCaP-Snail and MCF-7 Snail cells displayed significant 
increase in the formation of mature osteoclasts as seen by TRAP staining as compared to 
Neo controls, which was significantly inhibited by 5 µg/ml or 20 μg/ml MSKE, 5 µM Z-
FY-CHO or 50 ng/ml OPG (RANKL antagonist) (Figure 26 A and B pg. 135). Of note, 
although MCF-7 Snail cells displayed a significantly higher number of mature osteoclasts 
as compared to MCF-7 Neo, there were hardly any cancer cells noted on the MCF-7 Snail 
plate following TRAP staining (Figure 26 B pg.135); MCF-7 Snail cells generally attach 




protocol. Our results suggest that Snail mediates osteoclastogenesis in part via Cat L 
activity, which can be inhibited by MSKE. 
4.4 Targeting the Nuclear Cathepsin L- CCAAT Displacement Protein/Cut 
Homeobox Transcription Factor-EMT Pathway in Prostate and Breast Cancer Cells 
with Z-FY-CHO Inhibitor 
4.4.1 Mesenchymal Prostate and Breast Cancer Cells Display Increased Nuclear Cat 
L Expression and Activity.  
We analyzed the expression of EMT markers and Cat L in prostate and breast 
cancer cells using western blot analysis, and examined Cat L activity by zymography.  
For prostate cancer models, we utilized epithelial ARCaP (ARCaP-E), ARCaP-E stably 
overexpressing Snail (ARCaP-Snail) or Neo control (ARCaP-Neo), and mesenchymal 
ARCaP (ARCaP-M). For breast cancer models we utilized epithelial MCF-7, MCF-7 
stably overexpressing Snail (MCF-7 Snail) or Neo control (MCF-7 Neo), and 
mesenchymal MDA-MB- 468 and MDA-MB-231 cells. Their morphologies are depicted 
in Fig 27. Mesenchymal cells (MDA-MB-231, MDA-MB-468, MCF-7 Snail, ARCaP-
Snail) with high Snail and vimentin, and low E-cadherin expression displayed higher Cat 
L expression and activity as compared to epithelial cells (MCF-7, MCF-7 Neo, ARCaP-
Neo), except for ARCaP-M that despite being mesenchymal, had lower Cat L 
expression/activity as compared to ARCaP E (Fig 28A, B). Interestingly, Cat L was 
localized in the cytoplasm and nucleus of all the mesenchymal prostate and breast cancer 
cells (ARCaP-M, ARCaP-Snail, MDA-MB-231, MDA-MB-468, MCF-7 Snail), while it 




immunofluorescent analyses (Figure 28 D, E pg. 137; Figure 29 pg. 139). Moreover, 
epithelial cells lines expressed the CUX1 p200 full-length isoform compared to the 
mesenchymal cells that additionally expressed the p110 and p90 CUX1 cleavage products 
normally generated by nuclear Cat L activity (Figure 28 A, D pg. 137). This suggests that 
increase in Cat L expression/activity is associated with mesenchymal cells, as previously 
published 207 and additionally, nuclear Cat L is associated with mesenchymal cells and 
may promote cleavage of CUX1.  
4.4.2 Cat L Inhibitor (Z-FY-CHO) Promotes Nuclear to Cytoplasmic Re-
Localization of Cat L and Promotes MET in ARCaP-M Prostate and MDA-MB-468 
Breast Cancer Cells.  
Since cells with high Snail expression have an increase in nuclear Cat L activity 
as shown by increased cleavage of CUX1, we wanted to investigate the effect inhibition 
of Cat L would have on EMT.  We utilized a reversible and specific Cat L inhibitor (Z-
FY-CHO) that binds to the active site of Cat L, preventing its activity. In prostate and 
breast cancer cells (ARCaP-M and MDA-MB-468), Z-FY-CHO (especially 5-20 µM) 
led to a decrease in Snail and vimentin expression, while E-cadherin was restored in 
ARCaP-M and MDA-MB-468 (Figure 30 A pg. 140, 31 A pg. 142). Similar results were 
observed in MDA-MB-231 cells (decreased Snail and vimentin), except that E-cadherin 
was not restored upon Z-FY-CHO treatment, which suggests some variability between 
cell lines (Figure 32 pg. 144). We also showed that Z-FY-CHO decreased Cat L activity 
in MDA-MB-468 cells, as shown by zymography (Figure 31 B, C pg. 142).  




activity (Figure 30 B, C pg. 140), whereby it now resembled levels found in ARCaP-E 
from Figure 28. However, we show by subcellular fractionation in ARCaP-M cells, there 
is more nuclear mature Cat L as compared to cytoplasmic, and that treatment with Z-FY-
CHO decreased both nuclear Snail and Cat L, while increasing cytoplasmic Cat L 
(Figure 30 D, E pg. 140).  Immunofluorescence data supported western blot data (Figure 
30 E pg. 140, 31 D pg. 142).   Therefore, Z-FY-CHO can promote MET, possibly by 
decreasing Snail and promoting nuclear to cytoplasmic relocalization of Cat L in 
mesenchymal cells.    
4.4.3 Cat L Inhibitor (Z-FY-CHO), Promotes Nuclear to Cytoplasmic Re-
localization of Cat L and Antagonizes Snail-Mediated EMT in Prostate and Breast 
Cancer Cells.  
We had previously published that Snail can increase Cat L activity in prostate and 
breast cancer cells and that Cat L inhibition could antagonize Snail expression.207  We 
carried this study further to examine whether Snail could affect the localization of Cat L 
and whether Z-FY-CHO could antagonize Snail-mediated EMT.  We confirmed that 
Snail overexpression promoted EMT in prostate cancer cells overexpressing Snail 
(ARCaP-Snail), or breast cancer cells overexpressing Snail (MCF-7 Snail), as 
characterized by increased Snail and vimentin and decreased E-cadherin when compared 
to Neo controls (Figure 33 A pg. 145, 34A pg. 147). This was accompanied by increased 
Cat L expression and activity (Figure 33 B-C pg. 145, 34 B-C pg. 147). Z-FY-CHO 
reverted EMT marker expression and decreased Cat L expression and activity (Figure 33 




with Cat L localization to the nucleus and cytoplasm, while inhibition of Cat L with Z-
FY-CHO led to Cat L re-localization to the cytoplasm (Figure 33 D pg. 145, 34 D pg. 
147). Therefore, Z-FY-CHO can inhibit Snail-mediated EMT in part by decreasing Snail 
and Cat L expression.   
4.4.4 Cat L Knockdown Similarly Reverts Snail-Mediated EMT.  
We utilized ARCaP-Snail as a model system, and sought to compare Cat L 
knockdown with siRNA to Cat L inhibition with Z-FY-CHO. We confirmed that 
transient knockdown of Cat L with siRNA lead to decreased levels of Cat L as shown by 
western blot analysis (Figure 35 A pg. 149), and also decreased Cat L activity as seen by 
zymography (Figure 35 B, C pg. 149). Similar to Z-FY-CHO, Cat L knockdown also 
reverted Snail mediated EMT, as revealed by western blot analysis showing decreased 
Snail and vimentin, and increased E-cadherin (Figure 35 D pg. 149). To further confirm 
the localization of Cat L and its substrate, CUX1, in Snail overexpressing cells, we 
performed subcellular fractionation and examined Cat L and CUX1 expression in nuclear 
and cytoplasmic fractions.  Interestingly, the pre- and pro-forms of Cat L were 
predominantly in the cytoplasm, while mature Cat L as well as p200, p110 and p90 
isoforms of CUX1 were predominantly present within the nuclear fraction in ARCaP-
Snail cells as compared to ARCaP-Neo (Figure 35 E pg. 149). Inhibition of Cat L using 
Z-FY-CHO and Cat L siRNA led to decreased expression of Snail, the mature form of 
Cat L and p110/90 CUX1 in the nucleus (Figure 35 E pg. 149). Therefore, Cat L 
knockdown with siRNA can inhibit Snail-mediated EMT similarly to Z-FY-CHO, 




4.4.5 Z-FY-CHO and Cat L siRNA Decrease Snail-Mediated Cell Invasion and 
Migration.  
We had previously published that Z-FY-CHO had the ability to decrease cell 
migration and invasion in Snail-overexpressing cells;207 we next wanted to compare these 
results to the use of Cat L siRNA on functional EMT assays (cell migration and 
invasion). Cell migration and invasion decreased in ARCaP-M and MDA-MB-231, 
MDA-MB-468 cells that have high endogenous Snail expression, upon treatment with Z-
FY-CHO (Fig 36A, B pg. 151). ARCaP-Snail and MCF-7 Snail showed increased 
migration and invasion, as compared to empty vector Neo controls, which could be 
abrogated upon treatment with Cat L siRNA or Z-FY-CHO (Figure 36 A, B pg.151). 
Therefore, inhibiting Cat L with an inhibitor (Z-FY-CHO) or using siRNA can 
antagonize Snail-mediated cell migration and invasion.   
4.4.6 Snail Promotes its own Transcription and EMT by Increasing CDP/Cux 
Binding to the Snail and E-cadherin Promoter.  
CUX1 can physically bind to the Snail or E-cadherin promoter to increase or 
decrease its transcription, respectively, thereby promoting EMT.196  We investigated 
whether Snail can promote its own transcription via CUX1, and whether this could be 
antagonized with Z-FY-CHO. A ChIP assay was performed using ARCaP E, ARCaP M, 
ARCaP-Neo, MCF-7 Neo and Snail-transfected cells to immunoprecipitate CUX1 from 
chromatin and perform qRT-PCR with Snail and E-cadherin promoter primers.  Goat IgG 
and Snail control primers (primers to promoter region that is not bound by CUX1) were 




(Figure 37 pg. 152, Figure 38 pg. 154). The data revealed that CUX1 binds to Snail 
promoter and E-cadherin promoter more greatly in ARCaP-Snail and MCF-7 Snail cells 
and ARCaP M as compared to ARCaP-Neo, MCF-7 Neo and ARCaP E cells, 
respectively (Figure 37 A pg. 152). Z-FY-CHO (5 and 20 µM) prevented the binding of 
CUX1 to the Snail and E-cadherin promoter in ARCaP-Snail and MCF-7 Snail cells 
(Figure 37 B pg. 152). Therefore, a positive feedback loop exists whereby Snail 
overexpression may promote its own transcription and lead to E-cadherin repression in 
part through binding of CUX1 to the Snail and E-cadherin promoters, and this binding 















5.1 Proteomic Analysis of MSKE in C4-2 Cells 
We investigated the impact of MSKE on the C4-2 proteome using a quantitative 
TMT isobaric labeling approach with subsequent protein identification by mass 
spectrometry. Changes in C4-2 cells were also examined by Western blot.  Autophagy 
and apoptosis were determined by acridine orange, TUNEL/Annexin V analyses, 
respectively. The results indicated that MSKE significantly regulated components of the 
UPR stress inducing pathways that include chaperones, ER stress antioxidant enzymes, 
proteolytic enzymes, cytoskeletal proteins, as well as enzymes involved in autophagy or 
apoptosis. Autophagy is a dynamic process, whereby cytoplasmic proteins and cellular 
organelles are enveloped in autophagosomes and degraded by fusion with lysosomes for 
amino acid and energy recycling.208  There is evidence that autophagy can play a critical 
role in cellular survival 209 but, it is frequently activated in tumor cells following 
anticancer therapies such as drug treatment and gamma-irradiation.210  Apoptosis is 
defined as an active, fixed-pathway process of cell death characterized by cell shrinking, 
cytoplasmic condensation, ladder DNA degradation, and nuclear fragmentation resulting 
in the formation of apoptotic bodies. Initial studies on the mechanism of action of MSKE, 
suggest the ability to induce apoptosis via activation of the caspase cascade. The increase 




assays, in agreement with previous studies that have shown that MSKE promotes 
apoptosis in prostate cancer cells.6  Our current study identified several proteins 
associated with apoptosis triggered by MSKE treatment such as STEAP2, PDCD6, 
MTDH, RAB5B, and cytochrome C oxidase (Table 6 pg. 160). STEAP2, also known as 
6-transmembrane protein of the prostate 1 (STAMP1) is overexpressed in several types of 
human cancers, namely prostate, bladder, colon, pancreas, ovary, testis, breast, and 
cervix, but its clinical significance and role in cancer cells is still unclear.211  STEAP2 
participates in a wide range of biological processes, including molecular trafficking in the 
endocytic and exocytic pathways. It also controls cell proliferation and apoptosis. 
STEAP2 was down-regulated in C4-2 cells. It has been shown that STEAP2 blockage has 
a pro-apoptotic role that causes mitochondrial damage, and decreases cell proliferation 
and glucose uptake.211  MTDH was up-regulated by 1.91 fold upon MSKE treatment in 
C4-2 cells. MTDH has been proposed to promote tumor progression through the 
integration of multiple signaling pathways including ras, myc, Wnt, PI3K/AKT, and NF-
κB in various types of cancer.212  The nuclear protein Apoptotic Chromatin Condensation 
Inducer 1 (ACIN1) is known to function in DNA fragmentation and is activated during 
apoptosis by caspase-3. It also plays an active role in spliceosome assembly because it is 
a critical subunit of an apoptosis and splicing-associated protein (ASAP) complex.213 
ACIN1 was downregulated in our study by -1.60 fold and we speculate that MSKE 
induced an antiapoptotic/survival response in C4-2 cells by down-regulating ACIN1. 
Taxilin protein (TXLNA), a binding partner of the syntaxin family that functions as a 




was also upregulated upon MSKE treatment.  Several results support the induction of 
apoptosis by MSKE via autophagy. The acridine orange staining showed that induced 
autophagy increased with MSKE treatment in a dose-dependent manner. Additionally, 
ER stress was significantly induced upon MSKE treatment in C4-2 cells as seen in the 
up-regulation of several stress-related proteins (e.g., GRP78, PDIA4, PDIA6, eIF2B, 
eIF4EBP1). We also identified COL4A3BP whose down-regulation sensitizes cancer 
cells to multiple cytotoxic agents, potentiating ER stress.215  Lysosomal inhibitors such as 
chloroquine that inhibit acidification inside the lysosome or inhibit autophagosome-
lysosome fusion and can block the degradation of LC3BII, leading to the accumulation of 
LC3BII, are good indicators for autophagy.216  Co-treatment with MSKE plus 
chloroquine in C4-2 cells increased LC3B punctate staining as shown by 
immunofluorescence, and increased LC3-BII expression as shown by western blot 
analysis, proving that MSKE promotes autophagy which is blocked by chloroquine 
leading to accumulation of LC3BII. We speculated, however, that at 72 h we failed to see 
increased LC3BII with MSKE treatment alone due to high autophagic flux. This problem 
that sometimes arises when LC3BII expression does not increase when assayed at a 
certain time point as expected due to high autophagic flux is discussed in great detail with 
the conclusion that it is better to gauge autophagy by examining autophagosome 
accumulation in the presence of chloroquine.217  We also demonstrated that chloroquine 
was able to reverse the extensive acridine orange leakage into the cytosol.  Degradation 
of cytosolic proteins in lysosomes is a hallmark of autophagy.218  The absence of 




apoptosis.219  Recent studies have shown that a variety of anticancer therapies (including 
those that stimulate ER stress) activate autophagy in tumor cells, which has been 
proposed to either enhance cancer cell death or act as a mechanism of resistance to 
chemotherapy.220  Autophagy works as a tumor suppression mechanism by removing 
damaged organelles/proteins, limiting cell growth and minimizing genomic instability.221  
Phosphatidylinositol 4-Kinase (PI4KA), a protein involved in both nonselective and 
selective types of autophagy,222 was up-regulated in MSKE-treated C4-2 cells. The 
expression of metadherin (MTDH), also known as astrocyte-elevated gene-1, a protein 
that may protect normal cells from serum starvation-induced death through protective 
autophagy,223 increased 1.91 fold in the presence of MSKE. In addition, 
phosphoglycerate kinase (PGK2), a cytosolic and glycolytic marker, was downregulated 
by MSKE in C4-2 cells, suggesting that it may have been taken up into autophagic 
bodies.224  ER stress was evident by the up-regulation of key ER stress markers like 
GRP78 and PDIA4, A6. Proper protein folding, maturation, and stabilization of the 
nascent protein in the ER requires a highly oxidizing ER environment, which is essential 
for the diverse post-translational and co-translational modifications (e.g., glycosylation, 
disulfide bridge formation) to which proteins are subjected after entering the ER. These 
processes are assisted and monitored by several resident chaperones and binding proteins, 
including glucose-regulated proteins like GRP78, which was up-regulated in the presence 
of MSKE. Folding enzymes, such as the thioredoxin-like protein (PDI), oxidize cysteine 
residues in nascent proteins (i.e., oxidative folding) resulting in the formation of intra- 




subsequent translation initiation component activation (i.e., eIF4EPB, eIF2). Moreover, 
the upregulation of pro-apoptotic markers MTDH, caspase 12, Cytochrome C oxidase, 
PDCD6 and NQO1, along with the increased apoptosis visualized by TUNEL and 
Annexin V staining, suggest that the ER stress response might eventually trigger 
apoptosis.  Overexpression of MTDH, also known as LYRIC, is observed in a variety of 
cancers and is involved in cancer initiation, proliferation, invasion, metastasis and 
chemoresistance.225  MTDH also activates the PI3K/Akt pro-apoptotic pathway in cancer 
226 and its inhibition induces apoptosis in prostate cancer cells.227  Hudson et al. have also 
shown that treatment with MSKE activates the PI3K/Akt pro-apoptotic pathway in 
prostate cancer cells.6  The upregulation of cytoplasmic C oxidase and Glyoxalase I 
(GLO1) suggests that MSKE also interferes with glycolysis and mitochondrial 
metabolism in C4-2 cells. GLO1 is a ubiquitous cellular defense enzyme involved in 
detoxification. GLO1 expression may protect cells against methylglyoxal-dependent 
protein adduction and cellular damage associated with diabetes, cancer, and 
chronological aging. GLO1 upregulation has been shown to play a pivotal role in 
glycolytic adaptations of cancer cells.228  Phosphoglycerate kinase, a protein encoded by 
the PGK1 and PGK2 genes, is a glycolytic protein activated by MSKE. Phosphoglycerate 
kinase converts 1,3diphosphoglycerate into 3-phosphoglycerate in the glycolysis 
pathway. PGK1 is located on the X chromosome and is ubiquitously expressed whereas 
PGK2, whose differential expression was induced by MSKE in C4-2 cells, is a 
retrotransposed copy of PGK1 located on chromosome 6 that shows a testis specific 




DPYSL5, and downregulation of ABCA5 proteins in C4-2 cells. These proteins have 
been implicated in other cancer cells and tumor types and are involved in relevant cell 
mechanisms for apoptosis evasion, increased tumor invasiveness, tumor hypoxia, cellular 
respiration, and mitochondrial fragmentation.  ABCA5 is a member of the ATP-binding 
cassette transporter 1 subfamily of genes whose mutations are linked to several human 
genetic disorders including cystic fibrosis, neurological disease, retinal degeneration, 
cholesterol and bile transport defects, anemia, and drug response phenotypes.230  MSKE 
also activates oxidative stress and ROS pathways through aldehyde dehydrogenases 
(ALD), sideroflexin, sulfiredoxin and DHRS1. ALDH belongs to a group of NAD(P)+-
dependent enzymes involved in oxidation of a large number of aldehydes into their weak 
carboxylic acids.231  ALDH is important for drug resistance, cell proliferation, 
differentiation, and response to oxidative stress in prostate cancer and its activity is used 
to distinguish between normal cells and their malignant counterparts. In a previous study, 
high ALDH activity was used to isolate human prostate cancer cells with significantly 
enhanced clonogenic and migratory properties both in vitro and in vivo. As seen in other 
cancer tissues, the percentage of ALDH cells in prostate cancer cell lines are also related 
to tumorigenicity and metastatic behavior.232  MSKE induced apoptosis via the up-
regulation of ER stress-driven caspase-3,-7 and 12. Treatment with chloroquine blocked 
the effects of MSKE on apoptosis by upregulating BCL-2, decreasing BAX, preventing 
the cleavage of caspase-3 and -7 and antagonizing MSKE-mediated increase in early and 
late apoptosis. This further supports the findings that MSKE-mediated autophagy leads to 




proteins like Annexin A4 (ANXA4), a member of the Ca2+-regulated and phospholipid-
binding annexin superfamily. ANXA4 expression is increased in many cancer types, 
including cancers of renal, gastric, colonic, ovarian, and cervical origins.233  Its 
expression has been linked to loss of cell-to-cell adhesion, increased metastasis, and 
chemo-resistance, and it is considered a potential cancer diagnostic and therapeutic 
target.234  In vitro studies suggest that ANXA4 exhibits an anti-apoptotic effect by 
activating NF-κB transcriptional activity.235  Our data suggests that MSKE may induce 
apoptosis by decreasing ANXA4, and increasing MTDH.  Recently, the cross-talk 
between autophagy and apoptosis has been considered as a key factor in the development 
and treatment of cancer.236   The two pathways share molecular regulators and, in some 
cases, are activated by the same stimulus. Taken together, the results of this study suggest 
that MSKE induces apoptosis through signaling pathways that modulate ER stress, 
autophagy, cytoskeletal changes, cell matrix, and cell-cell adhesion, as well as glycolysis 
and mitochondrial metabolism (Figure 14 pg. 116 ); opening the door to novel therapeutic 
and clinical exploitations.  
5.2 Muscadine Grape Skin Extract Reverts Snail-Mediated Epithelial Mesenchymal 
Transition via Superoxide Species in Human Prostate Cancer Cells 
This study evaluated the molecular mechanism(s) by which Snail transcription 
factor may contribute to cancer progression in prostate cancer through regulation of 
superoxide ROS and whether it can be antagonized by MSKE, a product with antioxidant 
properties. ROS are important mediators of tumor progression; increased hydrogen 




superoxide levels were present in breast cancer tissue specimens.237  There has also been 
a report on increased hydrogen peroxide levels in human prostate tumors.238  Since ROS 
is associated with tumor progression, and EMT is also linked to tumor progression,239 
additional studies have shown that hydrogen peroxide can mediate EMT.240  Previous 
studies have shown that Snail can increase hydrogen peroxide and superoxide levels in 
prostate cancer cells in vitro and in vivo.199  However, the role of superoxide in prostate 
cancer is not well studied and its role in EMT has never been reported. We utilized 
prostate cancer cells overexpressing Snail, as an EMT model to study the role of 
superoxide in the EMT process. 
Androgen-independent ARCaPE and androgen-dependent LNCaP cells 
transfected with Snail have been previously shown to undergo EMT.19, 200  In our current 
study, we have shown that the levels of superoxide increased in both ARCaP and LNCaP 
cells transfected with Snail in vitro. Furthermore, the source of superoxide appears to be 
mitochondrial in origin, according to the Mitosox staining experiment. Previously, only 
hydrogen peroxide has been associated with EMT induction in cancer.194,240  One study 
showed that transfection of MMP-3 gene into breast cancer cells could induce both 
hydrogen peroxide and Snail.197 
We tested MSKE, a plant product that has been shown to induce apoptosis and 
reduce cell proliferation in prostate cancer cells but not normal cells, by antagonizing 
ERK and PI3K signaling.6  Muscadine grapes have unique aroma and flavor 
characteristics. Although a few studies reported high polyphenols content of muscadine 




bioactivities in any muscadine grape.16  The major phytochemical constitute of MSKE is 
anthocyanin 3, 5-diglucosides which is different from resveratrol.6  The phenolic 
structure of anthocyanins is responsible for their antioxidant activity (ability to scavenge 
ROS).241  In our study 5 μg/ml MSKE led to a mesenchymal epithelial transition (MET) 
characterized by reexpression of E-cadherin and reduced vimentin levels. However, the 
higher dose (20 μg/ml) that has been shown to induce apoptosis in LNCaP cells6 and 
decreased cell viability in ARCaP Snail high cells, was not as effective at inducing MET 
and affected re-expression of E-cadherin, but not vimentin levels. Further support came 
from examination of superoxide levels showing that 5 μg/ml effectively inhibited 
superoxide levels in ARCaP-Snail cells by more than 50%, while 20 μg/ml MSKE had 
minimal effect. This suggests lower doses of MSKE can be more effective at reverting 
EMT than higher doses, possibly by inhibiting superoxide. This is further supported by 
the data showing that the superoxide inhibitor, SOD, could significantly inhibit 
superoxide accompanied by a MET. This would be the first report of regulation of EMT 
by superoxide species. Interestingly, both doses of MSKE as well as SOD could inhibit 
Snail expression as well as cell migration. We do not currently understand why 20 μg/ml 
MSKE is just as effective as 5 μg/ml MSKE at reducing Snail levels and cell migration, 
yet it does not revert EMT or reduce superoxide levels as effectively. Studies have shown 
that it is possible that STAT-3 activation might be induced by ROS generation.242  In our 
study we observed that while 5 μg/ml MSKE affected STAT-3 activity but not levels, 
20 μg/ml MSKE did show an inhibition of STAT-3 levels and STAT-3 activity. There is 




high dose may act by inhibiting the JAK/STAT pathway leading to apoptosis while the 
lower dose may also inhibit STAT-3 activity and inhibit EMT. However, both doses 
inhibit Snail expression. Snail has not only been implicated in EMT but also in cell 
survival.201  The difference between low and high dose of MSKE needs to be investigated 
further.  Collectively, our results indicate that Snail leads to increased levels of 
mitochondrial superoxide and EMT (Figure 20 pg. 125). Furthermore, MSKE and SOD 
reverts EMT by targeting Snail expression (Figure 20 pg. 125), underscoring the 
importance of targeting these pathways with various inhibitors and antioxidants. These 
studies show that superoxide species may play a role in the EMT process and that use of 
various antioxidants such as MSKE may be able to antagonize EMT and prostate cancer 
progression in future. 
5.3 MSKE Extract can Antagonize Snail-Cathepsin L-Mediated Invasion, Migration 
and Osteoclastogenesis in Prostate and Breast Cancer Cells  
Our data indicate that MSKE, a natural product, can antagonize Snail-
mediated signaling and bone turnover. Cat L expression increases with prostate and 
breast cancer progression.159, 243  Although these cathepsin proteases are mostly 
secreted by macrophages in tumors,2 the mechanism(s) by which they are 
upregulated in prostate or cancer has not been elucidated. We have shown 
previously by IHC that Snail expression is higher in aggressive and bone metastatic 
prostate cancer patient tissue and can promote osteoclastogenesis in vitro and in 
vivo.19  It has also been indicated that Snail-positive breast cancer tends to home 




samples, we show that Cat L is highly expressed with advanced stages of prostate cancer 
and that the expression of Cat L shifts from predominantly cytoplasmic in lower grade to 
nuclear in higher grade tumor tissue. Additionally, we show that mature Cat L is more 
highly expressed in breast tumor lysates as compared to normal tissue. Nuclear 
localization of Cat L has been previously documented using in vitro cultures and has been 
found to have distinct DNA binding and transcriptional regulatory activities.164 In these 
studies, a truncated form of Cat L cleaves the CUX1 transcription factor and as a result 
accelerates progression into the S phase of the cell cycle.164  Cat L is also localized in the 
nucleus of breast cancer cells and patients with triple negative breast cancer have a higher 
levels of nuclear Cat L.4   We show also for the first time that with increasing progression 
of prostate cancer that Cat L is expressed in the nucleus (Figure 21 A), which may infer 
that Cat L activity in the nucleus is associated with a poor prognosis in prostate cancer. 
We further show that Snail increases Cat L expression and Cat L and Cat S activity 
(Figure 22 pg. 128). This is the first report showing that Snail can regulate Cat L and Cat 
S expression/activity.  When we knocked down STAT-3 in cells overexpressing Snail 
there was a decrease in Snail and mature Cat L expression, and Cat L activity (Figure 23 
pg. 130). This indicates that Snail activates Cat L in part via the STAT-3 signaling 
pathway. We also present novel findings that MSKE inhibits the activity of Cat L 
possibly by inhibiting Snail expression (Figure 24 pg. 132). MSKE has been shown 
previously to promote apoptosis of prostate cancer cells without affecting normal prostate 
epithelial cells 4b. Muscadine grape skin contains abundant and numerous types of 




compounds and their significant interactions.245  The recent growing interest in 
muscadine grapes stems from a great diversity of phenolic compounds contained within 
them, including the presence of anthocyanins and ellagic acid.245  We have shown 
previously that MSKE can antagonize Snail mediated epithelial mesenchymal 
transition.205  In our study, after treatment with MSKE for 72 h we observed that MSKE 
decreased Snail expression as well as Cat L and STAT-3 activity in C4-2 cells that 
display high levels of Snail, and ARCaP-Snail cells. MSKE may antagonize Snail-
mediated signaling by inhibiting the JAK/STAT pathway but further studies are required 
to confirm this. Interestingly, we also present novel data that Z-FYCHO can inhibit 
STAT-3 activity and Snail expression, which suggests that there is a positive feedback 
loop between Snail and Cat L that involves the STAT-3 signaling pathway. Upon 
activation of STAT-3, it has been shown that there is an increase in both the 
transcriptional activity of Snail 246 and cathepsin activity.247 Conversely, we show for the 
first time that Snail overexpression may be able to increase STAT-3 activity (Figure 24 
pg. 132). Functionally, MSKE decreased cell migration and invasion as well as Snail 
mediated osteoclastogenesis in both prostate and breast cancer cells to levels comparable 
to Cat L and RANKL antagonists (Figures 25 pg. 134 and 26 pg.135). This is the first 
report showing that MSKE can inhibit bone turnover.  Therefore, we show here for the 
first time that Snail may mediate migration, invasion and osteoclastogenesis in part via 
Cat L and this can be antagonized by MSKE. Cat L inhibition is already being discussed 
as a possible therapy for bone metastasis,202 but this is the first study suggesting that 




Phase II clinical trials for treatment of localized prostate cancer; our study suggests that it 
could also be a potential therapy for bone metastatic lesions by antagonizing Snail and 
Cat L signaling.  Overall, this study develops novel roles for bidirectional interactions 
between Snail transcription factor and Cat L that involves STAT-3 signaling. Even 
though the different compounds of MSKE have been identified such as anthocyanin 3, 5-
diglucosides, ellagic acid and ellagic acid precursors, further work is warranted to 
elucidate which of these compounds may be responsible for the effects reported in the 
current manuscript. Although the underlying mechanisms governing these effects are not 
yet fully understood, the available evidence collectively indicates that antagonizing Cat L 
activity with MSKE may be of therapeutic benefit in clinical settings, suggesting its 
potential use as an anticancer agent for prostate and breast cancer that has metastasized to 
bone. 
5.4 Targeting the Nuclear Cathepsin L- CCAAT Displacement Protein/Cut 
Homeobox Transcription Factor-EMT Pathway in Prostate and Breast Cancer Cells 
with Z-FY-CHO Inhibitor 
Targeting EMT with a small molecule inhibitor may be important in therapeutics 
since it is increasingly being proven that EMT plays an integral role in cell migration, 
invasion and metastasis.112, 119  Cat K and Cat S inhibitors have been tried in clinical 
trials with much side effects and little progress.248   However, no Cat L inhibitor has been 
evaluated in clinical trials. Our study was a preclinical mechanistic study to evaluate the 
feasibility of using Cat L small molecule inhibitor, Z-FY-CHO in prostate and breast 




that mesenchymal cells with high Snail expression displayed increased nuclear Cat L 
expression as well as increased expression of nuclear p110 and p90 isoforms of CUX1 
which indicates higher Cat L activity within the nucleus since CUX1 is a substrate of Cat 
L in the nucleus.164  So far, only few substrates of nuclear cysteine peptidases have been 
identified, namely CUX1, the histones H1 or H3, and  53BP1.249   Previous reports show 
that the p110 isoform of CUX1 works in cooperation with Snail gene to repress the 
transcriptional activation of E-cadherin, while also increasing Snail transcription.196  
Studies also show for Snail transcription factor to be active it has to be localized to the 
nucleus.112, 134   Our novel findings show that a positive feedback loop exists, whereby 
Snail transcription factor can promote Cat L activity and subsequent CUX1 cleavage, 
which then further promotes Snail transcription and EMT.  Interestingly, Cat L 
expression was cytoplasmic/nuclear in mesenchymal cells while it was predominantly 
cytoplasmic in epithelial cells. Moreover, Snail overexpression promoted nuclear 
localization of Cat L. Our findings support recent discoveries that Cat L function is not 
solely limited to lysosomes but that this enzyme can be also functional within the nucleus 
to enhance cancer progression. Cat L is normally processed as a zymogen and has to 
have removal of both the pre and pro forms to be activated. Our fractionation in Snail 
overexpressing cells shows that the in the cytoplasm, all three forms of Cat L are 
expressed, but the nuclear fractions show that the mature form is present. Of note, we 
also observe that mesenchymal cells and Snail-overexpressing cells do express low levels 
of pro-Cat L in the nucleus; it has been previously reported that Cat L containing a 




nuclear localization of Cat L.  Future studies will have to target the question that remains 
with regard to the mechanism by which Snail regulates the changes in subcellular 
localization of Cat L. We show for the first time that Cat L inhibition with Z-FY-CHO 
changes the localization of Cat L from nuclear and cytoplasmic expression, to mainly 
cytoplasmic expression, concomitant with MET, whereby overall levels of Snail and 
vimentin decrease, while E-cadherin increases. It was surprising that Z-FY-CHO changes 
Cat L subcellular localization. It may involve a complex mechanism whereby Cat L 
competitive inhibition reduces CUX1 cleavage and subsequently Snail expression. Since 
we find that Snail subsequently regulates Cat L expression and localization, future 
studies will examine whether Snail promotes nuclear Cat L localization via importins. 
Therefore, changes in Cat L subcellular localization upon treatment with Z-FY-CHO 
may involve an indirect mechanism that needs to be further explored.  Zymography using 
conditioned media shows that Z-FY-CHO inhibits secreted Cat L activity that is 
important for degrading extracellular matrix therefore, this small molecule may be useful 
to target both extracellular as well as intracellular nuclear Cat L. There are minor 
differences in the way Z-FY-CHO works in the different cells; it could decrease Snail 
and vimentin, and restore E-cadherin in both ARCaP-M and MDA-MB-468, but failed to 
restore E-cadherin in MDA-MB-231and HS-578-T cells. Surprisingly, mesenchymal 
ARCaP-M prostate cancer cells actually displayed lower Cat L expression/activity as 
compared to ARCaP-E, which could not be inhibited by Z-FY-CHO, but additional 
investigations showed that increased EMT, migration and invasion may depend on 




concomitant binding to Snail and E-cadherin promoter, when compared to ARCaP-E 
cells. However, mesenchymal MDA-MB-468 breast cancer cells displayed more Cat L 
expression/activity as compared to MCF-7 cells, and Z-FY-CHO could inhibit EMT in 
both ARCaP-M and MDA-MB-468 cells, but only partially in MDA-MB-231 and HS-
578-T cells.  These studies highlight differences in different cell types. More importantly, 
functional assays showed that Z-FY-CHO or Cat L siRNA could inhibit migration and 
invasion in both the mesenchymal prostate and breast cancer cells. Previously, the 
nuclear isoform of Cat L was shown to be able to regulate the proteolytic processing of 
CUX1, creating the p110 and p90 isoforms of CUX1 from the p200 isoform 164, 166, 196.  
p110 isoform was found to be responsible for malignancies in several organs and cell 
types 196, 250.  Studies indicate that the p110 isoform of CUX1 can act as both 
transcriptional activator of Snail as well as repressor of E-cadherin transcription.167  Our 
results indicated that cells with high Snail expression showed increased p90 and p110 
CUX1 expression, concomitant with increased binding to Snail and E-cadherin promoter. 
Therefore, a positive feedback loop between Snail-Cat L-CUX1 and back to Snail exists, 
and the inhibition of Cat L can antagonize this vicious cycle. Overall our novel data 
supports a role for nuclear Cat L that can be promoted by Snail, in the regulation of 
EMT. Snail does not only directly promote EMT by suppressing E-cadherin as is 
commonly known, but also promotes EMT indirectly by promoting nuclear localization 
of Cat L which then leads to CUX1 cleavage and further EMT via its activating Snail 
transcription and repressing E-cadherin transcription; this vicious cycle can be 




CHO may be an excellent therapeutic tool to target nuclear Cat L activity and EMT, as 
well as secreted Cat L activity that may promote invasion through extracellular matrix in 









Natural products are of particular interest as chemopreventive agents because of 
their potentially low toxicity profiles and potential effectiveness.  They have been used 
for the treatment of various diseases and are becoming an important research area for 
drug discovery. These products, especially phytochemicals have been extensively studies 
and have exhibited anti-carcinogenic activities by interfering with the initiation, 
development and progression of cancer through the modulation of various mechanisms 
including cellular proliferation, differentiation, apoptosis, angiogenesis, and metastasis.5  
Chemoprevention by phytochemicals is of great interest and is considered to be an 
inexpensive, readily applicable, acceptable, and accessible approach to cancer control and 
management.  Most of the drugs in chemotherapy act as monotarget molecules, whereas 
medicinal plants have multitarget molecules that can regulate the cancer growth and its 
progression.251  Several phytochemicals are in preclinical or clinical trials for cancer 
chemoprevention, with MSKE being one of them.192  Epidemiological studies have 
shown that high dietary consumption of vegetables and fruits reduced the risk of cancer. 
180-181  Collectively, our results indicate that by indirectly targeting a major player in 
cancer progression such as Snail with the use of various antioxidants such as MSKE may 
be able to antagonize EMT and cancer progression in future.  MSKE may also be a 




These studies show that there is a need to explore the full potential of the dietary 
supplements of natural products, and to assess their safety and efficacy in well-designed, 
double-blinded, randomized, placebo-controlled clinical trials as stand-alone treatments 
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Figure 1: Zonal Anatomy of the Prostate: the three glandular zones of the prostate and 







Figure 2: 22  Morphological and Cellular Features of the Prostate Gland. A diagram 
of a ductal cross-section is shown with labels indicating cell types that are present in 
prostatic ducts including luminal secretory epithelial cells, basal epithelial cells, 
neuroendocrine cells, stromal smooth muscle cells, and stem cell candidates. Beneath the 
label for each cell type is a list of differentiation markers commonly used to distinguish 
these cell types. In the case of stem cell candidates, two studies have associated 
expression of either a set of markers including cytokeratins 5, 14, 8, 18, or 19, GSTpi, 
and p63 or high expression of α2β1-integrin with rare basal cells proposed as prostatic 







Figure 3: Stages of Prostate Cancer.  As prostate cancer progresses from Stage I to 
Stage IV, the cancer cells grow within the prostate, through the outer layer of the prostate 
into nearby tissue, and then to lymph nodes or other parts of the body.(National Cancer 






Figure 4: Pathway for Human Prostate Cancer Progression. Stages of progression are 
shown, together with molecular processes and genes/pathways that are likely to be 












Figure 5: Human Body: Mammary Gland Anatomy. Milk-producing gland 
characteristic of all female mammals and present in a rudimentary and generally 
nonfunctional form in males. Mammary glands are regulated by the endocrine system and 






Figure 6: Breast Tumor Progression.  Cross-section of a duct shows loss of epithelial 







Figure 7: Vicious Cycle of Cancer Progression A.  Normal bone turnover and/or 
remodelling observed in healthy physiologic systems B.  Pathologic bone remodelling, 
characterized by increased osteoclast and osteoblast activities, causes a spectrum of bone 
lesions in patients with bone metastasis, ranging from predominately osteoblastic to 









Figure 8:  The Epithelial–Mesenchymal Transition. EMT process is induced and 
regulated by effectors such as growth factors (TGFβ, PDGF, EGF), cytokines (Il-8) and 
ECM components. It is characterized by loss of epithelial markers such as E-cadherin and 






Figure 9: Snail Genes Occupy a Central Position in Triggering EMT in 
Physiological and Pathological Situations. Different signaling molecules have been 
implicated in the activation of Snail genes in several processes that subsequently lead to 
the conversion of epithelial cells into mesenchymal cells. Although the action of Snail in 
the epithelial–mesenchymal transition (EMT) as a direct transcriptional regulator 
(repressor) has been shown only for E-cadherin, different in vitro and in vivo approaches 
point to a series of target genes that are directly or indirectly regulated by these 
transcription factors. BMP, bone morphogenetic protein; FGF, fibroblast growth factor; 
ILK, integrin-linked kinase; PTH(rP)R, parathyroid-hormone-related peptide receptor; 







Figure 10: TMT Labeled Proteins Identified by MS and Organized According to 
Biological Processes.  Shows proteins up-regulated or down-regulated at least 1.2 fold in 







Figure 11: Quantitative Western Blot of key ER Stress Markers. Western blot 
analysis in C4-2 cells treated with 20 µg/ml MSKE as compared to ethanol-treated 
controls. As a loading control (total protein) was assessed. Expression of ER stress 
markers IRE1-alpha and GRP78 and pro-apoptotic markers DFF45, PARP and Caspase-
12 was analyzed and quantification of western blot analysis performed using Image J, 






Figure 12: MSKE Treatment Induces Autophagy. A) C4-2 Prostate cells were treated 
with MSKE for 72 hours with increasing concentrations (0µg/mL, 5µg/mL, 10µg/mL, 
and 20µg/mL). Fixation was performed with methanol/ethanol 1∶1 volume followed by 
washes with 1× PBS. The cells were then exposed to AO (5 μg/ml) for 15 minute at 
37°C, followed by washes with 1× PBS, prior to counterstaining with DAPI We observed 
that treatment with higher concentrations of MSKE (10 and 20μg/ml) showed extensive 
AO leakage into the cytosol, producing a diffuse yellow color and an increase in 




(B) Treatment with chloroquine inhibits autophagy.  C4-2 cells were treated with MSKE 
with and without a one hour co-treatment of 20µM chloroquine.   The cells were then 
exposed to AO (5 μg/ml) for 15 minute at 37°C, followed by washes with 1× PBS, prior 
to counterstaining with DAPI.  Chloroquine treatment reversed the effects of MSKE. (C) 
Immunofluorescence staining for LC3-B.  (D) Western blot analysis of LC3-B. 

















Figure 13: MSKE Induces Apoptosis. (A) C4-2 prostate cells were treated with 
increasing concentrations of 0µg/mL, 5µg/mL, 10µg/mL, and 20µg/mL for 72 hours. The 
cells were fixed with 4% paraformaldehyde and permeabilized with 0.1% sodium citrate 
and 0.1% Triton X. DNA fragmentation was determined by TdT-mediated dUTP nick 
end labeling (TUNEL).  TUNEL assay (green channel). DAPI (blue channel) is used to 
locate the nuclei of the cells. Increasing concentrations of MSKE induces apoptosis  
(B)Analysis of Apoptosis by  Annexin V/cell death apoptosis kit further confirmed that 
MSKE treatment increases apoptosis and that a co-treatment with chloroquine leads to a 




markers (Bax, Cleaved caspase 3 and 7) and anti-apoptotic marker (BCL2).  MSKE 
treatment increased Cleavage of Caspase 3 and 7 and expression of BAX indicating an 
increase in apoptotic events.    Co-treatment with chloroquine shows there is an increase 














Figure 14: Proposed Model Highlighting UPR (unfolded protein response) Pathway 
with Pro-apoptotic Protein Signatures Triggered by ER Stress in MSKE Treated 
C4-2 Prostate Cancer Cells.  Proposed model highlighting the unfolded protein 
response (UPR) pathway in a mitochondria-specific stress response (UPRmt) with pro- 
and anti-apoptotic protein signatures triggered by ER stress in MSKE treated C4-2. The 
model highlights insufficiency of folding or degradation capacity in the mitochondria 






Figure 15: Snail is Overexpressed in ARCaP Prostate Cancer Cell Line is Associated 
with Increased Superoxide In Vitro. (A) ARCaPE cells transfected stably with empty 
vector (ARCaP-Neo L) or Snail cDNA (ARCaP-Snail med, -Snail high) were utilized to 
analyze Snail levels by Western blot analysis. Quantification of the Western blot results 
by densitometry with normalization to actin levels was done using the Quantity One 
quantification software (BioRad). (B) 20,000 ARCaP Neo control or Snail-transfected 
clones were plated in 6-well plates overnight. The next day the cells were serum starved 
for 3 h, then treated with 50 μM PMA plus or minus 500 U/ml SOD for live cells. 




Hydro-Cy3 for 1 h followed by OD measurement at 530/590 nm. (C) Whole cell lysate 
was prepared from Neo- or Snail-transfected ARCaP cells treated with 1 or 50 μM PMA 
plus or minus 500 U/ml SOD for 1 h. 100 μl was mixed with HEPES/PBS buffer and 
25 μM of Hydro-Cy3 for 1 h followed by OD measurement at 530/590 nm. Results were 
normalized to protein concentrations that were measured I whole cell lysate using BCA 
assay. (D) 5000 ARCaP-Neo L or ARCaP-Snail med cells were plated in duplicate, 
overnight in 16-well chamber slides. The following day, cells were incubated with 5 μM 
MitoSOX reagent in the dark at 37°C for 10 minutes. The cells were then washed three 
times with warm HBS/CA/Mg buffer. Cells stained with MitoSOX (red) were counter-
stained with DAPI (blue) to view the nucleus and images taken with a fluorescence 
microscope. The results are representative of three independent experiments. 







Figure 16: LNCaP Prostate Cancer Cells Stably Transfected with Snail Display 
Increased Superoxide In Vitro. (A) Snail expression was tested by Western blot 
analysis in various LNCaP cell clones stably expressing Snail or empty vector (Neo5), as 
well as parental LNCaP cells. (B) 20,000 LNCaP Neo control or Snail-transfected clones 
were plated in 6-well plates overnight. Subsequently, the media was replaced with 
HEPES/PBS buffer containing 25 μM of Hydro-Cy3 for 1 h followed by OD 
measurement at 530/590 nm. (C) Whole cell lysate prepared from Neo- or Snail-
transfected ARCaP cells was mixed with HEPES/PBS buffer and 25 μM of Hydro-Cy3 
for 1 h followed by OD measurement at 530/590 nm. Results were normalized to protein 
concentrations that were measured I whole cell lysate using BCA assay. (D) 5000 




chamber slides. The following day, cells were incubated with 5 μM MitoSOX reagent in 
the dark at 37°C for 10 minutes. The cells were then washed three times with warm 
HBS/CA/Mg buffer. Cells stained with MitoSOX (red) were counter-stained with DAPI 
(blue) to view the nucleus and images taken with a fluorescence microscope. The results 









Figure 17: Muscadine Grape Extract (MSKE) and SOD Abrogates Snail-Mediated 
Superoxide Species in LNCaP and ARCaP Cells and Reduces Cell Migration. (A) 
LNCaP-Snail high, ARCaP-Snail med and ARCaP-Snail high cells were plated 
overnight, serum starved for 3 h followed by treatments with either 5 μg/ml MSKE, 
20 μg/ml MSKE, or 500 u/ml SOD for 3 days. Ethanol (EtOH) treated cells Neo- or 




cell lysates were prepared and 100 μl incubated with 25 μM Hydro-Cy3 for 15 min. OD 
was measured at 530/590 nm and normalized to protein concentrations. (B) LNCaP-Snail 
high or (C) ARCaP-Snail med was treated with 5 μg/ml MSKE, 20 μg/ml MSKE or 500 
U/ml SOD for 3 days. Cells were then trypsinized and 50,000 cells plated on collagen-
coated boyden chambers overnight. For LNCaP cells, since their cell migratory potential 
is low, a serum gradient was applied with 0.1% serum in the top chamber and 10% serum 
in the bottom chamber. For ARCaP cells, the top and bottom chamber both contained 
0.1% serum. Cells that had migrated to the underside of the cell insert were solubilized 
with Sorenson solution and OD assayed at 590 nm to obtain relative cell migration. 
Results are representative of triplicate experiments performed independently, with data 








Figure 18:  MSKE and SOD can Revert Snail-Mediated EMT in ARCaP Cells. (A) 
ARCaP-Snail high cells were treated with 5 or 20 μg/ml MSKE for 3 days and Snail, E-
cadherin and vimentin EMT markers analyzed by Western blot analyses. 5 μg/ml reverted 
EMT more efficiently than 20 μg/ml as observed by decreased vimentin and increased E-
cadherin, as compared to untreated or EtOH-treated Snail high cells. (B) ARCaP-Snail 
med cells were treated with 5 μg/ml MSKE or 500 U/ml SOD for 3 days followed by 
analysis of Snail, E-cadherin and vimentin by Western blot. Both MSKE and SOD 
reverted EMT as shown by increased E-cadherin and decreased vimentin. Untreated or 







Figure 19: MSKE may Exert its Inhibitory Effect on EMT and/or Superoxide via 
Antagonizing the JAK/STAT Pathway in Prostate Cancer Cells (A) STAT-3 and p-
STAT-3 levels in ARCaP Neo and ARCaP-Snail med and ARCaP-Snail high (B) 
ARCaP-Snail med and (C) ARCaP Snail high cells were treated with 5 μg/ml MSKE and 
20 μg/ml for 3 days followed by analysis of STAT-3 and p-STAT-3 by western blot. 
Compared to untreated or DMSO control treated, 20 μg/ml showed a decrease in STAT-3 
and p-STAT-3 as compared to 5 μg/ml MSKE or control. Untreated cells were utilized as 








Figure 20: Pathway by Which MSKE Antagonizes Snail-Mediated EMT in Prostate 
Cancer Cells. Snail induces EMT via superoxide production which is characterized by 
decreased E-cadherin expression, increased vimentin expression and increased cell 
migration. MSKE antagonizes Snail-mediated EMT by inhibiting Snail expression 












Figure 21: Cat L Expression Increases with Tumor Progression. (A) 
Immunohistochemical (IHC) analysis was performed using a 96 core prostate 





prostate cancer show that Cat L increases with tumor progression. Bar represents 50 μM. 
(B) Normal/tumor matched invasive ductal carcinoma (IDC) grades 1 and 3, infiltrating 
carcinoma (IFC) grade 3, adenocarcinoma (grade 3) and metaplastic carcinoma (MPC) 
grade 3 were analyzed for expression of Cat L by western blot analysis. Mature Cat L 
expression was generally higher in tumor as compared to normal tissue. Alpha (α)-tubulin 
was used as a loading control (C) Matching H&E staining of the 96 core prostate 
adenocarcinoma tissue microarray with 36 duplicated cancers and 8 with match normal 
adjacent tissue, 3 cases of metastasis in bones and one in abdominal wall A-Normal 
prostate epithelium; B-stage II adenocarcinoma C-Stage III adenocarcinoma D-Stage IV 
Adenocarcinoma E- Stage IV metastatic adenocarcinoma to abdominal wall F-Stage IV 









Figure 22: Snail Overexpression Increases Cat L and Cat S Expression/Activity. 
Prostate cancer cells stably overexpressing Snail (ARCaP-Snail, LNCaP-Snail); breast 
cancer cells stably overexpressing Snail (MCF-7 Snail) or C4-2 prostate cancer cells with 
stable Snail knockdown (C4-2 Snail shRNA) were analyzed for Snail and Cat L 
expression as compared to Neo and nonsilencing (NS) controls, respectively, by (A) 
western blot analysis and (B) Zymography. For zymography, the acetate buffer at pH 6 
shows both Cat L and Cat S activity. Cat L activity was further quantified with 
densitometry of each band on the gel using NIH image J and shown below the 




SEM of data were obtained from three independent replicate experiments. Statistical 
analysis was done with Student’s t-test; (n = 3, ***P < 0.001, **P < 0.01, *P < 0.05). (C) 
2 million LNCaP-Neo or LNCaP-Snail cells were injected subcutaneously into nude male 
mice (N = 6) and 5 weeks later, mice were killed and tumor volumes measured and 
graphed. (D) Tumors were isolated from LNCaP-Neo and LNCaP-Snail xenografts, fixed 
and immunofluorescent analysis performed on tumor xenograft sections using Snail 
(green) and Cat L (red) antibodies. 4′, 6-diamidino-2-phenylindole was used to stain 












Figure 23: STAT-3 Knockdown Decreases Snail and Cat L Expression/Activity. C4-
2 and ARCaP-Snail cells were transiently transfected with control siRNA or STAT-3 
siRNA and (A) the expression levels of Snail and Cat L were determined by western blot 
analysis. Snail and Cat L expression decreased with STAT-3 knockdown. (B) Cat L 
activity examined by zymography upon STAT-3 knockdown. (C) Results of the 
zymography was quantified by densitometry using NIH Image J software which showed 
that STAT-3 knockdown significantly decreases Cat L activity. Asterisks represent P 




were normalized to untreated controls and the mean ± SEM of data were obtained from 
















Figure 24: MSKE Inhibits Snail Signaling. C4-2 (prostate), ARCaP- Snail (prostate) 
and MCF-7 Snail (breast) cancer cells were treated with 5μM Z-FY-CHO (Cat L-specific 
inhibitor), 5μg/ml or 20μg/ml MSKE for 72 h. (A) Subsequently, the expression levels of 
Snail, Cat L, phospho-STAT-3 (pSTAT-3) and total STAT-3 were determined by western 
blot analysis. α-tubulin was used as a loading control. (B) Additionally, Cat L activity 
was determined by gelatin zymography. (C) Cat L activity was quantified by 
densitometry using NIH Image J software which showed that MSKE similarly to Z-FY-




3, ***P < 0.001, **P < 0.01, *P < 0.05). Values were normalized to untreated controls 
and the mean ± SEM of data were obtained from three independent replicate experiments. 


















Figure 25: MSKE and Z-FY-CHO Inhibit Cell Migration and Invasion. ARCaP-
Snail (prostate) and MCF-7 Snail (breast) cancer cells were treated with 5 μM Z-FY-
CHO, 5 or 20 μg/ml MSKE for 72 h. 5 × 104 cells were plated on transwell inserts coated 
with (A, B) Type-I collagen for migration and (C, D) matrigel for invasion assays. The 
number of cells that migrated/invaded through the transwell membranes was determined 
by counting at least four random microscopic fields. Results were compared to Neo 
empty vector control or untreated cells. It showed that Snail overexpression increased cell 
migration and invasion which was abrogated by both MSKE and Z-FY-CHO. Asterisks 
represent P value of statistical significance (n = 3, ***P < 0.001, **P < 0.01, *P < 0.05). 
Values were normalized to untreated controls and the mean ± SEM of data were obtained 
from three independent replicate experiments with at least three wells per treatment group 






Figure 26: MSKE Inhibits Snail-Mediated Osteoclastogenesis. 3 × 103 (A) ARCaP-
Neo/Snail (prostate) or (B) MCF-7 Neo/Snail (breast) cancer cells were co-cultured with 
40 × 104 macrophages plus 1 ng/ml M-CSF for 14 days and treated with either 50 ng/ml 
Osteoprotegrin (RANKL antagonist known to inhibit osteoclastogenesis), 5 μM Z-FY-
CHO, 5 μg/ml or 20 μg/ml MSKE. Macrophages only were also used as a control. Half 
the media was replaced every 3 days with 1 ng/ml M-CSF plus or minus treatments. 
TRAP staining was subsequently performed to show mature osteoclasts (purple) having 
three or more nuclei (inset) while the cancer cells appeared yellow.  Graphical 
representation of the number of osteoclasts are shown as mean ± SEM of data were 




treatment group in each individual replicate. Neo empty vector was also included as a 
control. Statistical significance was assessed using GraphPad Prism software by paired 
Student’s t-test. Asterisks represent P value of statistical significance (n = 3, ***P < 










Figure 28. Mesenchymal Prostate and Breast Cancer Cells Display Increased 
Nuclear Cat L Expression and Activity.  (A) Western Blot analysis of EMT markers. 
Mesenchymal cells (MDA-MB-231, MCF-7 Snail, and ARCaP-Snail) with high Snail 
and vimentin, and low E-cadherin expression displayed higher Cat L expression and 
activity as compared to epithelial cells (MCF-7, MCF-7 Neo, ARCaP-Neo) except for 
ARCaP M that despite being mesenchymal, had lower Cat L expression/activity as 
compared to ARCaP E.  Mesenchymal cells have an increase in Cux1 cleavage products, 
particularly p90 isoform, but the overexpression of Snail leads to the p110 and p90 
isoforms (B) Zymogram showing Cat L activity. (C) Densitometry of Cat L activity (D) 
subcellular fractionation of parental cell lines.  Mesenchymal cells (ARCaP-M, MDA-
MB-231, and MDA-MB-468) have increase expression of Snail, mature Cat L and 




(ARCaP-E and MCF-7). Cytoplasmic fraction compared to GAPDH, nuclear fraction 
compared to Topoisomerase and Endoplasmic reticulum compared to calnexin.  (E) 
Immunofluorescence shows that Cat L was localized in the cytoplasm and nucleus of all 
the mesenchymal cells including ARCaP M while it was predominantly cytoplasmic in 
epithelial cells Graphical data represents three independent experiments * means 0.05 > p 











Figure 29: Single and Merged Images from Immunofluorescent Staining for EMT 
Markers (E-cadherin, Snail, and Vimentin) and Cat L in Breast Cancer Cells.  Cat L 
was localized in the cytoplasm and nucleus of all the mesenchymal cells (MDA-MB-231, 
MDA-MB-468 and MCF-7-Snail) while it was predominantly cytoplasmic in epithelial 






Figure 30: Z-FY-CHO Changes the Subcellular Location of Cat L from Nuclear to 
Cytoplasmic and Decreases the Expression of Snail. ARCaP-M cells were treated with 
1, 5, 20µm Z-FY-CHO for 72 hrs. (A) Western blot analysis shows treatments with Z-
FY-CHO led to decreased expression of vimentin and Snail and increased E-cadherin 
suggestive of mesenchymal to epithelial transition. (B) Subcellular fractionation of 
ARCaP-M cells treated with Z-FY-CHO show that there is decrease in expression of 
Snail and Cat L in the nucleus. ( C )  Immunofluorescence analysis shows treatments with  
Z-FY-CHO led to a change in localization of Cat L from nuclear/cytoplasmic to 
predominantly cytoplasmic, along with an increase expression of epithelial markers (E-




epithelial cell line ARCaP-E.  Graphical data represents three independent experiments * 

















Figure 31: Z-FY-CHO Changes the Subcellular location of Cat L from Nuclear to 
Cytoplasmic and decreases the expression of Snail. MDA-MB-468 cells were treated 
with 1, 5, 20 µm Z-FY-CHO for 72 hrs. (A)  Western blot analysis shows treatments with 
Z-FY-CHO led to decreased expression of vimentin and Snail and increased E-cadherin 
suggestive of mesenchymal to epithelial transition. (B) Zymogram shows a decrease in 
Cat L activity following treatment with Z-FY-CHO (C ) Densitometry of Cat L activity 
(D) Immunofluorescence analysis shows treatments with  Z-FY-CHO led to a change in 




an increase expression of epithelial markers (E-Cadherin) and a decrease in mesenchymal 
markers (Vimentin, Snail). Graphical data represents three independent experiments * 
means 0.05 > p value > 0.01, ** means 0.01 > p value > 0.001, and *** means p value < 


















Figure 32: Treatment with Z-FY-CHO Reverts EMT. MDA-MB-231 and HS-578-
Tcells were treated with 1, 5, 20um Z-FY-CHO for 72 hrs. Western blot analysis shows 
treatments with Z-FY-CHO led to decreased expression of vimentin and Snail suggestive 
of mesenchymal to epithelial transition. Zymogram shows a decrease in Cathepsin L 
activity following treatment with Z-FY-CHO (A) MDA-MB-231 (B) HS-578T (C) 





Figure 33: Z-FY-CHO Changes the Subcellular Location of Cat L from Nuclear to 
Cytoplasmic and Decreases the Expression of Snail. ARCaP-Snail cells were treated 
with 1, 5, 20µm Z-FY-CHO for 72 hrs. (A Western blot analysis shows treatments with 
Z-FY-CHO led to decreased expression of vimentin and Snail and increased E-cadherin 
suggestive of mesenchymal to epithelial transition. (B) Zymogram shows a decrease in 
Cat L activity following treatment with Z-FY-CHO (C) Densitometry of Cat L activity 
(D )  Immunofluorescence analysis shows treatments with  Z-FY-CHO led to a change in 
localization of Cat L from nuclear/cytoplasmic to predominantly cytoplasmic along with 




markers (Vimentin, Snail). Graphical data represents three independent experiments * 

















Figure 34: Z-FY-CHO Changes the Subcellular Location of Cat L from Nuclear to 
Cytoplasmic and Decreases the Expression of Snail. MCF-7 Snail cells were treated 
with 1, 5, 20 µm Z-FY-CHO for 72 hrs. (A) Western blot analysis shows treatments with 
Z-FY-CHO led to decreased expression of vimentin and Snail and increased E-cadherin 
suggestive of mesenchymal to epithelial transition. (B) Zymogram shows a decrease in 
Cat L activity following treatment with Z-FY-CHO (C ) Densitometry of Cat L activity 
(D) Immunofluorescence analysis shows treatments with Z-FY-CHO led to a change in 




an increase expression of epithelial markers (E-Cadherin) and a decrease in mesenchymal 
markers (Vimentin, Snail). Graphical data represents three independent experiments * 


















Figure 35: Z-FY-CHO and Cat L siRNA Decrease Snail levels While Z-FY-
CHO also Excludes Nuclear Localization of Cat L. ARCaP cells 
overexpressing Snail (ARCaP-Snail) were treated with 5 µM Z-FY-CHO for 72 
hrs and Cat L siRNA. (A) Western blot showing a knockdown of Cat L using 
Cat L siRNA (B) Zymogram showing decrease Cat L activity with Cat L 
siRNA. (C) Densitometry of Cat L activity (D) Comparison of EMT markers in 
ARCaP Snail cells treated with Z-FY-CHO and Cat L siRNA (E) Subcellular 
fractionation showed that mature Cat L is higher in the nucleus for ARCaP-
Snail as compared to ARCaP-Neo and that p110 and p90 isoforms of CUX1 are 
expressed only in ARCaP-Snail cells and that treatment with Z-FY-CHO and 
Cat L siRNA decreased levels of nuclear Cat L and prevents the proteolytic 




ARCaP-Snail.   Z-FY-CHO and Cat L siRNA decreases the expression of Snail.  
GAPDH and Topoisomerase I (TOPI) are used as controls for integrity of 
cytoplasmic and nuclear fractions. Calnexin is used as a control for integrity of 
















 Figure 36: Z-FY-CHO and Cat L siRNA Inhibits Snail-Mediated Cell Invasion 
and Migration. ARCaP-Snail prostate and MCF-7 Snail breast cancer cells were 
treated with 5 µM Z-FY-CHO or 50 nM Cat L siRNA for 72 h followed by  (A) 
Migration  assay  in a boyden chamber coated with collagen  and cells allowed to 
migrate for 5 h, or (B) invasion assay in a boyden chamber coated with matrigel for 
invasion allowed to invade for 24 h. ARCaP-E/ARCaP-M and MCF7/MDA-MB-
231/MDA-MB-468 cells were also included.  Treatment with Z-FY-CHO and Cat L 
siRNA decreased migration and invasion in mesenchymal cells. Graphical data 
represents three independent experiments; * means 0.05 > p value > 0.01, ** means 






Figure 37: CUX1 Factor Binds to the Snail and E-cadherin Promoter in 
Mesenchymal Cells and Binding can be Antagonized by Z-FY-CHO. Chromatin was 
immunoprecipitated with goat IgG as a negative control, anti-RNA polymerase II 
antibody as a positive control or anti-CDP/Cux antibody. Real-time PCR was 
subsequently performed with primers that recognize the Snail and E-Cadherin promoter.  
The samples were run on an agarose gel and input included as control for loading. ChIP 
PCR was also performed with primers to Snail control (area where CDP/Cux does not 
bind to the Snail promoter.as another negative control. The results of the real-time PCR 
were plotted as fold change of binding to Snail and E-cadherin promoter.  The 
experiments were performed in triplicate at least three times independently. Graphical 
data represents three independent experiments * means 0.05 > p value > 0.01, ** means 




ARCaP-Neo, ARCaP-Snail cells were used for ChIP analysis. In ARCaP M and ARCaP-
Snail cells CDP/Cux binds to Snail promoter and E-cadherin promoter as compared to 
ARCaP E and ARCaP-Neo. Results of RT-PCR on agarose gel.  (B) Z-FY-CHO (5 and 
20 µM) prevented the binding of CDP/Cux to the Snail and E-cadherin promoter. Results 
of RT-PCR on agarose gel (C) MCF-7 Snail cells CDP/Cux binds to Snail promoter and 
E-cadherin promoter as compared to MCF-7 Neo.  Treatment with Z-FY-CHO (5 µM) 
prevented the binding of CDP/Cux to the Snail and E-cadherin promoter. Results of RT-








Figure 38: Positive and Negative Controls of ChIP.  Chromatin was 
immunoprecipitated with goat IgG as a negative control, anti-RNA polymerase II 
antibody as a positive control.  Real-time PCR was subsequently performed with primers 
that recognize the Snail and E-Cadherin promoter. ChIP PCR was also performed with 
primers to Snail control (area where CDP/Cux does not bind to the Snail promoter as 
another negative control. The results of the real-time PCR were plotted as fold change of 
binding to Snail and E-cadherin promoter.  The experiments were performed in triplicate 
at least three times independently. Graphical data represents three independent 




ChIP analysis. (B). Treatment with Z-FY-CHO (5 and 20 µM) in ARCaP-Snail cells (C) 











Figure 39: Positive Feedback Loop between Snail-Cat L-CUX1 and Back to Snail 
Drives EMT and can be Inhibited by Cat L Inhibitor. A positive feedback loop may 
exist whereby Snail overexpression may promote its own transcription and lead to E-
cadherin repression in part through binding of CUX1 to the Snail and E-cadherin 
promoter, leading to an increase in EMT, migration and invasion in prostate and breast 
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Table 1. Anatomic Stage/Prognostic Group
Stage  T  N  M  PSA*  Gleason  
I 
T1a-c N0 M0 PSA < 10 Gleason ≤6 
T2a N0 M0 PSA < 10 Gleason ≤6 
T1-T2a N0 M0 PSA X Gleason X 
IIA 
T1a-c N0 M0 PSA < 20 Gleason 7 
T1a-c N0 M0 PSA ≥10 but < 20 Gleason ≤6 
T2a N0 M0 PSA < 20 Gleason ≤7 
T2b N0 M0 PSA < 20 Gleason ≤7 
T2b N0 M0 PSA X Gleason X 
IIB 
T2c N0 M0 Any PSA Any Gleason 
T1-2 N0 M0 PSA ≥20 Any Gleason 
T1-2 N0 M0 Any PSA Gleason ≥8 
III T3a-b N0 M0 Any PSA Any Gleason 
IV 
T4 N0 M0 Any PSA Any Gleason 
Any T N1 M0 Any PSA Any Gleason 
Any T Any N M1 Any PSA Any Gleason 
*If PSA or Gleason is not available, grouping should be determined by T stage and/or either 




Table 2. Histopathologic Grade 
Histopathologic grade (G)  
GX Gleason score cannot be assessed 
Gleason ≤6 Well differentiated (slight anaplasia) 
Gleason 7 Moderately differentiated (moderate anaplasia) 
Table 2. Histopathologic grade 
Gleason 8-10 
Poorly differentiated or undifferentiated 
Table 3. TNM Classification for Prostate Cancer  
Primary tumor (T)  
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
T1 Clinically inapparent tumor not palpable or visible by imaging 
T1a Tumor incidental histologic finding in ≤5% of tissue resected 
T1b Tumor incidental histologic finding in >5% of tissue resected 
T1c 
Tumor identified by needle biopsy (because of elevated prostate specific 
antigen [PSA] level) 
T2 
Tumor confined within prostate; tumors found in 1 or both lobes by 
needle biopsy but not palpable or reliably visible by imaging 
T2a Tumor involves one-half of 1 lobe or less 
T2b Tumor involves more than one-half of 1 lobe but not both lobes 
T2c Tumor involves both lobes 
T3 
Tumor extends through the prostatic capsule; invasion into the prostatic 
apex, or the prostatic capsule is classified not as T3 but as T2 
T3a Extracapsular extension (unilateral or bilateral) 
T3b Tumor invading seminal vesicle(s) 
T4 
Tumor fixed or invades adjacent structures other than seminal vesicles 
(eg, bladder, levator muscles, and/or pelvic wall) 
Pathologic (pT)*  
pT2 Organ confined 
pT2a Unilateral, involving one-half of 1 lobe or less 




pT2c Bilateral disease 
pT3 Extraprostatic extension 
pT3a Extraprostatic extension or microscopic invasion of the bladder neck 
pT3b Seminal vesicle invasion 
pT4 Invasion of the bladder and rectum 
*Positive surgical margin should be indicated by an R1 descriptor (residual 
microscopic disease). 
Regional lymph nodes (N)  
Clinical 
NX Regional lymph nodes were not assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in regional lymph node(s) 
Pathologic 
PNX Regional nodes not sampled 
pN0 No positive regional nodes 
pN1 Metastases in regional nodes(s) 
Distant metastasis (M)*  
M0 No distant metastasis 
M1 Distant metastasis 
M1a Nonregional lymph nodes(s) 
M1b Bone(s) 
M1c Other site(s) with or without bone disease 
*If more than 1 site of metastasis is present, use the most advanced category 
(pM1c). 
 
Table 4: Prostate Cancer Cell lines 
 
Parental and 
Transfectant Cell lines 
Classifications Cell line derivatives Origin 
LNCaP Androgen sensitive, 
adenocarcinoma 
LNCaP-Neo, LNCaP-Snail 50-yr Caucasian male, left supraclavicular 
lymph node metastasis 
C4-2 Androgen independent 
and sensitive 
C4-2 NS, C4-2 E8 Derived from LNCap cells that grows in 
the absence of androgens 
ARCaP Androgen repressed ARCaP-E, ARCaP-M, 
ARCaP-Neo, ARCaP-Snail 
Derived from the ascites fluid of an 83-
year-old Caucasian man diagnosed with 










Classifications Known expression 
Characteristics 
Origin 
MCF-7 Adenocarcinoma, epithelial, 
luminal A 
ER+ PR+ HER2- 69-yr Caucasian female 





MCF-7 Snail Mesenchymal, low adhesion Snail cDNA (6SA) ER-  
MDA-MB-231 Mesenchymal-like, 
Adenocarcinoma, TNBC 
ER- PR- HER2- 51-yr Caucasian female 
MDA-MB-468 Pleural effusion with 
metastatic adenocarcinoma a 
of the breast, Basal like-1 
ER- PR- HER2- 51-yr African American 
female 
 
Table 6. Differentially Expressed Proteins in MSKE-Treated and Control Cultures. 
Note: The asterisk (*) indicates the proteins discussed  




MW [kDa] calc. pI 
APOPTOSIS 
Peptidyl-prolyl cis-
trans isomerase F, 
mitochondrial 
85.79 2.63417E-09 PPIF 21.26 1.23 22.03 9.38 
Aldo-keto 
reductase family 1 
member C1 
20.02 0.009954054 AKR1C1 5.45 1.88 24.94 7.49 
PAX3- and PAX7-
binding protein 1  
31.82 0.000657658 PAXBP1 3.13 -1.43 57.40 5.25 









30.77 0.000837529 BCLAF1 3.64 -1.23 52.89 11.22 
Cyclin-dependent 
kinase 5 
31.84 0.000654636 CDK5 5.48 -1.20 33.28 7.66 
ARL-6-interacting 
protein 1 
647.58 1.7459E-65 CG10326 18.54 1.32 17.15 7.96 
*Cytochrome c 
oxidase subunit 4 
isoform 1, 
mitochondrial 





107.11 1.94405E-11 COX7A2 15.66 1.23 9.39 9.76 
casein kinase 2, 
alpha 1 
polypeptide 




*Catenin delta-1 818.43 1.43523E-82 CTNND1 19.21 -1.29 90.34 7.03 
Drebrin-like 
protein 
45.33 2.93089E-05 DBNL 3.4 -1.20 43.01 5.03 
Diablo homolog, 
mitochondrial 
29.52 0.001116863 DIABLO 37.66 1.46 8.84 5.01 
Dynein light chain 
2, cytoplasmic 
163.12 4.87128E-17 DYNLL2 32.58 -1.23 10.34 7.37 
elongation factor 
1-delta isoform 4 





140.93 8.07457E-15 GCLM 18.5 1.32 28.60 6.02 
Growth/differentia
tion factor 15 
188.91 1.28552E-19 GDF15 14.29 1.32 34.12 9.66 
*Lactoylglutathion
e lyase 
795.53 2.79874E-80 GLO1 55.62 -1.20 19.03 6.05 
Golgi 
phosphoprotein 3 
61.95 6.37832E-07 GOLPH3 12.85 -1.24 32.91 6.71 
High mobility 
group protein B1 
757.12 1.9406E-76 HMGB1 39.53 -1.27 24.88 5.74 
lamin-B1 isoform 
2 
55.31 2.94217E-06 LMNB1 2.66 1.24 43.00 5.12 
mitogen-activated 
protein kinase 3 




316.04 2.48889E-32 MIF 55.65 -1.26 12.47 7.88 
Cytochrome c 
oxidase subunit 2 





86.98 2.00638E-09 NAE1 5.17 1.27 50.59 5.27 
occludin 78.58 1.38788E-08 OCLN 10.5 -1.64 23.31 6.06 
*Programmed cell 
death protein 6 
428.90 1.28687E-43 PDCD6 9.63 1.31 15.57 8.19 
Prohibitin 1313.0
7 





28.56 0.001393157 PIN1 9.2 -1.60 18.23 8.82 
Protein kinase C 
delta type 









73.96 4.01791E-08 PTPN6 3.43 -1.20 66.19 7.23 
*Ras-related 
protein Rab-21 
116.33 2.32652E-12 RAB21 4.89 1.20 24.33 7.94 
*Ras-related 
protein Rab-5A 
157.52 1.76979E-16 RAB5A 12.44 1.27 22.16 8.82 
*Ras-related 
protein Rab-5B 
















25.09 0.00309803 VAV2 1.91 -1.27 96.97 6.90 
glycogen synthase 
kinase 3 beta 





inducer in the 
nucleus isoform 3 
124.92 3.21851E-13 ACIN1 3.23 -1.60 147.30 6.73 
*Protein LYRIC 25.49 0.00282488 MTDH 3.04 1.91 57.49 9.54 
*Phosphoglycerate 
kinase 2 
651.02 7.91169E-66 PGK2 20.14 -1.22 44.77 8.54 
*Phosphatidylinosi
tol 4-kinase alpha 
27.37 0.001832314 PI4KA 0.93 1.19 231.17 6.87 





72.86 5.17257E-08 ARL8A 9.14 -1.37 21.40 7.77 
BolA-like protein 
2 
150.26 9.41588E-16 BOLA2 23.03 -1.28 16.92 8.19 
Calcium-binding 
protein 39 















118.28 1.48531E-12 GSPT1 6.01 1.20 55.72 5.62 
Nucleolar GTP-
binding protein 1 

































95.87 2.58985E-10 MCM6 36.14 -1.63 9.53 4.41 

















12A isoform b 





85.59 2.76058E-09 PPP1R8 10.24 -1.49 22.27 5.92 
Serine/threonine-
protein 
phosphatase 2A 55 
kDa regulatory 
subunit B alpha 
isoform 




phosphatase 2A 56 
kDa regulatory 
subunit delta  










61.42 7.2062E-07 PRKAG1 7.69 -1.28 28.27 7.02 




40.85 8.22243E-05 SPC24 11.26 -1.24 17.30 4.93 







120.37 9.17712E-13 UBR5 1.5 1.21 308.38 5.85 






254.32 3.7017E-26 AHNAK 10.05 -1.24 628.70 6.15 
actin-related 
protein 2/3 
complex subunit 4 
isoform b 
27.12 0.001940886 ARPC4 10.26 -1.21 9.55 7.52 
Actin-related 
protein 2/3 
complex subunit 5 
42.98 5.03501E-05 ARPC5 9.63 1.37 14.80 5.06 
CCDC88A protein 61.95 6.37733E-07 CCDC88A 0.33 1.21 207.67 5.97 




40.21 9.52796E-05 CKAP5 4.93 1.32 22.74 8.05 
CLIP-associating 
protein 2 
105.22 3.00771E-11 CLASP2 1.81 1.31 138.78 8.34 
claudin domain-
containing protein 
1 isoform b 
28.75 0.001333521 CLDND1 5.07 1.43 31.03 6.11 
Protein cordon-
bleu 
22.69 0.005382698 COBL 0.55 1.61 136.60 8.07 
*cortactin 28.61 0.001377209 CTTN 9.81 1.69 29.60 4.91 
DmX-like protein 
2 




35.27 0.000297167 DNAJB6 19.7 1.25 7.88 7.40 
Niban-like protein 
1 
147.68 1.7054E-15 FAM129B 5.73 -1.22 82.63 6.15 
Filamin-B 2200.5
6 








36.74 0.000211836 IFT27 6.2 2.31 14.02 4.64 
Junction 
plakoglobin 
400.46 8.9848E-41 JUP 14.63 -1.24 81.69 6.14 
Kinesin-like 
protein 
26.05 0.002483133 KIF3C 0.89 1.91 75.75 7.15 
Kinesin light chain 
2 
23.07 0.004931738 KLC2 1.15 1.25 57.14 8.21 




0 KRT8 62.32 -1.27 53.67 5.59 
LIM domain and 
actin-binding 
protein 1 







49.94 1.01391E-05 MAEA 19.63 -1.28 11.83 8.00 
Microtubule-
associated proteins 
1A/1B light chain 
3 beta 2 
32.17 0.000606736 MAP1LC3B
2 





72.66 5.42001E-08 MPP5 8.05 -1.26 17.18 6.70 
Protein PRRC1 161.42 7.21439E-17 PRRC1 6.97 1.22 46.67 5.83 
Radixin 176.11 2.44856E-18 RDX 7.89 1.30 68.52 6.37 
Ras-related protein 
R-Ras 





98.76 1.32928E-10 SLC9A3R1 14.65 -1.42 29.42 6.80 
spectrin, beta, non-
erythrocytic 2 
35.29 0.000295801 SPTBN2 1.61 -1.48 105.60 7.75 




6.7485E-124 TUBB6 55.67 -1.22 44.57 4.93 









33.77 0.000419759 EIF2B1 4.61 1.51 16.92 6.90 


















364.95 3.20115E-37 ERP29 26.05 1.30 28.98 7.31 
Endoplasmin 6243.8
2 





0 HSPA5 60.24 1.67 72.29 5.16 

































30.71 0.00084918 TMX2 10.47 1.22 29.62 8.65 
E3 UFM1-protein 
ligase 1 




domain member 1 
protein (Fragment) 





family member E 
isoform 3 
313.17 4.81956E-32 ANP32E 22.27 -1.43 25.11 3.74 
Ataxin-2-like 
protein 




382.78 5.27164E-39 BANF1 40.45 -1.36 10.05 6.09 
C5orf38 protein 34.05 0.000393587 C5orf38 8.15 1.33 14.68 11.27 
chromobox 
homolog 1 
157.35 1.8397E-16 CBX1 24.4 -1.22 19.31 5.02 






45.54 2.79254E-05 CHCHD2 11.26 1.52 15.50 9.22 
UMP-CMP kinase 
isoform a 













349.20 1.20135E-35 EDC4 11.86 -1.25 109.66 5.99 
Elongation factor 
1-beta 
352.91 5.11228E-36 EEF1B2 44.89 1.20 24.75 4.67 
Zinc 
phosphodiesterase 
ELAC protein 2 
37.70 0.000169824 ELAC2 3.79 -1.20 56.06 7.43 
EWS RNA-
binding protein 1 





factor 1 isoform 2 
68.69 1.35317E-07 GRSF1 6.92 -1.34 36.59 5.69 
general 
transcription factor 
IIA, 1, 19/37kDa 
76.72 2.12814E-08 GTF2A1 18.64 -1.60 6.74 4.72 
General 
transcription factor 
IIF subunit 2 
59.04 1.24847E-06 GTF2F2 5.22 -1.28 28.36 9.23 
histone H2A.V 
isoform 2 











binding protein 1, 
37kDa) 
555.96 2.53589E-56 HNRNPD 50.89 -2.18 12.63 8.57 
insulin-like growth 
factor 2 mRNA 
binding protein 3 









188.09 1.5512E-19 MRPL12 29.29 1.47 21.33 8.87 
myb-related 
protein A isoform 
2 
28.34 0.001465548 MYBL1 1.45 1.30 78.90 6.68 
Myosin Ic 575.17 3.03883E-58 MYO1C 15.53 -1.25 92.27 8.87 
nuclear cap 
binding protein 
subunit 1, 80kDa 































33.65 0.000431519 PTRHD1 17.86 -1.26 15.80 9.10 
retinoblastoma 
binding protein 7 
33.52 0.000444631 RBBP7 7.69 -1.33 46.91 5.07 
RNA-binding 
protein 10 isoform 
5 
53.58 4.38531E-06 RBM10 3.92 1.51 110.30 6.28 
Splicing factor 45 36.91 0.00020387 RBM17 4.99 1.20 44.93 5.97 
ATP-dependent 
DNA helicase Q1 
47.07 1.9619E-05 RECQL 2.47 -1.46 73.41 7.88 
ribonuclease H2 
subunit B isoform 
2 








74.83 3.28852E-08 RPP38 6.36 -1.32 31.81 9.92 
splicing factor 3A 
subunit 1 isoform 
2 




31.32 0.000737904 SNW1 2.67 1.20 43.31 9.70 
Splicing regulatory 
glutamine/lysine-
rich protein 1 












120.94 8.056E-13 SRSF5 25.81 -1.37 14.43 10.08 
Transcription 
elongation factor 
A protein 1 








46.82 2.0797E-05 TRMT5 2.95 1.33 58.21 8.62 
Exportin-5 28.18 0.001521507 XPO5 12.21 -1.20 136.22 5.80 
zinc finger, CCHC 
domain containing 
8 
72.69 5.3827E-08 ZCCHC8 12.28 -1.52 18.10 4.65 
zinc finger protein 
2 (Fragment) 
27.62 0.001729816 ZNF2 0.83 1.43 118.55 6.43 
Zinc finger protein 
511 
59.64 1.08643E-06 ZNF511 5.56 -1.51 28.25 7.66 
*Zinc finger 
SWIM domain-










subunit 2 isoform 
2 precursor 
35.79 0.000263633 RPN2 15.77 1.22 67.68 6.06 
IMMUNE RESPONSE  
Beta-defensin 119 25.85 0.002601985 DEFB119 7.14 -1.92 9.81 8.57 
F-box/LRR-repeat 
protein 8 




74.73 3.36284E-08 GNL1 4.2 1.80 28.69 4.69 





25.92 0.002558586 HLA-DQB1 5.88 1.31 15.76 8.85 
Interferon 
regulatory factor 7 





38.59 0.000138357 MAP2K3 5.66 1.33 36.15 6.25 
Macrophage-
expressed gene 1 
protein 
49.94 1.01391E-05 MPEG1 0.84 1.49 78.54 7.65 
*G antigen family 
B member 1 




24.48 0.003564511 PIK3R4 0.44 1.46 153.01 7.17 
Pirin 158.71 1.3466E-16 PIR 7.24 1.31 32.09 6.92 
Parathymosin 230.82 8.27378E-24 PTMS 22.55 1.44 11.52 4.16 








1 receptor (TIR) 
domain 




60.83 8.26038E-07 TBK1 2.74 -1.39 83.59 6.79 
Zinc finger 
CCCH-type 
antiviral protein 1 














35.49 0.000282488 ABHD10 13.73 1.23 33.91 8.57 
acyl-CoA 
thioesterase 9 
49.12 1.22462E-05 ACOT9 9.56 -1.31 15.45 8.59 
Adenylate kinase 
isoenzyme 1 





91.18 7.61682E-10 AK3 22.93 1.29 18.18 8.78 
Argininosuccinate 
synthase 






0 ATP5B 72.78 1.20 56.52 5.40 
ATP synthase 
gamma chain 









198.92 1.28165E-20 ATP5F1 11.72 1.36 28.89 9.36 




C1 (Subunit 9) 
247.94 1.60823E-25 ATP5G1 7.07 2.35 10.19 10.40 
ATP synthase-
coupling factor 6, 
mitochondrial 



















42.39 5.76766E-05 ATPAF2 21.19 -1.24 13.05 9.51 
ADP-ribosyl 
cyclase 2 
49.30 1.17453E-05 BST1 1.89 1.21 35.70 7.80 




25.67 0.002710192 CLYBL 1.99 1.43 32.83 8.29 
Coatomer subunit 
gamma-2 




Cubilin 26.56 0.002208005 CUBN 0.28 1.26 398.48 5.35 
Lanosterol 14-
alpha demethylase 





2.2169E-288 EEF1A1 17.32 1.42 50.12 8.95 
Elongation factor 
1-gamma 
847.83 1.6494E-85 EEF1G 39.13 1.24 50.09 6.67 
Eukaryotic 
translation 
initiation factor 3 
subunit H 
219.98 1.0051E-22 EIF3H 12.78 1.29 39.91 6.54 
Eukaryotic 
translation 
initiation factor 3 
subunit K 





236.48 2.24941E-24 EIF4A2 40.61 -1.70 41.26 5.64 
Eukaryotic 
translation 
initiation factor 5 





31.06 0.00078343 ENOSF1 4.29 -1.21 49.75 6.48 
Squalene synthase 308.02 1.57875E-31 FDFT1 19.27 1.28 47.25 6.54 
Fibronectin 84.30 3.71838E-09 FN1 1.38 -1.75 222.84 5.68 
fibronectin 1 
(FN1), transcript 
variant 5, mRNA 
84.30 3.71838E-09 FN1 2.96 -1.32 111.23 6.21 








73.98 3.99945E-08 GFER 12.2 1.27 23.43 7.62 
Glutathione S-
transferase 
109.04 1.24616E-11 GSTA3 12.21 -1.22 19.73 9.16 
Glutathione S-
transferase Mu 3 
1530.9
2 




32.51 0.000561048 HAGH 8.08 -1.26 28.84 7.33 
Histone 
acetyltransferase 
type B catalytic 
subunit 





















113.45 4.51551E-12 LHPP 7.78 -1.23 29.15 6.15 
lanosterol synthase 
isoform 3 
54.26 3.7465E-06 LSS 3.07 1.49 74.17 6.46 
Leukotriene A-4 
hydrolase 




























45.67 2.70836E-05 MRPL53 13.39 1.65 12.10 8.76 
Arylamine N-
acetyltransferase 1 









sulfur protein 3, 
mitochondrial 





26.13 0.002437811 NOSIP 6.63 -1.81 17.93 8.00 
nucleoporin 
133kDa 








25.65 0.002722701 NUP93 1.15 -1.25 79.83 6.18 














113.80 4.17131E-12 PGM3 8.03 1.33 51.05 5.88 




29.39 0.0011508 PPAP2A 7.04 1.22 32.14 7.97 
Palmitoyl-protein 
thioesterase 1 




450.79 8.33915E-46 PRKCSH 20.19 1.28 59.14 4.42 
Prosaposin 1508.1
4 















8.4427E-132 RPLP2 70.43 -1.29 11.66 4.54 
SUMO-activating 
enzyme subunit 1 











344.95 3.19778E-35 SDHA 9.61 1.26 63.53 7.24 
Protein transport 
protein Sec24B 








3.3762E-187 SHMT2 49.28 1.24 53.42 8.15 
Monocarboxylate 
transporter 1 


































25.07 0.003111716 UGP2 4.02 1.23 55.64 7.88 
Cytochrome b-c1 
complex subunit 9 
57.97 1.5948E-06 UQCR10 38.1 1.31 7.30 9.47 
Cytochrome b-c1 
complex subunit 7 
94.76 3.34256E-10 UQCRB 21.62 1.22 13.52 8.78 
OXIDATIVE 
STRESS 
              
Cytoplasmic 
aconitate hydratase 
179.53 1.11364E-18 ACO1 6.97 -1.36 98.34 6.68 
*Retinal 
dehydrogenase 1 
385.17 3.03767E-39 ALDH1A1 17.95 1.32 42.57 5.80 
*Fatty aldehyde 
dehydrogenase 
262.18 6.06001E-27 ALDH3A2 12.99 1.23 54.81 7.88 
Alkylated repair 
protein alkB 





131.03 7.88327E-14 ASPH 4.39 2.23 83.22 4.92 
Cytochrome b561 86.52 2.22693E-09 CYB561 4.38 1.45 27.54 8.56 
Cytochrome b5 126.09 2.45962E-13 CYB5A 42.86 -1.22 11.26 5.14 
*Dehydrogenase/r
eductase SDR 
family member 1 
67.71 1.69434E-07 DHRS1 6.07 1.31 33.89 7.83 
Glycine N-
methyltransferase 















33.26 0.000472063 MTHFD2 5.41 2.00 23.85 9.76 
Myb-binding 
protein 1A 







sulfur protein 8, 
mitochondrial 





variant 3, mRNA 




36.08 0.000246604 P4HA2 2.25 1.41 60.59 5.71 
Protoporphyrinoge
n oxidase 




93.93 4.04761E-10 PYCR2 9.38 1.23 33.62 7.77 
Retinol 
dehydrogenase 14 
64.68 3.40408E-07 RDH14 7.14 1.44 36.84 8.79 




90.06 9.86169E-10 STEAP2 6.7 -1.47 45.95 8.91 












3.0244E-234 ASNS 38.89 1.31 62.13 7.06 
Cyclin-dependent 
kinase 1 
29.04 0.001247384 CDK1 8.33 -1.57 27.49 7.06 
*Collagen type IV 
alpha-3-binding 
protein 
48.53 1.40281E-05 COL4A3BP 1.67 -1.40 67.96 5.47 



















60.58 8.74071E-07 HM13 6.57 1.21 36.79 6.68 
*Hypoxia up-
regulated protein 1 
2096.9
0 
















27.45 0.001798871 MARCH5 3.6 1.69 31.21 8.70 





101.64 6.8544E-11 NEDD8 40 -1.34 5.86 6.70 
aminopeptidase 
NPEPL1 isoform 3 








102.58 5.52077E-11 OTUD6B 14.58 -1.37 21.79 5.10 
Proteasome 
subunit beta type-6 








62.59 5.50752E-07 TRIM28 33.05 -1.23 88.49 5.77 
*Ubiquitin-
conjugating 
enzyme E2 variant 
2 




39.23 0.000119399 UBR2 4 -1.27 66.01 7.42 
Deubiquitinating 
protein VCIP135 




P) 1, soluble 




36.31 0.000233884 ARMC2 9.41 2.12 9.41 6.92 
UPF0556 protein 
C19orf10 





34.93 0.000321366 CISD3 10.24 1.24 14.21 10.55 







60.68 8.55067E-07 HN1 9.35 -1.34 11.62 8.47 
kelch-like protein 
35 




55.50 2.81838E-06 LRRC47 2.57 1.43 63.43 8.28 
Nucleoside 
diphosphate-linked 
moiety X motif 22 
1000.3
5 




36.15 0.000242661 RGS10 10.18 -1.31 19.60 5.87 






76.44 2.27171E-08 SMEK1 3.15 -1.21 61.98 4.81 
Protein kish-A 37.02 0.000198609 TMEM167A 12.5 1.28 8.05 8.95 
Transmembrane 
protein 205 
34.49 0.000355631 TMEM205 8.99 -1.37 21.18 8.62 
Transmembrane 
protein 238 
42.68 5.39511E-05 TMEM238 10.23 1.40 18.03 11.53 
Transmembrane 
protein 87A 








-like protein 1 
31.60 0.000691831 UAP1L1 1.38 -1.24 56.99 6.32 
zinc finger CCCH-
type containing 18 
















282.98 5.03956E-29 DDX31 0.97 1.24 80.89 9.83 
Neurobeachin-like 
protein 2 
23.89 0.004083194 NBEAL2 0.43 1.66 282.68 6.54 
NHP2 
ribonucleoprotein 
351.04 7.86182E-36 NHP2 33.33 -1.22 15.01 9.25 
WD repeat protein 
55 
59.96 1.00925E-06 WDR55 21.74 -1.43 12.54 6.74 














84.77 3.3358E-09 ANKEF1 1.42 1.33 86.61 8.28 
Calmodulin 383.67 4.29621E-39 CALM 38.26 -1.40 16.83 4.22 
Calcyclin-binding 
protein 
64.99 3.17122E-07 CACYBP 13.16 1.30 26.19 8.25 
calcium/calmoduli
n-dependent 
protein kinase 2, 
beta 





25.23 0.002999163 CAMSAP3 0.48 1.56 134.67 8.35 
Calnexin 1219.6
9 
1.0747E-122 CANX 23.14 1.21 67.53 4.60 
Calcium-regulated 
heat stable protein 
1 
181.64 6.85365E-19 CARHSP1 10.88 -1.46 15.88 8.21 
S-
adenosylmethionin
e synthase isoform 
type-2 
22.48 0.00564937 MAT2A 3.98 1.62 19.46 9.10 
40S ribosomal 
protein S28 
416.48 2.24773E-42 RPS28 30.43 1.65 7.84 10.70 
*Tetraspanin 48.28 1.48594E-05 TSPAN13 6.29 -2.11 17.75 6.29 
Desmoglein-2 112.81 5.23745E-12 DSG2 7.6 1.23 122.22 5.24 
Integrin alpha-10 26.55 0.002213095 ITGA10 0.78 1.26 112.47 6.68 




46.62 2.17624E-05 WDR61 6.56 -1.20 33.56 5.47 




31.72 0.00067262 DPYSL5 3.68 1.67 20.85 6.42 
PDZ domain-
containing protein 
GIPC1 isoform 2 
33.42 0.000454988 GIPC1 7.2 -1.30 26.06 5.57 
Crk-II of Adapter 
molecule crk 
168.48 1.41897E-17 CRK 7.57 1.26 33.81 5.55 
Transducin-like 
enhancer protein 3 





113.69 4.27563E-12 PAFAH1B3 21.65 1.34 25.72 6.84 




Histone H1.5 536.77 2.10286E-54 HIST1H1B 21.24 2.49 22.57 10.92 
Histone H1.2 1007.8
0 
1.6588E-101 HIST1H1C 30.99 2.29 21.35 10.93 
Histone H1.4 1069.8
3 
1.0408E-107 HIST1H1E 30.59 2.89 21.85 11.03 




6.0583E-135 HIST1H2BC 62.7 1.84 13.90 10.32 
Histone H3.1 1117.9
8 
1.5924E-112 HIST1H3A 44.85 1.54 15.39 11.12 
Histone H4 1317.9
9 
1.5896E-132 HIST1H4A 52.43 1.85 11.36 11.36 
Histone H2A type 
2-C 
969.32 1.16911E-97 HIST2H2AC 55.04 1.97 13.98 10.90 




1.1021E-149 HIST2H2BE 62.7 1.86 13.91 10.32 
Histone H3.2 1363.4
7 
4.4975E-137 HIST2H3A 44.85 1.82 15.38 11.27 
Histone H2A.x 516.44 2.27136E-52 H2AFX 59.44 1.22 15.14 10.74 
replication factor 
C subunit 5 
isoform 4 
34.07 0.000391742 RFC5 2.67 2.24 38.14 7.80 
small ubiquitin-
related modifier 2 
isoform b 
precursor 















21.02 0.007906786 WDR72 0.54 1.73 123.35 6.67 
Alpha-2-HS-
glycoprotein 
51.23 7.53356E-06 AHSG 4.9 2.19 27.34 6.52 




278.12 1.54264E-28 PRMT1 34.46 -1.37 37.68 6.15 
Proline-, glutamic 
acid- and leucine-
rich protein 1 









204.85 3.27022E-21 NUCKS1 11.52 -1.23 27.28 5.08 
SLD5 homolog 
(SLD5), mRNA 








39.58 0.000110154 MTTP 1.23 1.98 99.29 8.41 









51.24 7.51623E-06 MRPL21 15.83 -1.20 13.74 10.07 
Serpin B6 108.58 1.38613E-11 SERPINB6 11.49 -1.21 46.34 5.76 
Vomeronasal type-
1 receptor 5 
23.95 0.00402717 VN1R5 1.96 -1.59 40.75 9.20 
cilia and flagella 
associated protein 
58 






156.79 2.09251E-16 PGRMC1 22.05 1.29 21.66 4.70 
FK506 binding 
protein12 
205.15 3.05816E-21 FKBP1A 35.14 -1.37 3.96 5.78 
Peptidyl-prolyl cis-
trans isomerase B 
548.34 1.4649E-55 PPIB 46.3 1.24 23.73 9.41 
selenide, water 
dikinase 1 isoform 
3 
221.26 7.4799E-23 SEPHS1 16.2 1.24 35.46 5.21 
Probable Xaa-Pro 
aminopeptidase 3 








52.08 6.19534E-06 MRPL4 15.21 -1.20 29.48 10.13 
MRPL43 protein 
(Fragment) 
88.64 1.36673E-09 MRPL43 8.97 1.23 15.95 8.66 
60S ribosomal 
protein L32 















800.51 8.88891E-81 STK39 13.35 -1.24 59.60 6.29 
toll interacting 
protein 












53.31 4.66317E-06 NSUN5P1 7.14 -1.70 16.47 9.26 
THO complex 
subunit 2 








79.07 1.23796E-08 HPCA 6.22 1.63 22.41 4.97 
Olfactory receptor 
5AC2 
37.52 0.000177011 OR5AC2 2.27 -1.39 35.28 8.94 
A-kinase anchor 
protein 8 





61.52 7.04693E-07 MYADM 15.65 1.74 15.92 8.65 
*NF-kappa-B-
activating protein 
26.49 0.002243882 NKAP 1.45 1.65 47.11 10.11 
*ATP-binding 
cassette sub-family 
A member 5 
30.05 0.000988553 ABCA5 0.86 -5.84 104.30 7.12 
AP-1 complex 
subunit mu-2 
47.21 1.90108E-05 AP1M2 4.02 -1.53 48.08 8.22 
AP-2 complex 
subunit mu-1 
44.57 3.49424E-05 AP2M1 8.27 -1.20 42.67 9.39 
ADP-ribosylation 
factor 5 




exchange factor 1 
(brefeldin A-
inhibited) 
440.40 9.12033E-45 ARFGEF1 3.27 -1.23 142.44 6.13 




117.58 1.74464E-12 CNBP 8.82 -1.62 18.73 7.71 
Metal transporter 
CNNM3 
22.85 0.005188 CNNM3 0.91 1.22 70.59 7.12 
Protein CWC15 
homolog 
66.10 2.45471E-07 CWC15 4.8 -1.30 26.61 5.71 
Acyl-CoA-binding 
protein 
504.05 3.93581E-51 DBI 50.57 -1.32 10.04 6.57 
Golgin subfamily 
A member 5 
27.96 0.001599558 GOLGA5 9.4 1.32 12.84 6.04 
Hook homolog 1 35.65 0.00027227 HOOK1 2.33 -1.28 79.97 5.19 
UPF0459 protein 
C19orf50 
24.35 0.003672823 KXD1 5.11 -1.64 19.66 4.89 
LPS-responsive 
vesicle trafficking, 


























93.79 4.17548E-10 MRPS18B 7.91 1.50 24.34 8.56 
myosin, light chain 
6, alkali, smooth 
muscle and non-
muscle 
497.53 1.76602E-50 MYL6 46.67 -1.25 15.01 5.00 
Myosin-Id 149.00 1.25876E-15 MYO1D 2.49 -1.30 116.13 9.39 
Ran-binding 
protein 6 
46.97 2.00815E-05 RANBP6 2.44 -1.25 124.63 5.01 
Ammonium 
transporter Rh type 
B 





135.77 2.64671E-14 SCAMP2 3.95 1.68 36.63 6.10 
Mitochondrial 
glutamate carrier 1 





7.3482E-128 SLC25A5 47.65 1.24 32.83 9.69 
spermatogenesis 
associated 7 
29.05 0.001244515 SPATA7 16.67 -1.46 4.76 10.26 








Table 7: Patient Characteristics of Prostate Cancer Microarray.  96 core prostate 
adenocarcinoma tissue microarray with 36 duplicated cancers and 8 with match normal 
adjacent tissue, 3 cases of metastasis in bones and one in abdominal wall  Clinical data.  
Age, pathology diagnosis, stage Gleason score Type, Prostate Sera Antigen status.  












Position Age Organ Pathology diagnosis Stage Gleason 
score 




G9 69 Prostate Normal * * * NAT * * 
B6 62 Prostate Adenocarcinoma II 7 T2cN0M1 Malignant 37.3 R1 
B10 60 Prostate Adenocarcinoma III 9 T3bN0M0 Malignant 40 R1 
B12 70 Prostate Adenocarcinoma IV 7 T4N0M0 Malignant 7 R1 





IV * M1 Metastatic * * 
G8 59 Bone Metastatic 
adenocarcinoma 
from Prostate 




Table 8:  Patient Characteristics of Breast Tumor Lysates.  Sex, Age, Location, 
Diagnosis, Stage, Grade. T=Primary Tumor N= Regional Lymph Nodes M= Distant 
Metastasis 
Sex Age Tissue Location Diagnosis Stage Grade 




IIB T2N1M0 I 




IIB T2N1M0 III 





Female 47 Breast Bilateral Adenocarcinoma IV T4N1M0 III 
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